Pathology In Depth

Library › Kidney pathology: glomerular, tubulointerstitial, vascular and transplant disease, renal cell carcinoma and pediatric renal tumors

Kidney pathology: glomerular, tubulointerstitial, vascular and transplant disease, renal cell carcinoma and pediatric renal tumors

Last reviewed 2026-11-17 by a board-certified pathologist. 284 references.

Renal Biopsy Evaluation and Nephrotic Glomerular Diseases: Minimal Change Disease, FSGS, Membranous and Diabetic Nephropathy, Amyloidosis and Monoclonal Immunoglobulin Deposition

Related page: Nephritic and Hematuric Glomerular Diseases: IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy, Infection-Related, Cryoglobulinemic, ANCA and Anti-GBM Glomerulonephritis, Alport Syndrome (IgA nephropathy, lupus nephritis, C3 glomerulopathy, ANCA and anti-GBM glomerulonephritis, Alport syndrome) Related page: Tubulointerstitial, Obstructive, Cystic and Developmental Kidney Disease (light chain cast nephropathy, crystalline nephropathies) Related page: Renal Vascular Disease, Thrombotic Microangiopathy and Kidney Transplant Pathology (thrombotic microangiopathy, recurrent disease in the allograft) Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (immunofixation and serum free light chains)

Handling of the native kidney biopsy

Tissue triage, fixation and stains for medical renal biopsy

  • Three modalities. Native kidney biopsies require light microscopy, immunofluorescence or immunohistochemistry and electron microscopy (Walker et al. 2004).
  • Light microscopy. Paraffin sections are stained with hematoxylin and eosin, periodic acid–Schiff (PAS), Masson trichrome, Jones methenamine silver and Congo red (Leung et al. 2019).
  • Immunofluorescence. Tissue for frozen-section immunofluorescence may be transported in Michel transport medium, in which calcium oxalate crystals dissolve while 2,8-dihydroxyadenine crystals remain birefringent (Ibrahim et al. 2022). Frozen tissue is stained for IgG, IgM, IgA, C1q, C3 and κ and λ light chains (Leung et al. 2019). The Mayo Clinic/Renal Pathology Society (RPS) panel adds fibrinogen and albumin, and intensity is graded as negative, ±, 1+, 2+ or 3+ (Sethi et al. 2016).
  • Electron microscopy. Electron microscopy is recommended for all native biopsies, because about 20% of renal biopsies cannot be diagnosed accurately without it (Sethi et al. 2016). Tissue is ideally fixed in 2–3% glutaraldehyde. Frozen tissue and tissue fixed in Zenker or B5 fixatives give poor ultrastructural preservation (Leung et al. 2019).
  • Selection for electron microscopy. The pathologist examines the stained 1-µm sections of the electron microscopy block and selects glomeruli representative of the light microscopic findings, avoiding sclerotic or ischemic glomeruli (Sethi et al. 2016). In monoclonal gammopathy at least two glomeruli are studied ultrastructurally (Leung et al. 2019).
  • Reprocessed paraffin tissue. Paraffin tissue can be reprocessed when the glutaraldehyde sample lacks glomeruli (Leung et al. 2019). Reprocessing reduced glomerular basement membrane (GBM) thickness by a mean of 23% in thin basement membrane cases and 40% in normal or minimal change cases, so thin basement membrane nephropathy cannot be diagnosed reliably on such tissue (Nasr et al. 2007).
  • Report elements. The report states the number and size of cores and the fixatives received for each modality, and documents poorly preserved tissue (Sethi et al. 2016).

Adequacy of the renal biopsy

Pathogenesis-based classification of glomerular disease

  • Nephrotic syndrome. Nephrotic syndrome consists of edema, massive proteinuria (>3.5 g/d in adults; >40 mg/m² per hour in children) and hypoalbuminemia (<2.5 g/dL) (Vivarelli et al. 2017).
  • Nephritic syndrome. The components of the nephritic syndrome are listed in Nephritic and Hematuric Glomerular Diseases: IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy, Infection-Related, Cryoglobulinemic, ANCA and Anti-GBM Glomerulonephritis, Alport Syndrome. Acute glomerulonephritis is diagnosed mainly from the urinary findings, especially red blood cell casts. In children with acute glomerulonephritis, hypocomplementemia is most characteristic of poststreptococcal GN, and a normal C3 level is most often found in IgA nephropathy (Welch 2012).
  • Five pathogenic classes. The Mayo Clinic/RPS consensus classifies glomerulonephritis (GN) as immune-complex GN, pauci-immune GN, anti-GBM GN, monoclonal immunoglobulin GN and C3 glomerulopathy (Sethi et al. 2016).
  • Diagnostic line. The primary diagnosis lists the disease entity or pathogenic type, then the pattern of injury, then the score, grade or class, then additional features. A pattern diagnosis alone is not an acceptable primary diagnosis. Coexisting lesions such as diabetic glomerulosclerosis, thin basement membrane nephropathy, drug-induced interstitial nephritis or atheroembolic disease are reported as secondary diagnoses (Sethi et al. 2016).
  • Additional features. The report gives the percentage of globally sclerotic glomeruli, the extent of interstitial fibrosis and tubular atrophy, and the severity of arteriosclerosis and arteriolosclerosis (Sethi et al. 2016).
Pathogenic class Immunofluorescence Representative entities Source
Immune-complex GN Granular polyclonal immunoglobulin, often with complement IgA nephropathy, lupus nephritis, infection-related GN, fibrillary GN Sethi et al. 2016
Pauci-immune GN Negative or scant immunoglobulin; ANCA in 80%–90% Microscopic polyangiitis, granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis Sethi et al. 2016
Anti-GBM GN Linear immunoglobulin, usually IgG, along the GBM Anti-GBM disease Sethi et al. 2016
Monoclonal immunoglobulin GN Monotypic immunoglobulin in glomeruli or tubular basement membranes Proliferative GN with monoclonal immunoglobulin deposits, proliferative monoclonal immunoglobulin deposition disease, immunotactoid GN Sethi et al. 2016
C3 glomerulopathy Dominant C3 with minimal or no immunoglobulin Dense deposit disease, C3 glomerulonephritis Sethi et al. 2016
Lesion or pattern Definition Source
Mesangial hypercellularity More than 3 mesangial cells per mesangial area Sethi et al. 2016
Endocapillary hypercellularity Increased cells within capillary lumina causing luminal narrowing Sethi et al. 2016
Cellular crescent (Oxford, Mayo/RPS) Extracapillary proliferation of more than two cell layers with >50% of the lesion occupied by cells Haas et al. 2017; Sethi et al. 2016
Fibrocellular crescent (Oxford, Mayo/RPS) Cells and extracellular matrix, with ≤50% cells and <90% matrix Haas et al. 2017; Sethi et al. 2016
Fibrous crescent (Oxford, Mayo/RPS) ≥90% matrix Haas et al. 2017; Sethi et al. 2016
Crescents in lupus nephritis (ISN/RPS 2018) Involve ≥10% of the Bowman capsule circumference; cellular >75% cells and fibrin, fibrocellular 25%–75% cells and fibrin, fibrous >75% fibrous matrix Lin et al. 2023
Fibrinoid necrosis Disruption of the GBM with fibrin exudation Sethi et al. 2016
Crescentic GN Crescents in ≥50% of glomeruli in immune-complex GN or C3 glomerulopathy; not applied to ANCA or anti-GBM GN Sethi et al. 2016
Membranoproliferative GN Mesangial or endocapillary hypercellularity with capillary wall thickening caused by subendothelial immunoglobulin or complement Sethi et al. 2016
Exudative GN Neutrophils account for >50% of glomerular hypercellularity Sethi et al. 2016

Minimal change disease

  • Epidemiology. Minimal change disease (MCD) accounts for about 15% of idiopathic nephrotic syndrome in adults and 70%–90% in children older than 1 year (Vivarelli et al. 2017).
  • Biopsy indications in children. Biopsy is reserved for features suggesting another diagnosis: age <1 or >12 years at onset, gross hematuria, low serum C3, marked hypertension, renal failure without severe hypovolemia, a history suggesting a secondary cause, steroid resistance, or calcineurin inhibitor therapy (Vivarelli et al. 2017).
  • Light microscopy and immunofluorescence. Glomeruli are normal or show mild focal mesangial prominence. Immunofluorescence is negative or shows low-intensity mesangial IgM, sometimes with C3 or C1q (Mirioglu et al. 2024).
  • Electron microscopy. Extensive foot process effacement is the hallmark. Cytoplasmic vacuoles and microvillous transformation may accompany it (Mirioglu et al. 2024).
  • Secondary causes. Reported causes include Hodgkin and non-Hodgkin lymphoma, leukemia, thymoma, nonsteroidal anti-inflammatory drugs (NSAIDs), lithium, gold, D-penicillamine, tyrosine kinase inhibitors, allergens such as bee stings and pollen, and infections (Vivarelli et al. 2017).
  • Anti-nephrin antibodies. Circulating nephrin autoantibodies were found during active disease in a subset of MCD patients and correlated with podocyte-associated punctate IgG colocalizing with nephrin on biopsy (Watts et al. 2022).
  • Course. Steroid-responsive MCD usually does not cause chronic damage. Steroid-unresponsive forms may later prove to be FSGS (Vivarelli et al. 2017).

Focal segmental glomerulosclerosis

Etiologic categories of FSGS (KDIGO 2021)

  • Four groups. KDIGO 2021 groups FSGS as primary, genetic, secondary, or of undetermined cause (Mirioglu et al. 2024).
  • Foot process effacement. In one study, all primary cases had effacement of more than 80%, and no genetic or maladaptive case exceeded 50%. Reliance on histology alone is not warranted, and genetic testing is offered when the category is unresolved (Mirioglu et al. 2024).
  • Immunofluorescence. IgM and C3 may stain sclerotic segments nonspecifically (Mirioglu et al. 2024).

Columbia classification of FSGS variants

The Columbia working proposal defines five mutually exclusive morphologic variants that apply to primary and secondary FSGS (D'Agati et al. 2004; Stokes and D'Agati 2014).

Variant Defining light microscopic feature Frequency in adults Outcome Source
Not otherwise specified (NOS) Segmental capillary luminal obliteration by extracellular matrix, with no collapsing, tip or cellular lesion and no predominance of perihilar sclerosis 42% 3-year ESRD 20% in steroid-resistant trial patients D'Agati et al. 2013; Thomas et al. 2006
Perihilar Segmental hyalinosis and sclerosis contiguous with the hilus in at least 50% of affected glomeruli, with no cellular, tip or collapsing lesion 26% Less proteinuria and higher serum albumin than collapsing and tip variants D'Agati et al. 2013; Thomas et al. 2006
Cellular At least one glomerulus with segmental endocapillary hypercellularity obliterating capillary lumina, with or without foam cells, hyalinosis and karyorrhexis, and without tip or collapsing lesions 3% Remission 44.5%; ESRD 27.8% D'Agati et al. 2013; Thomas et al. 2006; Stokes et al. 2006
Tip At least one glomerulus with a segmental lesion in the tip domain (outer 25% of the tuft next to the proximal tubule origin), with adhesion or confluence of podocytes with parietal or tubular cells at the tubular lumen or neck, and no collapsing lesion 17% Highest remission (75.8%); lowest ESRD (5.7%) D'Agati et al. 2013; Thomas et al. 2006; Stokes et al. 2006
Collapsing At least one glomerulus with segmental or global capillary wall collapse and hypertrophy and hyperplasia of the overlying epithelial cells 11% 3-year renal survival 33%; ESRD 65.3% D'Agati et al. 2013; Thomas et al. 2006; Stokes et al. 2006
  • Prospective data. In 138 children and young adults with steroid-resistant FSGS, NOS formed 68%, collapsing 12%, tip 10%, perihilar 7% and cellular 3%. At 3 years, 47% of collapsing, 20% of NOS and 7% of tip variant patients reached ESRD (D'Agati et al. 2013).
  • Demographics. Collapsing FSGS affects younger and more often Black patients. Tip variant is uncommon in Black patients and shows better renal function and less tubulointerstitial injury (Thomas et al. 2006).
  • Sampling. The cellular variant may include unsampled tip or collapsing lesions (Stokes et al. 2006).

APOL1 and collapsing glomerulopathy

  • APOL1 risk alleles. Two APOL1 variants on African chromosomes associate with FSGS (odds ratio 10.5) and hypertension-attributed ESKD (odds ratio 7.3) in African Americans (Genovese et al. 2010).
  • Risk magnitude. Two risk alleles confer 17-fold odds for FSGS and 29-fold odds for HIV-associated nephropathy, a 4% lifetime FSGS risk, and a 50% HIVAN risk in untreated HIV infection (Kopp et al. 2011).
  • Histologic correlate. Patients with the APOL1 risk genotype had more glomerulosclerosis, more interstitial fibrosis and more collapsing variants (Kopp et al. 2015).
  • Pamidronate. Collapsing FSGS developed in seven HIV-negative patients receiving pamidronate, often at escalating doses (Markowitz et al. 2001).
  • Interferon. Collapsing glomerulopathy with nephrotic syndrome and oliguric acute renal failure developed within 2 weeks after completion of pegylated interferon and ribavirin for hepatitis C, and renal function recovered with high-dose steroids (Berdichevski et al. 2010).
  • COVID-19. Six Black patients with COVID-19, AKI and nephrotic-range proteinuria had collapsing glomerulopathy and an APOL1 high-risk genotype, without viral particles in the kidney (Wu et al. 2020). Among 14 native biopsies from patients with COVID-19, 5 showed collapsing glomerulopathy (Kudose et al. 2020).

Membranous nephropathy

Morphology of membranous nephropathy

  • Pattern. The membranous pattern is a thickened GBM with or without spikes or pinholes on PAS and silver stains, granular IgG with or without C3, and subepithelial electron-dense deposits that are incorporated into the GBM over time (Sethi 2021).
  • IgG subclass. IgG4 is the predominant IgG subclass in PLA2R-associated deposits (Beck et al. 2009). Anti-PLA2R serology is covered in ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System.
  • Ehrenreich–Churg stages. Very early (stage I) membranous nephropathy shows histologically unremarkable glomeruli and equivocal IgG, so it may be indistinguishable from minimal change disease without electron microscopy (Yamashita et al. 2021). Extracellular matrix formation between deposits defines stage II, and progressive deposit resorption with GBM remodeling characterizes stages III and IV. The prognostic value of stage is controversial, and single-nephron GFR falls with advancing stage (Okabayashi et al. 2023).

Antigen-based classification of membranous nephropathy (Mayo Clinic 2023)

  • Current rule. The Mayo Clinic consensus classifies membranous nephropathy in two steps: identification of the target antigen by serology, tissue staining or mass spectrometry, then a search for the associated condition. At least 14 antigens account for 80%–90% of cases (Sethi et al. 2023).
  • Previous rule. Membranous nephropathy was classified as primary (70%) without a disease association or secondary (30%) with lupus, malignancy, infection or drugs (Sethi 2021).
  • Antigen list. Reported antigens include PLA2R, THSD7A, EXT1/EXT2, NELL1, SEMA3B, NCAM1, CNTN1, HTRA1, FAT1, PCDH7, NTNG1, PCSK6, NDNF and MPO (Sethi and Fervenza 2025).
Antigen Approximate share Typical patient and association Biopsy features Source
PLA2R 50%–60% of MN (serology in ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System) Mean age 54 years; male predominance; usually no association IgG4-dominant Sethi 2021; Beck et al. 2009
THSD7A 1%–2% Female predominance; malignancy IgG4-dominant Sethi 2021
EXT1/EXT2 10%–20% Mean age 37 years; female predominance; autoimmune disease, including 8 of 18 pure class V lupus nephritis Full-house immunoglobulin with C1q; IgG1; subepithelial, subendothelial and mesangial deposits Sethi 2021; Sethi et al. 2019
NELL1 3%–8% Mean age 66.8 years; malignancy in 33% Segmental or incomplete capillary loop IgG; IgG1-dominant Sethi 2021; Caza et al. 2021; Sethi et al. 2020a
SEMA3B 1%–3% Children (8 of 11), onset at ≤2 years in 5 Tubular basement membrane IgG in 4 of 11 Sethi et al. 2020b
PCDH7 2%–5% Mean age 61 years IgG1 and IgG4; minimal or absent C3 and C1q; minimal complement in 12 of 14 Sethi 2021; Sethi et al. 2021
NCAM1 5% of membranous lupus nephritis Lupus Full-house immunoglobulin in 40% Xia et al. 2024; Sethi 2021
HTRA1 4.2% of quadruple-negative MN Primary MN IgG4-dominant antibodies Al-Rabadi et al. 2021
FAT1 Majority of MN after allogeneic HSCT Hematopoietic stem cell transplant IgG4-dominant; mild C3 Sethi et al. 2022

Diabetic nephropathy

  • Lesions. Early lesions are GBM thickening, mild mesangial expansion and arteriolar hyalinosis. Established disease shows mesangial expansion, which may be nodular (Kimmelstiel–Wilson nodules), hyaline in afferent and efferent arterioles, markedly thickened GBM and tubular basement membranes, and interstitial fibrosis (Najafian et al. 2011).
  • RPS classification. The RPS divides diabetic nephropathy into four hierarchical glomerular classes and scores interstitial and vascular lesions separately. Interobserver reproducibility was good (intraclass correlation coefficient 0.84) (Tervaert et al. 2010).
RPS class Definition Source
I Isolated GBM thickening with only mild, nonspecific light microscopic change Tervaert et al. 2010
IIa Mild mesangial expansion Tervaert et al. 2010
IIb Severe mesangial expansion Tervaert et al. 2010
III At least one Kimmelstiel–Wilson nodule, without class IV changes Tervaert et al. 2010
IV Global glomerulosclerosis in >50% of glomeruli attributable to diabetic nephropathy Tervaert et al. 2010

Differential diagnosis of nodular glomerulosclerosis

Entity Distinguishing finding Source
Diabetic nephropathy (class III) Clinical diabetes; afferent and efferent arteriolar hyalinosis; GBM thickening Tervaert et al. 2010; Najafian et al. 2011
Idiopathic nodular glomerulosclerosis Lesions nearly identical to diabetic nephropathy without diabetes; aberrant vessels in all cases; worse survival in active smokers Baert et al. 2026
Monoclonal immunoglobulin deposition disease Linear monotypic light or heavy chain along GBM and tubular basement membranes; nodular sclerosis in 61% Nasr et al. 2012; Leung et al. 2019
AL amyloidosis Congo red positive with apple-green birefringence; 7–12 nm fibrils Said et al. 2013; Leung et al. 2019
Fibrillary GN Congo red negative; 10–30 nm fibrils; DNAJB9 positive Leung et al. 2019; Nasr et al. 2018

Renal amyloidosis

Morphology of renal amyloid

  • Definition. Amyloid deposits are Congo red positive and show apple-green birefringence under polarized light. Congo red intensity did not differ by amyloid type (Said et al. 2013).
  • Ultrastructure. Fibrils are solid, non-branching and randomly arranged, with diameters of 7–12 nm (Leung et al. 2019).
  • Distribution. Amyloid involves glomeruli and vessels in most patients and the interstitium in about 60% (Leung et al. 2019). ALECT2 and apolipoprotein amyloidosis show diffuse interstitial deposition, fibrinogen Aα amyloidosis shows obliterative glomerular involvement, and immunoglobulin amyloidosis is associated with amyloid spicules (Said et al. 2013).

Typing of renal amyloid by mass spectrometry

  • Method. Laser microdissection with tandem mass spectrometry identified the amyloid type with 100% sensitivity and specificity in a training set and 98% in a validation set (Vrana et al. 2009).
  • Immunohistochemical and immunofluorescence typing. Immunohistochemical typing has low sensitivity and specificity (Vrana et al. 2009). Immunofluorescence failed to diagnose 28 of 384 AL cases (7.3%), and mass spectrometry was needed to determine the type in 16% of 474 cases (Said et al. 2013).
  • Proteins detected. Renal amyloid by mass spectrometry contained immunoglobulin light and heavy chains, serum amyloid A, leukocyte cell-derived chemotaxin 2, fibrinogen Aα, transthyretin, apolipoproteins A-I and A-IV, gelsolin and β2-microglobulin (Sethi et al. 2012).
  • Organized-deposit proteomics. Apolipoprotein E and serum amyloid P component are abundant in amyloid. Serum amyloid P is absent in fibrillary GN (Sethi et al. 2013).
  • ISA 2024 nomenclature. The International Society of Amyloidosis lists 42 human amyloid fibril proteins, 19 associated with systemic deposition and 4 with localized or systemic deposits. AA and ATTR deposits usually consist of wild-type protein (Buxbaum et al. 2024).
Amyloid type Share of 474 renal biopsies Renal pattern Source
AL, AH, AHL (immunoglobulin) 85.9% Glomerular and vascular; spicules; lower creatinine and more proteinuria Said et al. 2013
AA 7.0% Glomerular and vascular; most common type in Egyptian biopsies (48%) Said et al. 2013; Larsen et al. 2016
ALECT2 2.7% Diffuse interstitial; oldest median age (68 years); 31% of Egyptian renal amyloid Said et al. 2013; Larsen et al. 2016
AFib (fibrinogen Aα) 1.3% Obliterative glomerular involvement Said et al. 2013
AApoAI, AApoAII, AApoAIV 0.6% Diffuse interstitial Said et al. 2013

Monoclonal gammopathy of renal significance

Definition and evaluation of MGRS

  • Term. MGRS was introduced in 2012 to indicate a causal relationship between a monoclonal gammopathy and kidney damage (Leung et al. 2012).
  • Current definition. The International Kidney and Monoclonal Gammopathy Research Group (IKMG) defines MGRS as a clonal proliferative disorder producing a nephrotoxic monoclonal immunoglobulin that does not meet criteria for treatment of a specific malignancy. Diagnosis requires kidney biopsy with immunofluorescence (Leung et al. 2019).
  • Classification. Lesions are grouped by immunofluorescence and ultrastructure as organized deposits (fibrillar, microtubular, crystalline or inclusion), non-organized deposits, or no immunoglobulin deposits (Leung et al. 2019).
  • Ancillary studies. IgG subclass staining confirms monotypic intact IgG deposits. Paraffin immunofluorescence after pronase digestion detects masked deposits, and 5%–10% of apparent C3 glomerulonephritis with monoclonal gammopathy proves to be membranoproliferative GN with masked monoclonal deposits (Leung et al. 2019).
  • RPS/IKMG 2025 terminology. The 2025 consensus defines prerequisite (mandatory) and supportive (nonmandatory) diagnostic criteria for each monoclonal gammopathy-associated lesion (Nasr et al. 2025).
Category Lesion Key findings Source
Organized, fibrillar AL, AH, AHL amyloidosis Congo red positive 7–12 nm fibrils Leung et al. 2019
Organized, microtubular Immunotactoid GN; type I and II cryoglobulinemic GN Hollow microtubules 17–52 nm Leung et al. 2019
Organized, crystalline or inclusion Light chain proximal tubulopathy; crystal-storing histiocytosis; crystalglobulin GN Crystals in proximal tubular cells or histiocytes Leung et al. 2019; Perazella and Herlitz 2021
Non-organized Monoclonal immunoglobulin deposition disease Linear punctate deposits along GBM and tubular basement membranes Leung et al. 2019
Non-organized Proliferative GN with monoclonal immunoglobulin deposits Glomerular mesangial and subendothelial deposits of intact immunoglobulin Leung et al. 2019
No immunoglobulin deposits C3 glomerulopathy with monoclonal gammopathy; thrombotic microangiopathy Monoclonal gammopathy in 60%–80% of C3 glomerulopathy patients older than 50 years Leung et al. 2019

Monoclonal immunoglobulin deposition disease

  • Subtypes. Of 64 patients, 51 had light chain, 7 heavy chain and 6 light and heavy chain deposition disease. Mean age was 56 years, and 59% had multiple myeloma (Nasr et al. 2012).
  • Morphology. Nodular mesangial sclerosis was present in 61% (Nasr et al. 2012). Linear punctate deposits line the GBM and tubular basement membranes. Heavy chain deposits usually lack the first constant domain (Leung et al. 2019).
  • Serology and outcome. The serum free light chain ratio was abnormal in all patients tested, whereas serum protein electrophoresis showed an M-spike in 73%. Of 56 patients followed, 39% reached ESRD, and disease recurred in three of four allografts (Nasr et al. 2012). Five-year renal survival was 57% in 88 patients (Kourelis et al. 2016).

Light chain proximal tubulopathy and crystal-storing histiocytosis

  • Crystalline variant. All 40 crystalline cases were κ-restricted and showed acute tubular injury. Antigen retrieval was frequently needed to show the monoclonal light chain, and crystals were visible only by electron microscopy in 5 of 38. Fanconi syndrome prompted biopsy in 38%, all crystalline (Stokes et al. 2016).
  • Non-crystalline variant. Among the six non-crystalline cases, one-third showed λ restriction or acute tubular injury; only crystalline cases frequently needed antigen retrieval (Stokes et al. 2016).
  • Crystalline podocytopathy. κ light chain crystals can involve podocytes as well as proximal tubular cells, and in a reported MGRS case the diagnosis depended on electron and immunoelectron microscopy (Yu et al. 2018).
  • Crystal-storing histiocytosis. Geometric and needle-shaped light chain crystals are present within interstitial histiocytes and cause chronic tubulointerstitial nephritis and Fanconi syndrome (Perazella and Herlitz 2021).

Proliferative glomerulonephritis with monoclonal immunoglobulin deposits

  • Morphology. In 37 patients, patterns were membranoproliferative (57%) or endocapillary proliferative (35%). Granular non-organized deposits stained for a single light chain and a single heavy chain subtype, most often IgG3κ (53%) (Nasr et al. 2009).
  • Clone. A matching serum monoclonal protein was found in 30%, and only one patient had myeloma. ESRD developed in 22% (Nasr et al. 2009).

Fibrillary and immunotactoid glomerulonephritis

  • Fibrillary GN definition. Fibrillary GN has randomly arranged fibrils 10–30 nm thick, on average twice the thickness of amyloid fibrils, which generally do not stain with Congo red (Leung et al. 2019). All 66 cases in one series showed glomerular IgG (Nasr et al. 2011), and the deposits are Congo red negative (Nasr et al. 2018).
  • DNAJB9. DNAJB9 immunohistochemistry showed smudgy glomerular staining with 98% sensitivity and >99% specificity, and immunogold labeling localized it to the fibrils (Nasr et al. 2018).
  • Associations and outcome. Malignancy, dysproteinemia and autoimmune disease were present in 23%, 17% and 15% of patients. The most common pattern was mesangial proliferative or sclerosing GN. ESRD developed in 44%, and disease recurred in 36% of 14 allografts (Nasr et al. 2011).
  • Immunotactoid GN. Microtubules measured 14–60 nm with hollow cores and parallel alignment. Deposits were light chain and IgG subclass restricted in 67%. Hematologic disease was present in 66%, including lymphoma, mainly chronic lymphocytic leukemia/small lymphocytic lymphoma, in 41% (Nasr et al. 2021).
  • Proteomic contrast. Immunotactoid deposits contained large amounts of IgG1 heavy chain constant region (Sethi et al. 2013).
Feature AL amyloidosis Fibrillary GN Immunotactoid GN Source
Congo red Positive Negative Negative Said et al. 2013; Nasr et al. 2018
Substructure Fibrils 7–12 nm Random fibrils 10–30 nm Hollow microtubules 14–60 nm, parallel arrays Leung et al. 2019; Nasr et al. 2021
Immunoglobulin Monotypic light chain Polyclonal IgG in most Monotypic in 67% Nasr et al. 2021
Marker Mass spectrometry typing DNAJB9 IgG subclass restriction Nasr et al. 2018; Vrana et al. 2009

Congenital nephrotic syndrome

  • Definition. Congenital nephrotic syndrome is nephrotic-range proteinuria, hypoalbuminemia and edema manifesting in utero or during the first 3 months of life, usually caused by podocyte gene defects and rarely by congenital infection or maternal alloimmune disease (Boyer et al. 2021).
  • Genetics. Biallelic NPHS1 (nephrin) or NPHS2 (podocin) variants are the most common causes. The Finnish type has an incidence of 1 in 8,000 live births with two NPHS1 founder mutations. WT1-associated glomerulopathy is the most frequent syndromic form, followed by Pierson syndrome (LAMB2) (Lipska-Ziętkiewicz et al. 2020).
  • Diffuse mesangial sclerosis. Diffuse mesangial sclerosis is associated with dominant WT1 variants (23.1%) and biallelic PLCE1 (17.8%), LAMB2 (13.6%) and NPHS1 (4.9%) variants (Lipska-Ziętkiewicz et al. 2020).
  • WT1 genotypes. Missense variants affecting DNA-binding residues cause diffuse mesangial sclerosis with early-onset steroid-resistant nephrotic syndrome. Truncating variants carry about an 80% Wilms tumor risk. Intronic KTS variants present as isolated steroid-resistant nephrotic syndrome with FSGS. Denys–Drash and Frasier syndromes overlap phenotypically (Lipska-Ziętkiewicz et al. 2020); their tumor associations are covered in Pediatric, Mesenchymal and Other Renal Tumors, Nephrectomy Grossing, WHO/ISUP Grading and Kidney Cancer Staging.
  • Genetic testing. Genetic testing is recommended as the first diagnostic test at initial evaluation (Lipska-Ziętkiewicz et al. 2020).

Fabry disease and lipid glomerulopathies

  • Fabry nephropathy. Fabry disease is an X-linked lysosomal storage disease caused by mutations in the gene encoding α-galactosidase A. Globotriaosylceramide (Gb3) accumulates in podocytes, epithelial cells and the tubular cells of the distal tubule and loop of Henle (Waldek and Feriozzi 2014). Electron microscopy shows lamellated lipid inclusions (zebra bodies) in podocyte cytoplasm (Waldek and Feriozzi 2014). Males had more podocyte vacuolization and more tubular, peritubular capillary and vascular inclusions than females, and segmental and global sclerosis and interstitial fibrosis were present even in CKD stages 1–2 (Fogo et al. 2010).
  • Zebra bodies in LCAT deficiency. Zebra bodies also occurred in familial LCAT deficiency with normal α-galactosidase A activity (Rodriguez Mori et al. 2026).
  • LCAT deficiency. Familial lecithin-cholesterol acyltransferase deficiency is autosomal recessive and causes markedly reduced HDL cholesterol, lipoprotein X accumulation, corneal opacity and hemolysis. The biopsy showed FSGS and mesangial expansion (Rodriguez Mori et al. 2026).
  • Lipoprotein glomerulopathy. Lipoprotein glomerulopathy shows lipoprotein thrombi in glomeruli with hyperlipoproteinemia and markedly increased serum apolipoprotein E. More than 12 APOE mutations cause it, including APOE-Sendai (Toyota et al. 2013).

Differential diagnosis of nephrotic glomerular diseases

Entity Light microscopy Immunofluorescence Electron microscopy Source
Minimal change disease Normal or mild mesangial prominence Negative or weak mesangial IgM Extensive foot process effacement Mirioglu et al. 2024
Primary FSGS Segmental sclerosis (Columbia variant) IgM and C3 in sclerotic segments Effacement >80% Mirioglu et al. 2024
Membranous nephropathy Thick GBM, spikes, pinholes Granular capillary loop IgG ± C3 Subepithelial deposits Sethi 2021
Diabetic nephropathy Mesangial expansion, nodules, arteriolar hyalinosis Nonspecific Thick GBM Najafian et al. 2011
Amyloidosis Congo red positive Monotypic light chain in AL 7–12 nm fibrils Leung et al. 2019
Monoclonal immunoglobulin deposition disease Nodular mesangial sclerosis Linear monotypic light or heavy chain Punctate GBM and tubular basement membrane deposits Nasr et al. 2012; Leung et al. 2019
Fibrillary GN Mesangial proliferative or sclerosing Smudgy IgG; DNAJB9 10–30 nm random fibrils Leung et al. 2019; Nasr et al. 2018

Nephritic and Hematuric Glomerular Diseases: IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy, Infection-Related, Cryoglobulinemic, ANCA and Anti-GBM Glomerulonephritis, Alport Syndrome

Related page: Autoantibody Testing in Systemic Autoimmune Rheumatic Diseases: ANA, ENA, Anti-dsDNA, Myositis Antibodies, Rheumatoid Factor and Anti-CCP (ANA and anti-dsDNA) Related page: ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System (ANCA and anti-GBM antibody testing) Related page: Complement Testing, Hereditary Angioedema, Cryoglobulins, Cytokines and Soluble IL-2 Receptor (C3, C4, C3 nephritic factor, cryoglobulins) Related page: Renal Biopsy Evaluation and Nephrotic Glomerular Diseases: Minimal Change Disease, FSGS, Membranous and Diabetic Nephropathy, Amyloidosis and Monoclonal Immunoglobulin Deposition (biopsy handling, pattern definitions, lupus podocytopathy differential with minimal change disease, monoclonal immunoglobulin GN) Related page: Renal Vascular Disease, Thrombotic Microangiopathy and Kidney Transplant Pathology (thrombotic microangiopathy, recurrent GN in the allograft) Related page: DIC, Thrombotic Microangiopathy and Viscoelastic Testing (complement-mediated TMA and ADAMTS13) Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (cryoglobulin typing and immunofixation)

Reporting framework for proliferative glomerulonephritis

IgA nephropathy

Pathogenesis and morphology of IgA nephropathy

  • Epidemiology. IgA nephropathy is the most common primary GN worldwide. Of patients, 30%–40% reach ESKD 20–30 years after presentation (Lai et al. 2016).
  • Pathogenesis. Galactose-deficient IgA1 and glycan-specific IgA and IgG autoantibodies form immune complexes that deposit in the mesangium and activate mesangial cells (Lai et al. 2016).
  • Biopsy. Light microscopy is scored with MEST-C and may be mesangial, endocapillary or crescentic (Trimarchi et al. 2017; Haas et al. 2017).

Oxford MEST-C classification (2016) and the 2009 MEST rule

  • 2009 rule. The 2009 Oxford classification identified mesangial hypercellularity (M), segmental glomerulosclerosis (S), endocapillary hypercellularity (E) and interstitial fibrosis/tubular atrophy (T) as reproducible lesions with independent prognostic value (Roberts et al. 2009; Cattran et al. 2009). Crescents were not scored because of their low prevalence in the original cohort (Cattran et al. 2009).
  • 2016 update. The 2016 update added a crescent score, so the report gives a MEST-C score. M, S and T predict outcome in specimens with at least 8 glomeruli. E lesions predict outcome only in patients without immunosuppression (Trimarchi et al. 2017).
  • Crescent evidence. In 3,096 patients, crescents in at least one fourth of glomeruli were associated with a hazard ratio of 2.29 for a ≥50% decline in eGFR or ESRD (Haas et al. 2017).
Score Definition Source
M0 / M1 M1: mean mesangial score >0.5 (score 0: <4 cells; 1: 4–5; 2: 6–7; 3: ≥8 cells in the most cellular mesangial area, excluding the vascular pole) Haas et al. 2017
E0 / E1 Endocapillary hypercellularity absent or present Haas et al. 2017
S0 / S1 Segmental sclerosis absent or present Haas et al. 2017
T0 / T1 / T2 Interstitial fibrosis and tubular atrophy ≤25%, 26%–50%, >50% of cortex Haas et al. 2017
C0 / C1 / C2 (2016 addition) No cellular or fibrocellular crescents; crescents in <1/4 of glomeruli; crescents in ≥1/4 of glomeruli Haas et al. 2017; Trimarchi et al. 2017
  • KDIGO 2025. The 2025 IgA nephropathy guideline encourages a more liberal biopsy policy and sets a proteinuria target of <0.5 g/d, ideally <0.3 g/d. Treatment combines therapy that reduces pathogenic IgA and immune complex formation with supportive therapy for nephron loss (Floege et al. 2025).

IgA vasculitis nephritis

  • Histology. IgA vasculitis nephritis is morphologically indistinguishable from IgA nephropathy (Barbour et al. 2024).
  • MEST-C in IgA vasculitis. In 262 children and 99 adults, M, E, T and C correlated with eGFR or proteinuria at biopsy. In immunosuppressed patients, E1, age ≤18 years, male sex, lower eGFR and extrarenal noncutaneous disease were associated with late eGFR decline. Fibrous crescents without active lesions were associated with stable eGFR (Barbour et al. 2024).
  • Adults. Among 250 adults, endocapillary GN was the most frequent lesion (61%). Interstitial fibrosis, percentage of sclerotic glomeruli and fibrinoid necrosis predicted poor renal outcome, and 11% reached ESKD (Pillebout et al. 2002). In a French series of 260 adults, GN was present in 70% and renal failure in 30% (Audemard-Verger et al. 2017).
  • Terminology. Adult infections are often ongoing at diagnosis, so the term infection-related GN replaces postinfectious GN in adults (Nasr et al. 2013).
  • Adult disease. In 86 adults, the mean age was 56 years, 38.4% were immunocompromised (diabetes 29.1%), and streptococcus (27.9%) and staphylococcus (24.4%) were the leading organisms. Hypocomplementemia was present in 73.9%. Diffuse proliferative GN (72.1%) was the dominant pattern (Nasr et al. 2008).
  • Outcome. Without diabetic glomerulosclerosis, 56.1% achieved complete remission and 17.1% reached ESKD. With diabetic glomerulosclerosis, 81.8% reached ESKD (Nasr et al. 2008).
  • Sites. Adult infections involve the upper respiratory tract, skin, lung, heart, urinary tract, teeth and bone. Nephritogenic streptococcal antigens include glyceraldehyde-3-phosphate dehydrogenase and pyrogenic exotoxin B (Nasr et al. 2013).
  • IgA-dominant infection-related GN. In 13 cases, IgA-dominant deposits accompanied subepithelial humps. Six patients had recent Staphylococcus aureus infection and five were diabetic (Haas et al. 2008).
  • Endocarditis. Heart and endocarditis infections accounted for 11.6% of adult cases (Nasr et al. 2008).
  • Shunt nephritis. Of 79 reported patients with infected cerebrospinal fluid shunts, 62 had biopsies, which mostly showed mesangial proliferative or membranoproliferative GN. Immunofluorescence most often showed mesangial IgM, C1q and C3, and electron microscopy showed subendothelial deposits in 18 of 28 biopsies examined. Coagulase-negative staphylococci were the predominant organisms when cultures were positive (Babigumira et al. 2017).
  • C3-dominant pattern. Typical postinfectious GN beyond the acute stage may show C3 without immunoglobulin. A biopsy is then reported as "GN with dominant C3", and C3 glomerulopathy is reconsidered if serum C3 does not normalize within 8–12 weeks (Pickering et al. 2013).

C3 glomerulopathy and membranoproliferative glomerulonephritis

  • Definition. C3 glomerulopathy is a disease process caused by abnormal control of complement activation, deposition or degradation, with predominant glomerular C3 and electron-dense deposits (Pickering et al. 2013).
  • Immunofluorescence threshold. "GN with dominant C3" is defined as C3 at least two orders of magnitude more intense than any other immune reactant on a 0–3+ scale (Pickering et al. 2013). This definition identified 88% of dense deposit disease, compared with 50% for a "C3 only" definition (Hou et al. 2014).
  • Dense deposit disease and C3 glomerulonephritis. Dense deposit disease has very electron-dense osmiophilic, band-like intramembranous deposits and rounded mesangial deposits, often in Bowman capsule and tubular basement membranes. C3 glomerulonephritis has less dense, ill-defined mesangial, subendothelial, intramembranous and subepithelial deposits. Both may show subepithelial humps (Pickering et al. 2013).
  • Light microscopy. Patterns include mesangial proliferative, membranoproliferative and endocapillary proliferative GN, with or without crescents (Pickering et al. 2013).
  • Mechanism. C3 glomerulopathy results from alternative pathway dysregulation. Most cases are caused by autoantibodies to C3 or C5 convertases, and genetic variants are less frequent (Smith et al. 2019). Acquired causes include C3 nephritic factors and anti-factor B and anti-factor H antibodies. CFHR5 nephropathy is a familial C3 glomerulonephritis caused by an internal CFHR5 duplication (Pickering et al. 2013).
  • Workup. Complement and paraprotein testing for C3 glomerulopathy is covered in Complement Testing, Hereditary Angioedema, Cryoglobulins, Cytokines and Soluble IL-2 Receptor. The association with monoclonal gammopathy in patients older than 50 years is covered in Renal Biopsy Evaluation and Nephrotic Glomerular Diseases: Minimal Change Disease, FSGS, Membranous and Diabetic Nephropathy, Amyloidosis and Monoclonal Immunoglobulin Deposition.
  • Atypical postinfectious GN. Most patients with persistent "atypical" postinfectious GN had alternative pathway defects, including complement regulator mutations and C3 nephritic factors (Sethi et al. 2013a).
  • Outcomes. In 32 patients with dense deposit disease, 26% reached ESKD, and adults fared worse than children (Nasr et al. 2009). Recurrence in the allograft is covered in Renal Vascular Disease, Thrombotic Microangiopathy and Kidney Transplant Pathology.
Feature C3 glomerulonephritis Dense deposit disease Immune-complex MPGN Infection-related GN Source
Immunofluorescence C3 ≥2 orders above immunoglobulin C3 ≥2 orders above immunoglobulin Immunoglobulin with complement Immunoglobulin and C3; C3 alone in late phase Pickering et al. 2013; Sethi et al. 2016
Electron microscopy Ill-defined, less dense deposits; humps possible Highly osmiophilic intramembranous deposits Subendothelial deposits Subepithelial humps Pickering et al. 2013
Mechanism Alternative pathway dysregulation Alternative pathway dysregulation Immune complexes from infection or autoimmune disease Infection-triggered immune complexes Smith et al. 2019; Sethi et al. 2016

Lupus nephritis

ISN/RPS classification: 2018 revision and the 2003 rule

  • Classes. Class I and II are purely mesangial (I without, II with mesangial hypercellularity). Class III is focal GN in <50% of glomeruli and class IV diffuse GN in ≥50%. Class V is membranous lupus nephritis and class VI advanced sclerosing lupus nephritis. Combined classes III+V or IV+V are reported individually (Weening et al. 2004).
  • 2018 changes. The 2018 revision provided new definitions of mesangial hypercellularity and of cellular, fibrocellular and fibrous crescents. It eliminated the term "endocapillary proliferation" in favor of endocapillary hypercellularity, eliminated the IV-S and IV-G subdivisions and replaced the A, C and A/C designations with modified NIH activity and chronicity indices applied to all classes (Bajema et al. 2018).
  • Previous rule (2003). Class IV was subdivided into segmental (IV-S) and global (IV-G) involvement, and classes III and IV carried active (A), chronic (C) or active and chronic (A/C) designations (Weening et al. 2004).
  • KDIGO 2024 treatment summary. For active class III or IV lupus nephritis, KDIGO 2024 recommends glucocorticoids with mycophenolic acid analogs, low-dose intravenous cyclophosphamide, belimumab combinations or, with eGFR >45 mL/min/1.73 m², a mycophenolic acid analog with a calcineurin inhibitor; class I or II disease with nephrotic-range proteinuria is treated as minimal change disease (Rossi and Vaglio 2025).
  • Practice survey. The 2018 ISN/RPS classification and the modified NIH activity and chronicity indices are used by 92.4% and 88.1% of responding RPS members (Uzzo et al. 2026a).
Class Definition Source
I Mesangial immune deposits without mesangial hypercellularity Weening et al. 2004
II Mesangial immune deposits with mesangial hypercellularity, defined in 2018 as four or more nuclei fully surrounded by matrix in the mesangial area Weening et al. 2004; Bajema et al. 2018; Moon 2026
III Focal GN involving <50% of glomeruli Weening et al. 2004
IV Diffuse GN involving ≥50% of glomeruli; IV-S and IV-G subdivisions removed in 2018 Weening et al. 2004; Bajema et al. 2018
V Membranous lupus nephritis, alone or reported with III or IV Weening et al. 2004
VI Advanced sclerosing lesions Weening et al. 2004

Modified NIH activity and chronicity indices

  • Scoring. Each lesion is scored 0–3 by the percentage of glomeruli or interstitium involved (<25% = 1, 25%–50% = 2, >50% = 3). Fibrinoid necrosis and cellular or fibrocellular crescents are weighted twice. The activity index ranges from 0 to 24 and the chronicity index from 0 to 12 (Bajema et al. 2018; Choi et al. 2023).
  • 2018 modification. Karyorrhexis was separated from fibrinoid necrosis and combined with neutrophil infiltration (Choi et al. 2023).
  • Observed ranges. In 194 biopsies, the highest observed activity index was 16 and chronicity index 10. Endocapillary hypercellularity was present in >70% of biopsies and correlated with neutrophils/karyorrhexis (Querin et al. 2026).
Index Lesion Score Source
Activity (0–24) Endocapillary hypercellularity 0–3 Bajema et al. 2018; Choi et al. 2023
Activity Neutrophils and karyorrhexis 0–3 Bajema et al. 2018; Choi et al. 2023
Activity Fibrinoid necrosis 0–3, ×2 Bajema et al. 2018; Choi et al. 2023
Activity Hyaline deposits (wire loops, hyaline thrombi) 0–3 Bajema et al. 2018; Choi et al. 2023
Activity Cellular or fibrocellular crescents 0–3, ×2 Bajema et al. 2018; Choi et al. 2023
Activity Interstitial inflammation 0–3 Bajema et al. 2018; Choi et al. 2023
Chronicity (0–12) Total glomerulosclerosis (global and segmental) 0–3 Bajema et al. 2018; Choi et al. 2023
Chronicity Fibrous crescents 0–3 Bajema et al. 2018; Choi et al. 2023
Chronicity Tubular atrophy 0–3 Bajema et al. 2018; Choi et al. 2023
Chronicity Interstitial fibrosis 0–3 Bajema et al. 2018; Choi et al. 2023

Tubuloreticular inclusions, lupus podocytopathy and thrombotic microangiopathy in lupus nephritis

  • Tubuloreticular inclusions. Endothelial tubuloreticular inclusions were found in 63.3% of 327 lupus nephritis biopsies. They were associated with lower chronicity, more segmental necrosis and type I interferon activation (Wei et al. 2026).
  • Membranous lupus antigens. The membranous antigen table, including EXT1/EXT2 and NCAM1 in class V lupus nephritis, is in Renal Biopsy Evaluation and Nephrotic Glomerular Diseases: Minimal Change Disease, FSGS, Membranous and Diabetic Nephropathy, Amyloidosis and Monoclonal Immunoglobulin Deposition.
  • Lupus podocytopathy. Diffuse foot process effacement without capillary wall immune deposits or proliferation was found in 50 of 3,750 lupus biopsies (1.33%). Patterns were minimal change (13), mesangial proliferation (28) and FSGS (9). All had nephrotic syndrome, and 94% remitted with immunosuppression (Hu et al. 2016).
  • Thrombotic microangiopathy. Renal TMA was found in 36 of 148 lupus nephritis biopsies and was an independent risk factor for poor renal outcome (hazard ratio 2.772) (Song et al. 2013).

Anti-glomerular basement membrane disease

  • Classic disease. Bright linear polytypic IgG along the GBM accompanies diffuse crescentic and necrotizing GN, with or without pulmonary hemorrhage (Nasr et al. 2016). Circulating ANCA, usually MPO, are found in 30%–40% of patients (McAdoo and Pusey 2025); ANCA and anti-GBM serology is covered in ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System.
  • Synchronous crescents. Synchronous crescents tended to be more frequent in single-positive anti-GBM disease than in double-positive disease (73% versus 33%; P = 0.092) (McAdoo et al. 2017).
  • Double-positive disease. Biopsies from patients with ANCA and anti-GBM antibodies showed more chronic damage (median interstitial fibrosis 27% compared with 5%) (McAdoo et al. 2017). Renal survival and relapse are covered in ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System.
  • Atypical anti-GBM nephritis. In 20 patients, linear GBM immunoglobulin occurred without diffuse crescents or pulmonary hemorrhage and without circulating α3NC1 antibodies. Patterns were endocapillary, mesangial or membranoproliferative, and the deposits were monotypic in 10 (Nasr et al. 2016). IgA- and IgM-mediated disease and anti-GBM assay limitations are covered in ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System.
  • Prognosis. The ANCA renal risk score also applies to anti-GBM disease. Renal survival at 36 months was 96.4% without dialysis and ≥10% normal glomeruli, and 14.1% with dialysis and <10% normal glomeruli (Floyd et al. 2023).

ANCA-associated glomerulonephritis

  • Definition. Pauci-immune necrotizing and crescentic GN has negative or scant immunoglobulin, and 80%–90% of patients have ANCA. The diagnosis names the clinicopathologic phenotype and the ANCA specificity, for example MPO-ANCA microscopic polyangiitis (Sethi et al. 2016; Jennette et al. 2013).
  • MPO versus PR3. Glomerulosclerosis was more extensive with MPO-ANCA. Interstitial fibrosis, tubular necrosis and tubular atrophy were more frequent with MPO-ANCA than with PR3-ANCA. Normal glomeruli were more common in granulomatosis with polyangiitis than in microscopic polyangiitis (Hauer et al. 2002).
  • Berden classification. Focal: ≥50% normal glomeruli. Crescentic: ≥50% of glomeruli with cellular crescents. Sclerotic: ≥50% globally sclerotic glomeruli. Mixed: <50% normal, <50% crescentic and <50% globally sclerotic glomeruli. The class predicts 1- and 5-year renal outcome (Berden et al. 2010; Uzzo et al. 2026b).
  • KDIGO 2024 treatment summary. KDIGO 2024 recommends avacopan as an alternative to glucocorticoids and suggests 18–48 months of remission maintenance (Chau et al. 2025).
  • ANCA renal risk score. Points are assigned for the percentage of normal glomeruli (N0 >25% = 0; N1 10%–25% = 4; N2 <10% = 6), tubular atrophy and interstitial fibrosis (T0 ≤25% = 0; T1 >25% = 2) and eGFR (G0 >15 mL/min/1.73 m² = 0; G1 ≤15 = 3). Totals of 0, 2–7 and 8–11 define low, intermediate and high risk, with 36-month ESKD of 0%, 26% and 68% in the training cohort (Brix et al. 2018).
Tool Components Risk groups Source
Berden class Focal ≥50% normal; crescentic ≥50% cellular crescents; sclerotic ≥50% globally sclerotic; mixed otherwise Predicts 1- and 5-year renal outcome Berden et al. 2010; Uzzo et al. 2026b
ANCA renal risk score Normal glomeruli, tubular atrophy/interstitial fibrosis, eGFR Low 0; intermediate 2–7; high 8–11 points Brix et al. 2018

Cryoglobulinemic glomerulonephritis

  • Cryoglobulin types. Cryoglobulin typing is covered in Complement Testing, Hereditary Angioedema, Cryoglobulins, Cytokines and Soluble IL-2 Receptor. Only type I and II cryoglobulinemia are MGRS-associated (Leung et al. 2019).
  • HCV-related disease. In 146 Italian patients, 87% had HCV infection, diffuse membranoproliferative GN was present in 83%, and type II IgMκ cryoglobulin in 74.4% (Roccatello et al. 2007).
  • Morphology. Cryoglobulinemic GN shows a membranoproliferative pattern with intracapillary hyaline pseudothrombi (Sethi et al. 2016). Deposits may be microtubular, and glomerular protein thrombi and vasculitis distinguish it from immunotactoid GN (Leung et al. 2019). Apolipoprotein E is absent from cryoglobulinemic deposits (Sethi et al. 2013b).

Alport syndrome and thin basement membrane nephropathy

  • Genetics. X-linked Alport syndrome is caused by COL4A5 variants, and autosomal recessive Alport syndrome by biallelic COL4A3 or COL4A4 variants (Torra et al. 2025).
  • Biopsy findings prompting genetic testing. Basket-weave lamellation or irregular bulging of the GBM, thinned GBM, electron-dense GBM deposits that differ from immune complexes, GBM lucencies and abnormal collagen IV chain immunostaining prompt testing of COL4A3, COL4A4 and COL4A5 (Torra et al. 2025).
  • Collagen IV immunostaining. Electron microscopy alone does not reliably separate thin basement membrane nephropathy, X-linked carriers, autosomal recessive and early X-linked Alport syndrome. Immunostaining for α3(IV) and α5(IV) resolves most cases (Haas 2009).
  • Heterozygous COL4A3 or COL4A4 variants (ERKNet 2024). These variants occur in about 1 in 106 people. Labels in use include thin basement membrane nephropathy, autosomal dominant Alport syndrome, type IV collagen-associated kidney disease and Alport spectrum nephropathy. The guideline states that the term "benign" (as in benign familial hematuria) should no longer be used. Risk of kidney failure is <3% by age 60 years (Torra et al. 2025).
  • Previous rule. Thin basement membrane nephropathy was treated as a separate condition, with genetic testing considered in some patients to exclude X-linked Alport syndrome (Savige et al. 2013).
  • Biopsy in heterozygotes. Light microscopy may be normal or show FSGS, mesangial proliferation or IgA deposits, while electron microscopy usually shows GBM thinning (Torra et al. 2025).
  • Thin GBM threshold. Thin basement membrane nephropathy is usually defined as GBM thickness <250 nm. Patients with 250–320 nm had a similar course (Szeto et al. 2010). The effect of paraffin reprocessing on GBM thickness is covered in Renal Biopsy Evaluation and Nephrotic Glomerular Diseases: Minimal Change Disease, FSGS, Membranous and Diabetic Nephropathy, Amyloidosis and Monoclonal Immunoglobulin Deposition.
  • IgA nephropathy with thin GBM. Diagnostic COL4A3–COL4A5 variants were found in 31.1% of IgA nephropathy patients with thinned GBM (Yuan et al. 2023).
  • Biopsy indication. A kidney biopsy is not needed when X-linked or autosomal recessive Alport syndrome is genetically confirmed (Torra et al. 2025).

Differential diagnosis of nephritic glomerular diseases

Entity Immunofluorescence Electron microscopy Distinguishing feature Source
IgA nephropathy Mesangial IgA1-containing deposits Mesangial deposits MEST-C score Trimarchi et al. 2017
IgA-dominant infection-related GN IgA dominant with C3 Subepithelial humps Staphylococcal infection; diabetes Haas et al. 2008
Lupus nephritis Immunoglobulin and complement in multiple compartments Tubuloreticular inclusions ISN/RPS class with NIH indices Weening et al. 2004; Wei et al. 2026
C3 glomerulopathy C3 ≥2 orders above immunoglobulin Dense or ill-defined deposits Alternative pathway dysregulation Pickering et al. 2013
Anti-GBM disease Linear GBM IgG No deposits Synchronous crescents Sethi et al. 2016; McAdoo et al. 2017
ANCA GN Negative or scant No or few deposits MPO or PR3 ANCA; Berden class Sethi et al. 2016; Berden et al. 2010
Cryoglobulinemic GN IgM and IgG; IgMκ in type II Microtubular deposits possible Pseudothrombi; HCV Roccatello et al. 2007; Leung et al. 2019
Alport syndrome Abnormal collagen IV α3/α5 Basket-weave GBM lamellation COL4A3–COL4A5 variants Torra et al. 2025; Haas 2009

modified NIH activity and chronicity index calculator for lupus nephritis

Tubulointerstitial, Obstructive, Cystic and Developmental Kidney Disease

Related page: Renal Biopsy Evaluation and Nephrotic Glomerular Diseases: Minimal Change Disease, FSGS, Membranous and Diabetic Nephropathy, Amyloidosis and Monoclonal Immunoglobulin Deposition (MGRS lesions, light chain proximal tubulopathy, crystal-storing histiocytosis) Related page: Renal Cell Carcinoma and Oncocytic Renal Tumors (acquired cystic disease-associated renal cell carcinoma, SMARCB1-deficient renal medullary carcinoma) Related page: Renal Vascular Disease, Thrombotic Microangiopathy and Kidney Transplant Pathology (infarction, cortical necrosis, BK polyomavirus nephropathy) Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (serum free light chains in cast nephropathy) Related page: Liver, Kidney and Gastrointestinal Function Tests (AKI indices, urinalysis, stones)

Acute tubular injury

  • Acute tubular injury and necrosis. Acute tubular injury shows tubular dilatation, simplification of the lining epithelium, loss of the proximal brush border, loss of nuclei and regenerative mitoses. Acute tubular necrosis, with coagulative necrosis and detachment from the basement membrane, is much less common, except in cortical necrosis from an acute ischemic process (Gaut and Liapis 2021).
  • Grading of acute tubular injury. Acute tubular injury is graded semiquantitatively as mild, moderate or severe, or as focal or diffuse, and it affects proximal and distal tubules (Gaut and Liapis 2021).
  • Ischemic and toxic acute tubular injury. Ischemic acute tubular injury follows hemodynamic compromise. Toxic acute tubular injury follows drugs, including aminoglycosides, vancomycin, chemotherapy, immunotherapy and cocaine. Drugs are so common a cause that drug exposure is excluded first (Gaut and Liapis 2021).
  • Ischemic and toxic acute tubular necrosis. Ischemic acute tubular necrosis shows patchy, focal tubular necrosis with tubulorrhexis (disruption of the tubular basement membrane). Toxic acute tubular necrosis shows more continuous necrosis of proximal tubules with intact basement membranes (owner review, board-certified pathologist).
  • Osmotic nephrosis and isometric vacuolization. Osmotic nephrosis is vacuolization and swelling of proximal tubular cells caused by accumulation of lysosomes after exogenous solutes such as sucrose, hydroxyethyl starch, dextrans and contrast media. It is a nonspecific pattern and can cause AKI (Dickenmann et al. 2008). Isometric tubular vacuolization, usually from swollen lysosomes, is typical of acute calcineurin inhibitor toxicity and also follows intravenous immunoglobulin, dextran and contrast media (Gaut and Liapis 2021).
  • Myoglobin cast nephropathy. In 57 cases confirmed by myoglobin immunohistochemistry on biopsies with pigment casts, acute tubular injury was present in all. Rhabdomyolysis had been suspected clinically in only 31, and snake envenomation and unaccustomed exertion were frequent causes (Jansi Prema and Kurien 2021).
  • Hemoglobin cast nephropathy. When haptoglobin is saturated, free hemoglobin is filtered, taken up by proximal tubules and forms casts with Tamm–Horsfall protein. Translucent hemoglobin casts are confirmed by hemoglobin immunohistochemistry with a negative myoglobin stain, because myoglobin, hemoglobin, myeloma and Tamm–Horsfall protein casts overlap on H&E. Chronic hemolysis causes tubular hemosiderin, shown by Prussian blue (Gaut and Liapis 2021).
  • Anticoagulant-related nephropathy. The biopsy shows many intratubular red blood cell casts with tubular epithelial thinning, luminal dilatation and loss of the brush border. Red blood cell casts from hematuric glomerular diseases such as IgA nephropathy also cause obstructive acute tubular injury (Gaut and Liapis 2021).
  • Bile cast nephropathy. Bile or bilirubin casts obstruct nephrons, usually the distal tubules. Bile casts require sustained liver disease with high serum bilirubin (Gaut and Liapis 2021).
  • Lysozyme nephropathy. Lysozyme from myelomonocytic cells, as in chronic myelogenous leukemia, or from high macrophage turnover, as in sarcoidosis, is filtered and absorbed by proximal tubular cells, causing acute tubular injury (Gaut and Liapis 2021).

Acute and chronic interstitial nephritis

Drug-induced and checkpoint inhibitor interstitial nephritis

  • Drug-induced AIN. Drugs cause 60%–70% of acute interstitial nephritis (AIN). The lesion consists of interstitial inflammation, tubulitis and edema, sometimes progressing to fibrosis. Diagnosis requires biopsy, because gallium scintigraphy and eosinophiluria have limited utility (Perazella and Markowitz 2010).
  • Drug classes and eosinophils. Most drug-induced AIN is caused by NSAIDs or antibiotics, mainly β-lactams, and fever, rash and eosinophilia occur in 27%–36%, 15%–22% and 23%–35% of patients. In 29 biopsied patients, interstitial eosinophils were present in 79.3% and eosinophiluria in 20.6% (Ramachandran et al. 2015). Current proton pump inhibitor use carried a matched odds ratio of 5.16 for AIN (Blank et al. 2014).
  • Checkpoint inhibitors. Of 13 biopsied patients with checkpoint inhibitor AKI, 12 had acute tubulointerstitial nephritis, 3 with granulomatous features. Median latency was 91 days (Cortazar et al. 2016).
  • Multicenter data. Tubulointerstitial nephritis was the dominant lesion in 93% of 60 biopsies. Proton pump inhibitor use, combination checkpoint therapy and lower baseline eGFR increased the risk. Median latency was 14 weeks, and 43% had extrarenal immune-related adverse events (Cortazar et al. 2020).
  • IgG4-related TIN. All 35 cases showed plasma cell-rich TIN, most with expansile interstitial fibrosis, and eosinophils were present in all but four. Tubular basement membrane immune complex deposits were present in 83%. IgG4 immunostaining had 100% sensitivity and 92% specificity, after excluding pauci-immune necrotizing and crescentic GN. Other organs were involved in 83% (Raissian et al. 2011).
  • IgG4 counts. Moderate (11–30 per high-power field) or marked (>30 per high-power field) IgG4+ plasma cells also occurred in 17% of control biopsies, including pauci-immune GN and drug-induced TIN (Raissian et al. 2011).
  • Sarcoidosis. Of 47 patients, 37 had noncaseating granulomatous interstitial nephritis and 10 had interstitial nephritis without granulomas. Hypercalcemia was present in 32%, and renal function improved with corticosteroids (Mahévas et al. 2009).
  • Sjögren syndrome. Of 24 biopsied patients, 17 had TIN as the primary lesion, chronic in 11. Cryoglobulinemic GN and FSGS each occurred in two (Maripuri et al. 2009).
  • TINU syndrome. Tubulointerstitial nephritis and uveitis affects females twice as often as males, with a median age of 19 years. At follow-up, 40% had GFR <90 mL/min/1.73 m² (Southgate et al. 2023).
  • Lithium. Long-term lithium causes slowly progressive chronic TIN, with a mean latency of 20 years to ESKD. Fibrosis correlated with duration and cumulative dose (Presne et al. 2003).
  • Aristolochic acid. Aristolochic acid nephropathy is a rapidly progressive interstitial fibrosis caused by medicinal or environmental exposure (Zhou et al. 2023).
Pattern Leading causes Distinguishing finding Source
Drug-induced AIN NSAIDs, β-lactam antibiotics, proton pump inhibitors Interstitial inflammation, tubulitis, edema; eosinophils in most biopsies Perazella and Markowitz 2010; Ramachandran et al. 2015; Blank et al. 2014
Checkpoint inhibitor TIN Immune checkpoint inhibitors; risk raised by proton pump inhibitors Granulomatous features in a subset; long latency Cortazar et al. 2016; Cortazar et al. 2020
Granulomatous interstitial nephritis Sarcoidosis; checkpoint inhibitors Noncaseating granulomas; hypercalcemia in sarcoidosis Mahévas et al. 2009; Cortazar et al. 2016
IgG4-related TIN IgG4-related disease Plasma cell-rich expansile fibrosis; IgG4+ cells; tubular basement membrane deposits Raissian et al. 2011
Sjögren syndrome Primary Sjögren syndrome Chronic TIN Maripuri et al. 2009
TINU syndrome Idiopathic Bilateral uveitis Southgate et al. 2023

Pyelonephritis, xanthogranulomatous pyelonephritis and malakoplakia

  • Acute pyelonephritis. Acute pyelonephritis shows neutrophils within tubules and the interstitium, neutrophil (white cell) casts and patchy, often wedge-shaped involvement, usually from ascending infection (owner review, board-certified pathologist).
  • Xanthogranulomatous pyelonephritis. This form of chronic pyelonephritis destroys renal parenchyma and replaces it with foam cells. It usually occurs in middle-aged women with ureteral obstruction or chronic infection caused by renal stones, and produces the "bear paw" sign on CT (Garrido-Abad et al. 2018). It is correctly identified before surgery in less than half of cases, and radical nephrectomy remains the definitive treatment (Mehr et al. 2026).
  • Malakoplakia. Defective macrophage phagolysosomal function leaves bacteria incompletely digested. Histiocytes contain Michaelis–Gutmann bodies, basophilic concretions highlighted by von Kossa and Perls stains. It is associated mainly with gram-negative infection, especially Escherichia coli. Of 52 immunocompromised patients, 19.2% had genitourinary disease, including renal allograft involvement (Bishara et al. 2026).
  • Chronic pyelonephritis. Chronic pyelonephritis shows a prominent inflammatory component, sclerotic glomeruli or periglomerular fibrosis, clusters of atrophic tubules with thick replicated basement membranes, atrophic tubules with colloid casts (thyroidization) and dense interstitial fibrosis. These findings are absent in segmental hypoplasia (Ask-Upmark kidney) (Bonsib 2020). Vesicoureteral reflux is listed in the CAKUT table.
  • Reflux nephropathy. Intrarenal reflux enters compound papillae, which have open orifices perpendicular to the papillary surface and lie mainly at the upper and lower poles. Simple papillae have oblique, closed apertures. Parenchymal scars correspond to the sites of intrarenal reflux. Scars developed in 43% of kidneys with urinary tract infection and high-grade vesicoureteral reflux and in 8% with low-grade reflux (Saraga et al. 2024).
  • Segmental hypoplasia and reflux. Vesicoureteral reflux is found in 70%–80% of segmental hypoplasia (Ask-Upmark kidney), which shows a female predominance (72%) and renin-mediated hypertension (Bonsib 2020).

Crystalline nephropathies

Crystal Setting Biopsy appearance Polarization Source
Calcium oxalate Enteric hyperoxaluria (gastric bypass), vitamin C, primary hyperoxaluria Translucent to pale blue fan-like or sunburst crystals in tubules and interstitium Positive birefringence Perazella and Herlitz 2021; Nasr et al. 2024
Calcium phosphate Oral sodium phosphate bowel purgative (acute phosphate nephropathy) Granular bluish-purple deposits; von Kossa positive Not birefringent Perazella and Herlitz 2021; Markowitz et al. 2005
2,8-Dihydroxyadenine Adenine phosphoribosyltransferase deficiency Irregular, fan-like intratubular crystals, faint brownish-green on H&E and PAS, light blue on trichrome, silver positive on Jones; also intracellular and interstitial Strongly birefringent; Maltese cross in urine Perazella and Herlitz 2021; Helgudottir et al. 2026
Methotrexate High-dose methotrexate Annular aggregates of needle-shaped yellow, golden or brown crystals; black on Jones silver Positive birefringence Perazella and Herlitz 2021
Indinavir, atazanavir HIV protease inhibitors Translucent needle-shaped intratubular crystals with monocytes and giant cells Positive birefringence Perazella and Herlitz 2021
Acyclovir Rapid intravenous infusion Needle-shaped intratubular crystals Positive birefringence Perazella and Herlitz 2021
Ciprofloxacin Fluoroquinolone therapy Needle-shaped intratubular crystals Strong birefringence Perazella and Herlitz 2021
Triamterene Diuretic therapy Yellow-brown crystals on H&E and PAS; silver positive Strong birefringence Perazella and Herlitz 2021
Light chain crystals Monoclonal gammopathy Geometric crystals in proximal tubular cells, histiocytes or casts Negative or weak birefringence in urine Perazella and Herlitz 2021
  • Crystal injury. Crystals injure tubules by obstruction, direct cytotoxicity and secondary inflammation (Perazella and Herlitz 2021).
  • Acute phosphate nephropathy. Of 31 nephrocalcinosis biopsies, 21 followed oral sodium phosphate bowel preparation in normocalcemic patients, mostly older women with hypertension treated with ACE inhibitors or angiotensin receptor blockers. All 21 developed chronic renal insufficiency or dialysis dependence (Markowitz et al. 2005). Calcium phosphate precipitates in the distal tubules and collecting ducts when hypovolemia increases proximal reabsorption and a large phosphate load reaches the distal nephron (Markowitz and Perazella 2009).
  • Secondary oxalate nephropathy. Of 113 patients, causes were enteric hyperoxaluria (60%, most often Roux-en-Y gastric bypass), excessive ingestion of oxalate or precursors such as vitamin C (23%) and idiopathic disease (17%). Kidney failure developed in 54%, and interstitial fibrosis and tubular atrophy predicted it better than crystal burden (Nasr et al. 2024).
  • Uric acid nephropathy. Acute uric acid nephropathy presents with oliguric or anuric AKI and most often follows massive tumor lysis. Chronic uric acid (gouty) nephropathy causes granulomas and interstitial fibrosis (Gaut and Liapis 2021).
  • Urate crystals. Urate crystals are needle-shaped and dissolve in formalin, so alcohol fixation preserves them. Chronic urate nephropathy forms medullary tophi surrounded by giant cells (owner review, board-certified pathologist).

Light chain cast nephropathy

  • Mechanism. Monoclonal free light chains coprecipitate with Tamm–Horsfall protein (uromodulin) in the distal nephron and form obstructive casts (Wang et al. 2026). Light chain cast nephropathy is a myeloma-defining event (Martins et al. 2024), although it is not exclusive to myeloma and occurs rarely in Waldenström macroglobulinemia (Leung et al. 2019).
  • Morphology. Casts in distal tubules are PAS negative or pale with a fractured appearance and κ or λ restriction (Wang et al. 2026). Trichrome shows polychromatophilic casts with a giant cell reaction around fractured casts (Martins et al. 2024).
  • Electron microscopy. Multiple fracture planes, crystals or amyloid in the casts and reactive lining cells were present in 95.2% of myeloma cast nephropathy and in none of the casts from 10 patients with other kidney diseases, most of which stained for both κ and λ, IgA and IgM (Herrera et al. 2024).
  • Uromodulin-negative casts. Tamm–Horsfall protein immunostaining was negative in 40.6% of cases, which had more AKI, dialysis dependence and tubular injury (Wang et al. 2026).
  • Non-myeloma cast nephropathy. Of 23 patients, 14 had IgM lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Casts per square millimeter correlated inversely with eGFR (Martins et al. 2024). Tamm–Horsfall protein extravasation was present in 26% of these biopsies (Martins et al. 2024).
  • Clinical clue. About 80%–90% of patients meet myeloma criteria after workup. Disparity between a negative or trace dipstick albumin and nonalbumin proteinuria suggests light chains (Perazella and Herlitz 2021).

Papillary necrosis, obstruction and sickle cell nephropathy

  • Papillary necrosis. Renal papillary necrosis is a descriptive term. Causes include diabetes, analgesic use, sickle cell disease, pyelonephritis, renal vein thrombosis, tuberculosis and obstructive uropathy. The medulla and papillae are vulnerable to ischemia because of their blood supply and hypertonic environment. Sloughed papillae cause hydronephrosis and filling defects (Jung et al. 2006).
  • Obstructive uropathy. Lower urinary tract obstruction occurs in 2–3 per 10,000 births, most often from posterior urethral valves. Ureteropelvic junction obstruction occurs in 0.5–1 per 1,000 and presents with hydronephrosis alone (Brockwell et al. 2024).
  • Sickle cell nephropathy. Hypoxia, acidosis and hyperosmolality in the medulla promote HbS polymerization. Histologic findings include capillary congestion, mesangial proliferation, GBM reduplication, tubular iron deposition, vasa recta congestion and interstitial fibrosis. FSGS is the major glomerular lesion, and papillary necrosis follows vasa recta occlusion (Nath and Hebbel 2015).
  • Sickle trait. Renal involvement is most severe in HbSS and typically mild in sickle cell trait. Sickle hemoglobinopathies, including sickle cell trait, carry an increased risk of renal medullary carcinoma (Nath and Hebbel 2015), covered in Renal Cell Carcinoma and Oncocytic Renal Tumors.

End-stage kidney disease and acquired cystic kidney disease

  • Acquired cystic kidney disease. Multiple small cysts develop in bilaterally small kidneys, predominantly in ESKD. The incidence in children on dialysis is 21.6%–45.8% and increases with dialysis duration. Renal cell carcinoma is a complication (Chan and Warady 2018).
  • Associated carcinoma. Cysts adjacent to carcinomas arising after more than 5 years of hemodialysis showed atypical papillary hyperplasia (Rioux-Leclercq and Epstein 2003). Acquired cystic disease-associated RCC is covered in Renal Cell Carcinoma and Oncocytic Renal Tumors.

Hereditary cystic kidney diseases

Autosomal dominant polycystic kidney disease

  • Prevalence. Prevalence has been reported as 1 in 400 to 1 in 1,000 live births, and phenotype-based studies give 1 in 2,700 to 1 in 4,000 (Bergmann et al. 2018).
  • Genes. PKD1 causes almost 80% and PKD2 about 15% of cases. PKD1 disease causes earlier ESKD and larger kidneys. Cyst formation requires a second hit such as somatic inactivation of the remaining allele (Bergmann et al. 2018). Minor genes include ALG5, ALG9, DNAJB11, GANAB, IFT140 and NEK8, which usually cause atypical disease with fewer cysts (Gordon et al. 2025).
  • Extrarenal disease. Liver cysts, pancreatic, seminal vesicle and arachnoid cysts, aortic root dilatation and intracranial aneurysms occur (Bergmann et al. 2018). Unruptured intracranial aneurysms are 4-fold more common than in the general population, with a prevalence of 9%–19% (Gordon et al. 2025).

Autosomal recessive polycystic kidney disease

  • Incidence and gene. ARPKD occurs in about 1 in 20,000 live births and is caused by PKHD1 (Guay-Woodford et al. 2014). Some families with moderate disease carry DZIP1L variants (Bergmann et al. 2018).
  • Pathology. Severe ARPKD shows bilaterally enlarged, echogenic kidneys with retained reniform contour and multiple tiny cysts confined to the distal tubules and collecting ducts. The liver invariably shows defective ductal plate remodeling with congenital hepatic fibrosis (Bergmann et al. 2018).
  • Perinatal course. Oligohydramnios produces Potter sequence, and at least 20% of severe neonatal cases die of respiratory distress (Bergmann et al. 2018; Guay-Woodford et al. 2014).

Nephronophthisis and autosomal dominant tubulointerstitial kidney disease

  • Nephronophthisis. Nephronophthisis is an autosomal recessive ciliopathy caused by more than 20 genes and a frequent genetic cause of kidney failure in children. Extrarenal disease in 15%–20% involves the retina (Senior–Løken syndrome), central nervous system (Joubert syndrome), liver or bone (Wolf et al. 2024).
  • Adult nephronophthisis. In adults, thick tubular basement membrane duplication (>10 µm) was the specific finding in genetically proven cases with NPHP1, NPHP3, NPHP4 or CEP164 variants (Fujimaru et al. 2021).
  • ADTKD. Autosomal dominant tubulointerstitial kidney disease is caused by UMOD, HNF1B, REN and MUC1 variants. KDIGO replaced the terms medullary cystic kidney disease types 1 and 2 and familial juvenile hyperuricemic nephropathy with ADTKD plus the gene name, because cysts are not pathognomonic (Eckardt et al. 2015).
Disease Inheritance and genes Kidney pathology Extrarenal features Source
ADPKD Dominant; PKD1 (~80%), PKD2 (~15%), minor genes Enlarged kidneys with cysts, mostly of distal segments Liver cysts, intracranial aneurysms Bergmann et al. 2018; Gordon et al. 2025
ARPKD Recessive; PKHD1, DZIP1L Enlarged echogenic kidneys; cysts of distal tubules and collecting ducts Congenital hepatic fibrosis; Potter sequence Bergmann et al. 2018; Guay-Woodford et al. 2014
Nephronophthisis Recessive; >20 genes, including NPHP1 Tubular basement membrane duplication; tubular cysts Retina, CNS, liver, bone Wolf et al. 2024; Fujimaru et al. 2021
ADTKD Dominant; UMOD, MUC1, REN, HNF1B Tubulointerstitial fibrosis; cysts inconstant Hyperuricemia in UMOD disease Eckardt et al. 2015
Medullary sponge kidney Variants in GDNF, RET, PKHD1 reported Dilated collecting ducts Stones, hematuria, infection Camolese et al. 2025

Other renal cysts and imaging classification

  • Simple cysts. A simple cyst (Bosniak class 1) is round, smooth and thin walled (<1 mm), with homogeneous content and no septa, calcification or solid component. A minimally complex cyst (class 2) may have thin septations or fine calcifications. Neither is associated with malignant transformation, and even a single cyst in an at-risk child younger than 15 years is considered highly suggestive of ADPKD (Dell and Hartung 2024).
  • Localized cystic disease. Localized cystic disease of the kidney is unilateral, nonhereditary and nonprogressive. Multilocular cysts measured 1.8–20 cm, and septa contained normal tubules and glomeruli without blastema or immature stroma. It mimics a neoplasm (Tannous et al. 2025).
  • Medullary sponge kidney. Medullary sponge kidney is a congenital dilation of collecting ducts presenting with stones, hematuria, infection or no symptoms, and it is diagnosed by imaging (Camolese et al. 2025).
  • Bosniak classification, version 2019. The 2019 update incorporates MRI, defines previously vague imaging terms and moves more masses into lower-risk classes (Silverman et al. 2019). An enhancing nodule (any size with acute margins, or ≥4 mm with obtuse margins) is a Bosniak IV feature, irregular thickening ≤3 mm with obtuse margins is a Bosniak III feature, and a cystic mass contains less than about 25% enhancing tissue (Silverman et al. 2019).
  • Previous rule. The CT-based classification introduced in 1986 had four classes. In its 2012 summary, classes I and II were considered benign, IIF probably benign, III indeterminate (about half malignant) and IV malignant (Silverman et al. 2019).

Renal dysplasia and congenital anomalies of the kidney and urinary tract

Multicystic dysplastic kidney and renal dysplasia

  • Definition. Multicystic dysplastic kidney consists of multiple noncommunicating cysts without functioning parenchyma on DMSA scan. It occurs in about 1 in 4,000 live births, more often in boys and on the left (Gupta et al. 2024).
  • Histology. All 30 cases showed immature disorganized tubules surrounded by a collarette of immature mesenchymal stroma. Immature cartilage was present in 4 and osteoid in 1 (Gupta et al. 2024).
  • Course. Most cases are managed conservatively because of involution. Cystic nephroma and cystic partially differentiated nephroblastoma are differential diagnoses (Gupta et al. 2024), covered in Pediatric, Mesenchymal and Other Renal Tumors, Nephrectomy Grossing, WHO/ISUP Grading and Kidney Cancer Staging. Large neonatal lesions may cause compression requiring nephrectomy (Pettit and Chalmers 2021).
  • Genes. PAX2 and TCF2 (HNF1B) dysregulation has been linked to multicystic dysplastic kidney (Brockwell et al. 2024).

CAKUT spectrum

  • Burden. CAKUT affects 4–60 per 10,000 births (Brockwell et al. 2024) and is the leading cause of ESRD in children (Nicolaou et al. 2015).
Anomaly Definition or frequency Associated findings Source
Unilateral renal agenesis 1 per 1,000 births; failure of ureteric bud formation Zinner syndrome in males Brockwell et al. 2024
Bilateral renal agenesis 1–3 per 10,000 births Potter sequence; pulmonary hypoplasia Brockwell et al. 2024
Simple hypoplasia Kidney <50% of expected weight with preserved architecture Hypertension risk Brockwell et al. 2024
Oligomeganephronia Bilateral hypoplasia with few, enlarged nephrons Bimodal age at presentation Brockwell et al. 2024
Horseshoe kidney Fused inferior poles trapped below the inferior mesenteric artery at L3 Ascent arrest Brockwell et al. 2024
Duplex collecting system 1%–5% of the population; female predominance Reflux in 56% of complete duplications, in the lower ureter in 75%; Weigert–Meyer rule Brockwell et al. 2024

| Vesicoureteral reflux | Shortened intravesical ureteral tunnel | Infection and renal damage | Brockwell et al. 2024 |

Differential diagnosis of tubulointerstitial lesions

Finding Favored diagnosis Distinguishing test Source
Fractured PAS-pale casts with giant cells Light chain cast nephropathy Light chain restriction of casts Wang et al. 2026; Martins et al. 2024
Pigmented granular casts Myoglobin cast nephropathy Myoglobin immunohistochemistry Jansi Prema and Kurien 2021
Translucent casts, hemoglobin immunohistochemistry positive Hemoglobin cast nephropathy Hemoglobin and myoglobin immunohistochemistry Gaut and Liapis 2021
Proximal tubular vacuolization Osmotic nephrosis History of sucrose, starch, dextran or contrast Dickenmann et al. 2008
Plasma cell-rich expansile fibrosis IgG4-related TIN IgG4 immunostain; tubular basement membrane deposits Raissian et al. 2011
Noncaseating interstitial granulomas Sarcoidosis or drug reaction Hypercalcemia; drug history Mahévas et al. 2009; Cortazar et al. 2016
Purple von Kossa-positive tubular deposits Acute phosphate nephropathy No birefringence Perazella and Herlitz 2021
Michaelis–Gutmann bodies in histiocytes Malakoplakia von Kossa and Perls stains Bishara et al. 2026

Renal Vascular Disease, Thrombotic Microangiopathy and Kidney Transplant Pathology

Definition. Renal vascular disease comprises injury to the renal arteries, arterioles and glomerular capillaries from thrombotic microangiopathy (TMA), hypertension, fibromuscular dysplasia, atheroemboli, vasculitis and infarction. Kidney transplant pathology comprises donor biopsy evaluation, rejection, drug toxicity, infection, recurrent disease and post-transplant lymphoproliferative disorder in the allograft. Rejection is classified by the Banff classification. Banff 2022 is the current kidney classification, and the Banff 2024 meeting made no changes to it (Naesens et al. 2024; Naesens et al. 2026). Banff 2019 is the previous version (Loupy et al. 2020).

Related page: DIC, Thrombotic Microangiopathy and Viscoelastic Testing (TTP, ADAMTS13 assays, PLASMIC score, HUS and complement-mediated TMA, schistocytes) Related page: HLA Typing, HLA Antibody Testing, Crossmatch and Platelet and Neutrophil Antibody Testing (HLA typing, donor-specific antibody testing, crossmatch, cPRA and Banff laboratory correlates) Related page: Normal and Benign Findings in Urine Cytology (polyomavirus decoy cells in urine) Related page: Renal Biopsy Evaluation and Nephrotic Glomerular Diseases: Minimal Change Disease, FSGS, Membranous and Diabetic Nephropathy, Amyloidosis and Monoclonal Immunoglobulin Deposition and Nephritic and Hematuric Glomerular Diseases: IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy, Infection-Related, Cryoglobulinemic, ANCA and Anti-GBM Glomerulonephritis, Alport Syndrome (native glomerular diseases that recur in the allograft; ANCA-associated small vessel vasculitis) Related page: ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System and Complement Testing, Hereditary Angioedema, Cryoglobulins, Cytokines and Soluble IL-2 Receptor (ANCA, anti-GBM and complement serology)

Thrombotic microangiopathy in the kidney: lesions and causes

  • Clinical definition. TMA is defined by thrombocytopenia, microangiopathic hemolytic anemia and organ injury, frequently acute kidney injury. Lactate dehydrogenase is raised, haptoglobin is low, and the direct antiglobulin test is negative except in pneumococcal HUS (Brocklebank et al. 2018).
  • Acute lesions. Active lesions reflect endothelial injury: endothelial swelling, mesangiolysis, fibrin thrombi in glomerular capillaries and arterioles, fragmented erythrocytes in vessel walls, mucoid intimal thickening and fibrinoid necrosis of arteries (Brocklebank et al. 2018).
  • Chronic lesions. Double contours of the glomerular basement membrane develop in chronic lesions. Overt fibrin-platelet thrombi may be absent, and the term microangiopathy with or without thrombosis has been proposed (Brocklebank et al. 2018).
  • TTP. TTP shows platelet-rich and von Willebrand factor-rich thrombi in capillaries and arterioles. Severe AKI is rare in TTP (Brocklebank et al. 2018).
  • Distribution of thrombi. In scleroderma renal crisis, small vessel thrombi outnumbered glomerular thrombi (65% versus 18% of biopsies). In HUS, glomerular TMA was more frequent than small vessel TMA (92% versus 33%) (Batal et al. 2010).
  • Gross findings. Kidneys with TMA show petechial surface hemorrhages, small wedge-shaped infarcts and foci of cortical necrosis. These changes are shared by HUS, TTP, malignant hypertension, drug-induced TMA and scleroderma renal crisis (Batal et al. 2010).
Cause of TMA Mechanism or defining test Kidney-specific point Source
TTP, hereditary or acquired ADAMTS13 activity <10%; ADAMTS13 mutations or autoantibodies AKI usually mild; 10%–36% of women with TTP present during pregnancy Brocklebank et al. 2018
STEC-HUS Shiga toxin enters cells through the Gb3 receptor and inhibits protein synthesis Glomerular TMA predominates in HUS biopsies Brocklebank et al. 2018; Batal et al. 2010
Complement-mediated (atypical) HUS Mutations in complement genes; factor H autoantibodies associated with homozygous CFHR3/1 deletion Pregnancy triggers TMA in about 20% of women with aHUS Brocklebank et al. 2018
Cobalamin C deficiency MMACHC mutations Treated with hydroxocobalamin and betaine Brocklebank et al. 2018
Drug-induced TMA Calcineurin inhibitors, interferon, gemcitabine, mitomycin, VEGF inhibitors TMA in 2%–10% of mitomycin-treated and 1%–4.7% of tacrolimus-treated patients; ADAMTS13 is tested even when a drug is suspected Brocklebank et al. 2018
Autoimmune disease SLE, catastrophic antiphospholipid syndrome (TMA in 14% of 522 episodes), scleroderma renal crisis Complement activation reported in SLE and CAPS Brocklebank et al. 2018
Malignant hypertension Endothelial injury from severe hypertension Renal TMA in 95.2% of biopsies (pooled) Maisons et al. 2026
De novo TMA after kidney transplant Drugs, antibody-mediated rejection, infection; complement gene mutations in up to 29% Incidence 0.8% in USRDS data and up to 14% in single-center series Brocklebank et al. 2018

Scleroderma renal crisis and antiphospholipid syndrome nephropathy

  • Scleroderma renal crisis (SRC) clinical profile. In a single-center series of 110 SRC cases (1990–2005), SRC occurred in 5% of patients with scleroderma under follow-up. Patients were 81% female and 78% had diffuse cutaneous disease. RNA polymerase antibodies were present in 59% of patients tested, and 108 of 110 received ACE inhibitors (Penn et al. 2007).
  • SRC sequence of vascular lesions. Early lesions are intimal myxoid change, thrombosis and fibrinoid necrosis. Onion-skin lesions develop later. Fibrointimal sclerosis with or without adventitial fibrosis represents chronic damage (Batal et al. 2010).
  • SRC renin axis. Arterial narrowing reduces renal perfusion and can produce juxtaglomerular apparatus hyperplasia, renin secretion and accelerated hypertension (Batal et al. 2010).
  • SRC prognostic biopsy findings. Patients who did not recover renal function had more thrombosed vessels (25.1% versus 5.6%), more severe glomerular ischemic collapse and higher peritubular capillary C4d scores (Batal et al. 2009). Mucoid intimal thickening of arteries and arteriolar fibrinoid necrosis were associated with poorer renal outcome (Penn et al. 2007).
  • SRC versus crescentic GN. Crescents are extremely rare and small in SRC. Crescentic GN in systemic sclerosis is usually ANCA-associated and pauci-immune (Batal et al. 2010).
  • Antiphospholipid syndrome (APS) nephropathy. Acute lesions are TMA. Chronic lesions are fibrous intimal hyperplasia of interlobular arteries, recanalizing arterial and arteriolar thrombi, fibrous arterial occlusion and focal cortical atrophy. APS also causes renal artery thrombosis or stenosis, renal vein thrombosis and thrombotic allograft loss (Tektonidou 2018).

Arterionephrosclerosis and malignant hypertension

  • Definition of arterionephrosclerosis. Arterionephrosclerosis consists of arterial intimal thickening, medial hypertrophy and duplication of the internal elastic lamina, with glomerulosclerosis and tubular atrophy. It mainly affects the terminal interlobular arteries, particularly those <150 μm in diameter (Kopp 2013).
  • Arteriolar hyalinosis. Arteriolar hyalinosis correlates more closely with age than with hypertension (Kopp 2013).
  • Glomerular patterns. Three glomerular patterns occur: obsolescent glomeruli with collapsed tufts and collagen in Bowman space, solidified global glomerulosclerosis with an expanded tuft replaced by matrix, and segmental glomerulosclerosis. Solidified glomerulosclerosis is more common in African American patients (Kopp 2013).
  • APOL1. Coding variants in APOL1 are restricted to populations of recent African descent and are associated with clinically diagnosed arterionephrosclerosis. About one quarter of African Americans with hypertension-attributed CKD in the AASK cohort had two risk alleles (Kopp 2013). APOL1 in FSGS and collapsing glomerulopathy is described in Renal Biopsy Evaluation and Nephrotic Glomerular Diseases: Minimal Change Disease, FSGS, Membranous and Diabetic Nephropathy, Amyloidosis and Monoclonal Immunoglobulin Deposition.
  • Malignant hypertension. In a systematic review of 1781 patients, nephrosclerosis was present in 68.4% of biopsies, IgA nephropathy in 11.8%, FSGS in 6.9% and atypical HUS in 4.1%. Pooled prevalence of renal TMA was 95.2% and of hematologic TMA 72.8% (Maisons et al. 2026).
Lesion Vessels involved Morphology Main associations Source
Arterionephrosclerosis Interlobular arteries <150 μm Fibrointimal thickening, medial hypertrophy, reduplicated internal elastic lamina Age, hypertension, APOL1 risk alleles Kopp 2013
Arteriolar hyalinosis Arterioles Hyaline deposits in the arteriolar wall Age; diabetes; calcineurin inhibitors Kopp 2013; Liptak and Ivanyi 2006
Acute TMA of malignant hypertension or SRC Interlobular arteries and arterioles Mucoid intimal thickening, fibrinoid necrosis, thrombi Malignant hypertension, scleroderma Batal et al. 2010; Maisons et al. 2026
Onion-skin lesion Interlobular arteries Concentric proliferative endarteropathy with pinpoint lumen Later phase of SRC and malignant hypertension Batal et al. 2010

Fibromuscular dysplasia, renal artery stenosis and atheroembolic renal disease

  • Fibromuscular dysplasia (FMD) definition. FMD is a group of nonatherosclerotic, noninflammatory arterial diseases that most commonly involve the renal and carotid arteries. Symptomatic renal artery FMD has a prevalence of about 4 per 1000 (Plouin et al. 2007).
  • FMD histologic subtypes. The histologic classification separates intimal, medial and perimedial FMD, and subtypes can coexist in one patient. The multifocal angiographic type with a string-of-beads appearance corresponds to medial FMD and is seen in more than 80% of cases (Plouin et al. 2007).
  • FMD clinical pattern. Multifocal renal FMD mostly affects women aged 30–50 years and involves the middle and distal two-thirds of the main renal artery. FMD is familial in 10% of cases, and renovascular hypertension is the most common manifestation (Plouin et al. 2007).
  • Renovascular hypertension. Renal artery stenosis increases renin secretion from the affected kidney, and the hyperreninemia induces FSGS lesions with proteinuria in the contralateral kidney (Ubara et al. 2026).
  • Juxtaglomerular hyperplasia in renal artery stenosis. In 10 kidneys removed for hypertension due to renal artery stenosis, renin-containing cells were hyperplastic in the juxtaglomerular apparatus of every kidney and extended into arteries outside it as far as the interlobular arteries. Ischemic damage ranged from negligible to end-stage atrophy (Graham et al. 1990).
  • Ischemic nephropathy. In 62 small kidneys removed for atherosclerotic renal artery stenosis, tubulointerstitial atrophy with relative glomerular sparing was the predominant pattern (71%), and 23% showed diffuse global glomerulosclerosis. Atheroembolic, atherosclerotic and hypertensive vascular changes were present in 39%, 98% and 52% (Keddis et al. 2010).
  • FMD differential diagnosis. Atherosclerotic stenosis and stenoses associated with vascular Ehlers-Danlos syndrome, Williams syndrome and neurofibromatosis type 1 enter the differential diagnosis (Plouin et al. 2007).
  • Atheroembolic renal disease: clinical setting. Cholesterol crystals released from ruptured aortic plaques occlude small renal arteries. Most cases follow vascular surgery, catheterization or anticoagulation. The triad of a precipitating event, acute or subacute renal failure and skin lesions suggests the diagnosis, and eosinophilia supports it (Scolari and Ravani 2010).
  • Atheroemboli: biopsy findings. Crystals lodge in arteries 150–200 μm in diameter. Biopsies show needle-shaped biconvex clefts in arcuate and interlobular arteries and arterioles, surrounded by macrophages, giant cells and intimal fibrosis (Jansi Prema and Kurien 2019).
  • Atheroemboli: sampling. Biopsy sensitivity is about 75% and rises to 94% with two biopsies, so the entire specimen is examined. C3 hypocomplementemia and transient eosinophilia may accompany the disease (Jansi Prema and Kurien 2019).

Medium and large vessel vasculitis in the kidney (Chapel Hill 2012 nomenclature)

The 2012 Chapel Hill Consensus Conference nomenclature defines vasculitis by the predominant vessel size involved (Jennette 2013). ANCA-associated small vessel vasculitis and pauci-immune crescentic GN are described in Nephritic and Hematuric Glomerular Diseases: IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy, Infection-Related, Cryoglobulinemic, ANCA and Anti-GBM Glomerulonephritis, Alport Syndrome.

Disease Chapel Hill 2012 definition Kidney involvement and distinguishing feature Source
Polyarteritis nodosa Necrotizing arteritis of medium or small arteries without glomerulonephritis or vasculitis in arterioles, capillaries or venules; not associated with ANCA Absence of ANCA separates it from microscopic polyangiitis Jennette 2013
Kawasaki disease Arteritis associated with the mucocutaneous lymph node syndrome, predominantly in medium and small arteries Coronary arteries often involved; infants and young children. Kidney involvement includes pyuria, AKI from tubulointerstitial nephritis, HUS, immune complex-mediated nephropathy, and renal artery aneurysms and stenosis Jennette 2013; Watanabe 2013
Takayasu arteritis Arteritis, often granulomatous, of the aorta and its major branches Onset usually before age 50. Renal artery involvement in 37 of 122 patients (30%), bilateral in 51%, with hypertension in 73% at presentation; no patient reached ESRD over a median 7 years Jennette 2013; Baldwin et al. 2018
Giant cell arteritis Arteritis, often granulomatous, of the aorta and major branches, with predilection for carotid and vertebral branches Onset usually after age 50; age is the main discriminator from Takayasu arteritis Jennette 2013

Renal infarction and renal cortical necrosis

  • Renal infarction causes. A meta-analysis of 34 cohorts (12,727 cases) found embolic causes in 42%, hypercoagulable states in 12%, renal artery damage in 11%, trauma in 3% and other or idiopathic causes in 31% (Nour Eldine et al. 2026).
  • Renal infarction presentation and outcome. Flank or abdominal pain was the most common symptom (64%). Chronic kidney disease followed in 25%, and 32% of patients were already taking antithrombotic therapy (Nour Eldine et al. 2026).
  • Renal cortical necrosis definition. Renal cortical necrosis is patchy or diffuse ischemic destruction of all elements of the renal cortex from diminished arterial perfusion due to vascular spasm and microvascular injury. Diffuse cortical necrosis progresses to end-stage renal disease (Prakash and Singh 2015).
  • Renal cortical necrosis causes. Cortical necrosis causes 1.9%–2% of AKI in developed countries and 6%–7% in developing countries. Obstetric complications (septic abortion, puerperal sepsis, placental abruption, postpartum hemorrhage and eclampsia) account for 60%–70% of cases in developing countries. Sepsis and HUS cause most nonobstetric cases (Prakash and Singh 2015).

Kidney donor biopsy evaluation

  • Indication. OPTN policy recommends preimplantation biopsy for kidneys with a Kidney Donor Profile Index >85% or at the request of the accepting surgeon. The discard rate of recovered kidneys exceeds 40% (Liapis et al. 2017).
  • Wedge versus core biopsy. In the Banff preimplantation study, wedge biopsies were superior to needle core biopsies for glomerular counts and percentage of globally sclerosed glomeruli. Good wedge biopsies are not restricted to the subcapsular cortex (Liapis et al. 2017).
  • Frozen section limits. Freeze artifact impairs assessment of arteriolar hyalinosis and interstitial fibrosis. Interobserver agreement for arteriolar hyalinosis was poor on frozen wedge sections (intraclass correlation 0.133) and fair on paraffin sections (0.377) (Liapis et al. 2017).
  • Reproducible parameters. Number of glomeruli, number and percentage of globally sclerosed glomeruli, interstitial fibrosis and arteriosclerosis showed good or fair reproducibility. Interstitial fibrosis, tubular atrophy and arterial intimal fibrosis are scored as none (<5%), mild (6%–25%), moderate (26%–50%) or severe (>50%) (Liapis et al. 2017).
  • Glomerulosclerosis cutoff. A rigid cutoff such as 20% glomerulosclerosis is not used in isolation to discard kidneys. Arteriolar hyalinosis, acute tubular injury, TMA, diabetic nephropathy, cholesterol emboli and extensive thrombosis are recorded (Liapis et al. 2017).
  • Predictive value. In a systematic review of 47 studies, percentage glomerulosclerosis failed to predict graft failure in 7 of 14 studies, and none of 15 semiquantitative scores consistently predicted outcome (Wang et al. 2015). Kidneys from donors older than 60 years selected by preimplantation histology had graft survival similar to kidneys from younger donors (Remuzzi et al. 2006).

Banff lesion scores in kidney allograft biopsies

The Banff scores below are those of the Banff 2019 reporting scheme, which Banff 2022 and Banff 2024 retained (Loupy et al. 2020; Naesens et al. 2026). Intimal arteritis (v) and chronic allograft arteriopathy are scored only in arteries with a continuous media of at least two smooth muscle layers (Loupy et al. 2020).

Score Lesion Grades 1, 2 and 3 Source
i Inflammation in non-scarred cortex 10%–25%; 26%–50%; >50% (0 is <10%) Loupy et al. 2020
t Tubulitis in non-scarred cortex, most severe tubule 1–4; 5–10; >10 mononuclear cells per tubular cross-section; t >0 needs ≥2 foci; severely atrophic tubules are not scored Loupy et al. 2020
v Intimal arteritis <25% luminal occlusion; ≥25%; transmural arteritis or fibrinoid necrosis Loupy et al. 2020
g Glomerulitis <25%; 25%–75%; >75% of glomeruli Loupy et al. 2020
ptc Peritubular capillaritis, most involved capillary 3–4; 5–10; >10 leukocytes, with ≥1 leukocyte in ≥10% of capillaries Loupy et al. 2020
C4d Linear C4d in peritubular capillaries or vasa recta 1 is <10%; 2 is 10%–50%; 3 is >50% of capillaries; positive is ≥2 by immunofluorescence or >0 by immunohistochemistry Loupy et al. 2020
ci Interstitial fibrosis 6%–25%; 26%–50%; >50% (0 is ≤5%) Loupy et al. 2020
ct Tubular atrophy 1%–25%; 26%–50%; >50% Loupy et al. 2020
cv Arterial intimal fibrosis ≤25%; 26%–50%; >50% luminal narrowing Loupy et al. 2020
cg Transplant glomerulopathy, most affected glomerulus 1a: EM only; 1b: double contours in 1%–25% of capillaries; 2: 26%–50%; 3: >50% Loupy et al. 2020
ptcml Peritubular capillary basement membrane multilayering (EM) ptcml1: ≥7 layers in one capillary and ≥5 in two more Loupy et al. 2020
ti Total cortical inflammation, including scarred cortex 10%–25%; 26%–50%; >50% Loupy et al. 2020
i-IFTA Inflammation in scarred cortex 10%–25%; 26%–50%; >50% of scarred cortex Loupy et al. 2020
t-IFTA Tubulitis in scarred cortex 1–4; 5–10; >10 mononuclear cells Loupy et al. 2020
pvl Polyomavirus load level (SV40 large T antigen or inclusions) ≤1%; >1% and <10%; ≥10% of tubules Loupy et al. 2020
ah Arteriolar hyalinosis (PAS-positive hyaline thickening; a purely descriptive score that defines no diagnostic category) Mild to moderate in ≥1 arteriole; moderate to severe in >1 arteriole; severe in many arterioles Roufosse et al. 2018
aah (optional since Banff 2007) Hyaline arteriolar thickening of calcineurin inhibitor type Hyaline replacing degenerated smooth muscle cells in 1 arteriole without circumferential involvement; >1 arteriole without circumferential involvement; circumferential in any number of arterioles Roufosse et al. 2018
mm Mesangial matrix expansion (matrix exceeding the width of 2 mesangial cells in at least 2 lobules) At least moderate increase in ≤25%; 26%–50%; >50% of nonsclerotic glomeruli Roufosse et al. 2018
  • Specimen adequacy (Banff 97). An adequate allograft biopsy contains ≥10 glomeruli and ≥2 arteries, and a minimal sample contains 7 glomeruli and 1 artery (Marokakis et al. 2025). C4d staining by IF or IHC is considered indispensable (Roufosse et al. 2018).
  • Severely atrophic tubule. A severely atrophic tubule has a diameter <25% of unaffected tubules, undifferentiated cuboidal or flattened epithelium and wrinkled or thickened tubular basement membrane (Loupy et al. 2020).

T cell-mediated rejection and borderline changes (Banff)

Category Banff 2019 criteria (retained in Banff 2022 and 2024) Source
Borderline (suspicious) for acute TCMR Tubulitis t1–t3 with i1, or t1 with i2–i3; v0 Loupy et al. 2020
Acute TCMR grade IA i2–i3 with t2 Loupy et al. 2020
Acute TCMR grade IB i2–i3 with t3 Loupy et al. 2020
Acute TCMR grade IIA v1, with or without interstitial inflammation and tubulitis Loupy et al. 2020
Acute TCMR grade IIB v2 Loupy et al. 2020
Acute TCMR grade III Transmural arteritis or arterial fibrinoid necrosis with mononuclear intimal arteritis (v3) Loupy et al. 2020
Chronic active TCMR grade IA or IB i-IFTA2–3 and ti2–3 with t2 or t-IFTA2 (IA) or t3 or t-IFTA3 (IB); other causes of i-IFTA excluded Loupy et al. 2020
Chronic active TCMR grade II Chronic allograft arteriopathy: intimal fibrosis with mononuclear inflammation and neointima Loupy et al. 2020
  • Borderline threshold. Banff 2019 restored the Banff 97 threshold: the minimum borderline lesion is i1t1. Tubulitis with i0, and inflammation with t0, are no longer borderline and are described in the microscopic findings (Loupy et al. 2020).
  • Chronic active TCMR. Banff 2017 added moderate i-IFTA with moderate or severe tubulitis as diagnostic of chronic active TCMR (Haas et al. 2018). i-IFTA alone is nonspecific and also occurs with BK polyomavirus nephropathy and ABMR (Loupy et al. 2020).
  • Mixed reports. A second diagnosis of borderline or acute TCMR is reported when criteria for both chronic active TCMR and acute TCMR are met (Loupy et al. 2020).
  • Historical types. Banff 97 separated tubulointerstitial rejection (type I), vascular rejection with intimal arteritis (type II) and transmural arterial rejection (type III) (Racusen et al. 1999).
  • Banff 2024 flowchart. Banff 2024 added a clinical reasoning flowchart for tubulointerstitial inflammation and intimal arteritis (v lesion) without changing the criteria (Naesens et al. 2026).

Antibody-mediated rejection: Banff 2019 criteria and Banff 2022 changes

Banff 2019 category Criteria (all required unless stated) Source
Active ABMR (1) Acute injury: microvascular inflammation (g >0 and/or ptc >0, with g ≥1 required when TCMR, borderline infiltrate or infection is present), intimal or transmural arteritis, acute TMA, or acute tubular injury without other cause; (2) antibody interaction with endothelium: C4d positivity, g + ptc ≥2, or validated ABMR transcripts; (3) circulating DSA, for which C4d or validated transcripts may substitute Loupy et al. 2020
Chronic active ABMR (1) Chronic injury: cg >0 including cg1a, ptcml1, or new-onset arterial intimal fibrosis; (2) and (3) as for active ABMR Loupy et al. 2020
Chronic (inactive) ABMR cg >0 or ptcml1, without current antibody interaction, with prior ABMR or prior DSA Loupy et al. 2020
C4d staining without evidence of rejection Linear C4d without acute or chronic injury, molecular ABMR, TCMR or borderline changes Loupy et al. 2020
  • C4d interpretation. Linear C4d in peritubular capillaries is positive at C4d2–3 by immunofluorescence on frozen sections or C4d >0 by immunohistochemistry on paraffin sections (Loupy et al. 2020).
  • ABO-incompatible grafts. C4d without injury in ABO-incompatible allografts may represent accommodation (Loupy et al. 2020).
  • Hyperacute rejection. Hyperacute rejection is typically caused by preformed donor-specific antibodies to HLA or ABO blood group antigens (Zhang et al. 2026). In one HLA- and ABO-compatible graft lost to hyperacute rejection attributed to non-HLA antibodies, the kidney showed thrombi with neutrophils in glomerular and peritubular capillaries, fibrinoid necrosis of interlobular arteries, interstitial hemorrhage and endothelial IgG. C4d was focal in glomerular capillary loops and absent in peritubular capillaries (Zhang et al. 2026).
  • Banff 2022 changes. Banff 2022 created "probable AMR" for DSA-positive cases with microvascular inflammation below the AMR threshold and C4d negativity. It created "MVI, DSA-negative and C4d-negative" for microvascular inflammation above the threshold without DSA or C4d (Naesens et al. 2024; Shimizu et al. 2025).
  • Banff 2022 exclusions. Acute tubular injury without another cause and new-onset arterial intimal fibrosis used alone no longer count as injury criteria for AMR. Non-HLA antibodies, except anti-blood group antibodies in ABO-incompatible grafts, are not counted as DSA (Shimizu et al. 2025).
  • Prognosis of DSA-negative MVI. DSA-negative, C4d-negative MVI carries a significant risk of graft failure (Böhmig et al. 2025). In the largest multicenter cohort, its graft-loss hazard ratio was 2.1, compared with 2.7 for AMR (El Hennawy et al. 2026).
  • Banff 2024. Banff 2024 reaffirmed the Banff 2022 flowchart for MVI and AMR, issued guidance for incomplete or mixed phenotypes and published guidelines for reporting glomerular disease after transplant (Naesens et al. 2026).

Transplant glomerulopathy and electron microscopy of the allograft

  • Morphology. Transplant glomerulopathy shows thickened capillary walls with double contours by light microscopy and reduplication or lamination of the GBM by electron microscopy (Fotheringham et al. 2009).
  • Incidence and associations. Its incidence is about 20% by 5 years after transplantation. It is associated with prior acute rejection, pretransplant antibody status, de novo HLA antibodies and class II DSA. Peritubular capillary or glomerular C4d is not required at diagnosis (Fotheringham et al. 2009).
  • cg1a definition. cg1a requires no double contours by light microscopy and at least 3 capillary loops in one glomerulus with subendothelial neo-densa GBM and endothelial cell enlargement or subendothelial electron-lucent widening (Loupy et al. 2020).
  • EM sampling. Banff recommends resin-embedded tissue for EM, at least 1 and preferably 2 or more glomeruli, examination at ≥5000× and at least 10 peritubular capillaries. EM is recommended when glomerular disease is suspected and in patients at risk for ABMR (sensitized, DSA-positive or with prior ABMR features). It is useful in for-cause biopsies at ≥3 months and all biopsies at ≥6 months to detect cg1a (Loupy et al. 2020).

Calcineurin inhibitor toxicity and its distinction from rejection

  • Shared lesions. Cyclosporine and tacrolimus produce identical, focal lesions that require serial sections (Liptak and Ivanyi 2006).
  • Acute toxicity. Acute toxicity shows necrosis and early hyalinosis of individual smooth muscle cells in afferent arterioles and isometric vacuolization of proximal straight tubules. TMA is a rare manifestation (Liptak and Ivanyi 2006).
  • Chronic toxicity. Damaged medial smooth muscle cells are replaced by beaded medial hyaline deposits bulging into the adventitia, with striped interstitial fibrosis and tubular atrophy (Liptak and Ivanyi 2006).
  • Clinical correlation. Systemic drug levels correlate poorly with nephrotoxicity. Older kidney age, salt depletion, NSAIDs and variation in P-glycoprotein and CYP3A4/5 activity increase susceptibility (Naesens et al. 2009).
Feature Calcineurin inhibitor toxicity T cell-mediated rejection Antibody-mediated rejection Source
Arterioles Nodular or beaded medial hyalinosis bulging into adventitia; myocyte necrosis No specific arteriolar lesion Acute TMA possible Liptak and Ivanyi 2006; Loupy et al. 2020
Arteries No intimal arteritis Intimal arteritis (v1–v2) or transmural arteritis (v3) Intimal or transmural arteritis possible Loupy et al. 2020
Tubules Isometric vacuolization (acute); atrophy (chronic) Tubulitis Acute tubular injury Liptak and Ivanyi 2006; Loupy et al. 2020
Interstitium Striped fibrosis Mononuclear inflammation of non-scarred cortex Little inflammation Liptak and Ivanyi 2006; Loupy et al. 2020
Capillaries No microvascular inflammation ptc ≥1 alone insufficient for ABMR in the presence of TCMR Glomerulitis and peritubular capillaritis; C4d in a subset Loupy et al. 2020
Glomeruli TMA rare No specific lesion Transplant glomerulopathy in chronic active ABMR Liptak and Ivanyi 2006; Fotheringham et al. 2009

Recurrent and de novo glomerular disease in the allograft

  • Overall burden. Among 1505 Australian recipients with biopsy-proven GN, the 10-year incidence of allograft loss from recurrence was 8.4%, the third most frequent cause of graft loss (Briganti et al. 2002).
  • Diagnostic approach. Recurrent GN is diagnosed with light microscopy, immunofluorescence and electron microscopy, together with markers such as anti-PLA2R antibodies for membranous nephropathy and complement studies for C3 glomerulopathy (Koirala et al. 2025).
  • De novo anti-GBM disease. De novo anti-GBM disease occurs in 2%–3% of transplanted patients with Alport syndrome and causes rapid graft loss (Koirala et al. 2025).
Native disease Recurrence Timing and graft impact Source
Dense deposit disease Near 100% Graft loss more frequent and earlier than in C3 glomerulonephritis Koirala et al. 2025
C3 glomerulopathy >60%–70% Early; graft failure in 11%–77% Koirala et al. 2025
Primary FSGS 40%–60%; up to 80% after loss of a prior graft to recurrence Median 1.5 months; 5-year graft survival 52% versus 83% without recurrence Koirala et al. 2025
IgA nephropathy 10%–30% on indication biopsies; 25%–53% on protocol biopsies Median about 59 months Koirala et al. 2025
Membranous nephropathy 10%–45% Median 6.3 years; mediated by anti-PLA2R IgG4 Koirala et al. 2025
Lupus nephritis 2.44% in registries; 30%–54% in single-center reports Rarely causes graft loss Koirala et al. 2025
ANCA-associated vasculitis <10% Usually after the first year Koirala et al. 2025

Post-transplant lymphoproliferative disorder in the kidney allograft

  • Definition. PTLD is uncontrolled lymphoid proliferation caused by extrinsic immunosuppression after solid organ or hematopoietic stem cell transplantation (Dharnidharka et al. 2016).
  • Pathogenesis and risk. Epstein-Barr virus causes many early-onset cases. Recipient EBV seronegativity and intensity of immunosuppression are key risk factors (Dharnidharka et al. 2016).
  • Diagnosis and treatment. Diagnosis requires histopathology. Treatment includes reduction of immunosuppression, rituximab, chemotherapy and EBV-specific cytotoxic T cells (Dharnidharka et al. 2016).

BK polyomavirus nephropathy

  • Incidence. Biopsy-proven polyomavirus nephropathy (PVN) affects about 5% of kidney allografts (Nickeleit et al. 2018).
  • Diagnosis. Definitive PVN requires viral inclusions or nuclear SV40 large T antigen staining in tubular epithelium. Immunohistochemistry is more sensitive than light microscopy, and pvl scoring requires it (Loupy et al. 2020).
  • Sampling. An adequate sample contains 2 cores and medulla. In class 1 PVN, 55% of patients had viral replication in only one of several cores, and inclusions were absent by light microscopy in 48% (Nickeleit et al. 2018).
  • Coexisting rejection. PVN can coexist with ABMR or with TCMR grade II or III (Loupy et al. 2020).
  • Screening. AST guidelines recommend screening kidney recipients for BKPyV DNAemia monthly until month 9 and every 3 months until 2 years. Plasma DNAemia >1000 copies/mL sustained for 3 weeks indicates probable nephropathy, and >10,000 copies/mL indicates presumptive nephropathy. Biopsy is not required before reducing immunosuppression in DNAemic patients with baseline renal function (Hirsch et al. 2019).
PVN class (Banff Working Group 2018) pvl and ci scores Graft failure at 24 months, 2018 cohort Graft failure, 2021 validation Source
Class 1 pvl1 and ci0–1 16% 5% Nickeleit et al. 2018; Nickeleit et al. 2021
Class 2 pvl1 and ci2–3; pvl2 with any ci; or pvl3 and ci0–1 31% 30% Nickeleit et al. 2018; Nickeleit et al. 2021
Class 3 pvl3 and ci2–3 50% 50% Nickeleit et al. 2018; Nickeleit et al. 2021

Differential diagnosis of allograft dysfunction on biopsy

Dominant biopsy finding Diagnoses to separate Discriminating findings Source
Tubulitis with interstitial inflammation TCMR; BK polyomavirus nephropathy SV40 large T antigen in tubular nuclei; medullary involvement Loupy et al. 2020; Nickeleit et al. 2018
Glomerulitis and peritubular capillaritis Active ABMR; DSA-negative MVI; recurrent or de novo GN DSA, C4d, immune deposits by IF and EM Loupy et al. 2020; Naesens et al. 2024
Arteriolar hyalinosis Calcineurin inhibitor toxicity; donor arteriolosclerosis; diabetes Beaded medial hyaline bulging into adventitia; findings on implantation biopsy Liptak and Ivanyi 2006; Liapis et al. 2017
TMA ABMR; calcineurin inhibitor toxicity; recurrent aHUS; recurrent SRC DSA and C4d; drug history; complement genetics Brocklebank et al. 2018; Batal et al. 2010
GBM double contours Transplant glomerulopathy; chronic TMA; recurrent MPGN pattern GN Immune deposits on IF and EM; DSA Loupy et al. 2020; Koirala et al. 2025

Renal Cell Carcinoma and Oncocytic Renal Tumors

Definition. Renal cell carcinoma (RCC) is a group of malignant epithelial tumors of the renal tubules. The WHO Classification of Tumours of the Urinary and Male Genital Organs, 5th edition (2022), gives essential and desirable diagnostic criteria that combine morphology, immunohistochemistry and molecular tests. It introduced a group of molecularly defined RCCs and accepted eosinophilic solid and cystic RCC as a new morphologically defined entity (Moch et al. 2022). The CAP Kidney Resection protocol, version 4.3.0.0 (June 2026), applies to all RCC types. Clear cell papillary renal cell tumor, multilocular cystic renal neoplasm of low malignant potential and low-grade oncocytic neoplasms are not required to be reported with it (CAP 2026a).

Related page: Renal Cell Carcinoma Subtypes on FNA (full WHO 5th versus 4th edition change table, cytomorphology and biopsy elements) Related page: Kidney FNA: Indications, Normal Elements and Benign Lesions (renal mass biopsy, oncocytoma on FNA and the WHO 5th edition rule against a definitive oncocytoma diagnosis on core biopsy) Related page: Urothelial Carcinoma of the Renal Pelvis, Wilms Tumor, Metastases and Lymphoma in Kidney FNA (urothelial carcinoma of the renal pelvis and the GATA3, p63 and PAX8 panel that separates it from collecting duct carcinoma) Related page: Pediatric, Mesenchymal and Other Renal Tumors, Nephrectomy Grossing, WHO/ISUP Grading and Kidney Cancer Staging (WHO/ISUP grade definitions, nephrectomy grossing, AJCC 8th edition pTNM and the CAP case summary) Related page: Tubulointerstitial, Obstructive, Cystic and Developmental Kidney Disease (acquired cystic kidney disease, end-stage kidney and sickle cell nephropathy)

Epidemiology, risk factors and presentation of renal cell carcinoma

  • Incidence. RCC accounts for 2% of cancer diagnoses and deaths worldwide. Two thirds of cases occur in men, and the average age at diagnosis in the United States is 64 years. Patients with von Hippel-Lindau disease develop RCC at an average age of 44 years and more often bilaterally (Padala et al. 2020).
  • Risk factors. Current and former smokers had relative risks of 1.5 and 1.6. High body mass index carried a relative risk of 2.25 and was associated with clear cell (1.8) and chromophobe (2.2) RCC but not papillary RCC (1.2). Hypertension doubled the risk, and trichloroethylene is the main occupational exposure (Padala et al. 2020).
  • Presentation. Most RCCs in developed countries are found incidentally on imaging. Only 10% of patients have the triad of hematuria, flank pain and a palpable mass. About 20% have paraneoplastic syndromes: hypercalcemia from parathyroid hormone-related peptide, polycythemia from erythropoietin, Cushing syndrome from ACTH and hypertension from renin (Padala et al. 2020).
  • Survival by stage. Five-year relative survival in the United States was 93% for localized disease, 72.5% for regional disease and 12% for distant metastases. About one third of RCCs are metastatic at diagnosis (Padala et al. 2020).

WHO 5th edition classification of renal epithelial tumors

WHO 5th edition category Entities (WHO 5th edition) Previous rule where changed (WHO 4th edition, 2016) Source
Clear cell renal tumors Clear cell RCC; multilocular cystic renal neoplasm of low malignant potential Unchanged CAP 2026a
Papillary renal tumors Papillary adenoma; papillary RCC, without type 1 or type 2 subtyping Papillary RCC divided into types 1 and 2 Lobo et al. 2022; CAP 2026a
Oncocytic and chromophobe renal tumors Oncocytoma; chromophobe RCC; other oncocytic tumors of the kidney Oncocytoma and chromophobe RCC only Lobo et al. 2022; CAP 2026a
Collecting duct tumors Collecting duct carcinoma Unchanged CAP 2026a
Other renal tumors Clear cell papillary renal cell tumor; mucinous tubular and spindle cell carcinoma; tubulocystic RCC; acquired cystic disease-associated RCC; eosinophilic solid and cystic RCC; RCC NOS Clear cell papillary RCC (carcinoma); eosinophilic solid and cystic RCC not listed Moch et al. 2022; CAP 2026a
Molecularly defined renal carcinomas TFE3-rearranged RCC; TFEB-altered RCC; ELOC-mutated RCC; fumarate hydratase-deficient RCC; succinate dehydrogenase-deficient RCC; ALK-rearranged RCC; SMARCB1-deficient renal medullary carcinoma MiT family translocation RCC; HLRCC syndrome-associated RCC; SDH-deficient RCC; renal medullary carcinoma; no molecular group Moch et al. 2022; Moch et al. 2016; CAP 2026a
  • Reason for dropping papillary subtypes (WHO 5th edition). Mixed type 1 and type 2 phenotypes are frequent, and the former type 2 category contained entities with different molecular backgrounds (Lobo et al. 2022). WHO/ISUP grade and tumor architecture predict outcome better than the type (Trpkov, Hes et al. 2021).
  • RCC NOS (WHO 5th edition). RCC NOS is reserved for carcinomas that cannot be placed in a morphologically or molecularly defined type and is usually high grade. Difficult low-grade oncocytic tumors are placed in "other oncocytic tumors of the kidney" (CAP 2026a).
  • Subtype pending. CAP 4.3.0.0 offers "renal cell carcinoma, subtype pending additional studies" for preliminary sign-out, followed by an addendum (CAP 2026a).
  • Emerging entities. Biphasic hyalinizing psammomatous RCC and thyroid-like follicular RCC are reported as "other histologic type not listed" (CAP 2026a).

Immunohistochemical panel for renal epithelial tumors

A CK7, carbonic anhydrase IX (CA9) and AMACR panel was the best first-line panel in 214 renal tumors. CD10, EMA, cathepsin K, CD117, HNF1β and E-cadherin form the adjunctive panel (Kim et al. 2020). PAX2 and PAX8 are sensitive and relatively specific markers of renal neoplasms of every subtype. Markers are expressed less often and less diffusely in metastatic RCC, and a panel of at least CD10, RCC marker, PAX2 and PAX8 is advised (Truong and Shen 2011).

Tumor CK7 CA9 AMACR CD117 Other markers Source
Clear cell RCC Negative 10%, focal 90% Diffuse box-like 100% Focal 70%, diffuse 26% Negative CD10 saw-tooth membranous Kim et al. 2020
Papillary RCC (former type 1 series) Diffuse 94% Negative 100% Diffuse 93% Negative HNF1β positive Kim et al. 2020
Chromophobe RCC Diffuse 85% Negative 100% Negative 65% Positive Hale colloidal iron positive; vimentin negative Kim et al. 2020; Din et al. 2013
Oncocytoma Negative 80%, focal 20% Negative Negative Positive HNF1β positive Kim et al. 2020
Clear cell papillary renal cell tumor Diffuse 100% Cup-like 100% Negative 80%, focal 20% Negative GATA3 and high-molecular-weight keratin often positive Kim et al. 2020; Williamson 2021
Multilocular cystic renal neoplasm of low malignant potential Positive 100% Box-like 100% Positive 30% Not tested CD10 positive 80% Kim et al. 2020
TFE3-rearranged and TFEB-altered RCC Negative 100% Negative 100% Negative or focal Negative Cathepsin K, melan-A, HMB45; TFE3 or TFEB Kim et al. 2020; CAP 2026a
Collecting duct carcinoma Diffuse 100% Negative 100% Focal or diffuse Negative PAX8 positive 100%; GATA3 positive 6% Kim et al. 2020; Gonzalez-Roibon et al. 2013
Acquired cystic disease-associated RCC Positive 25% Negative Positive 60% Not tested CD10 positive 100% Kim et al. 2020
SDH-deficient RCC Negative Not reported Not reported Negative SDHB loss; GATA3 and L1CAM positive Trpkov et al. 2026
FH-deficient RCC Not reported Not reported Not reported Not reported FH loss with nuclear and cytoplasmic 2SC Trpkov et al. 2026
SMARCB1-deficient renal medullary carcinoma Heterogeneous Not reported Not reported Not reported INI1 (SMARCB1) loss Calderaro et al. 2012; Swartz et al. 2002
ALK-rearranged RCC Not reported Not reported Not reported Not reported ALK (5A4, D5F3) positive; PAX8 positive; FH and INI1 retained Trpkov et al. 2026
Eosinophilic solid and cystic RCC Negative Not reported Not reported Negative CK20 positive in 85%; cathepsin K focal; vimentin positive Trpkov et al. 2026

Clear cell renal cell carcinoma

  • Genetics. Inherited and sporadic clear cell RCCs are characterized by inactivation of both copies of VHL by mutation or hypermethylation (Latif et al. 1993; Schmidt et al. 1997). Chromosome 3p loss is the characteristic copy-number change of clear cell RCC (Hakimi et al. 2015). The TCGA analysis of more than 400 tumors identified 19 significantly mutated genes, including VHL, the SWI/SNF gene PBRM1 and SETD2 (Cancer Genome Atlas Research Network 2013).
  • Prognostic features. WHO/ISUP grade, pTNM stage, coagulative necrosis, and rhabdoid and sarcomatoid differentiation are the key prognostic features. Subclonal SETD2, PBRM1 and BAP1 alterations and loss of 14q and 9p are associated with variable prognosis (Trpkov, Hes et al. 2021).
  • Sarcomatoid and rhabdoid change. Sarcomatoid change is a pattern of dedifferentiation that can occur in any RCC type. When the underlying type is recognized, it is reported as the histologic type, and pure sarcomatoid carcinoma is classified as RCC NOS. About 25% of tumors with rhabdoid features also show sarcomatoid features (CAP 2026a).
  • Grading. WHO/ISUP grading is validated for clear cell RCC (CAP 2026a).
  • Gross appearance. Clear cell RCC has a golden yellow cut surface (Wobker and Williamson 2017).

Multilocular cystic renal neoplasm of low malignant potential, clear cell papillary renal cell tumor and ELOC-mutated RCC

  • Multilocular cystic renal neoplasm of low malignant potential (MCRNLMP). MCRNLMP is composed entirely of variably sized, noncommunicating cysts with no solid component. The septa and linings contain clear cells with low-grade (WHO/ISUP 1–2) nuclei, without expansile or solid nodular growth, necrosis, vascular invasion or sarcomatoid change. It is PAX8, CA9 and CK7 positive and AMACR negative, and it carries 3p deletion and VHL mutation (Pitra et al. 2022). All 45 patients in a multi-institutional series were alive without disease at a mean follow-up of 66.1 months. Fuhrman grade was 1 in 62% and 2 in 38% (Suzigan et al. 2006). Low WHO/ISUP grade features are essential to its classification (CAP 2026a).
  • Clear cell papillary renal cell tumor (CCPRCT) morphology. CCPRCT shows clear cells lining branching glands and papillae with linear nuclear alignment. It occurs with and without end-stage renal disease and may be multifocal or bilateral (Williamson 2021).
  • CCPRCT profile. CCPRCT is positive for CA9 and CK7 and often for high-molecular-weight keratin and GATA3. AMACR and CD10 are negative or minimal, and VHL and chromosome 3p alterations are typically lacking. Most tumors are small, pT1a and grade 1–2 (Williamson 2021).
  • CCPRCT nomenclature (WHO 5th edition). WHO renamed clear cell papillary RCC as clear cell papillary renal cell tumor to reflect its indolent behavior (CAP 2026a). In 66 tumor-bearing end-stage kidneys, clear cell papillary tumors formed the dominant mass in 23% (Tickoo et al. 2006).
  • ELOC-mutated RCC (WHO 5th edition). ELOC-mutated RCC (formerly TCEB1-mutated) carries hotspot ELOC mutations with loss of chromosome 8 heterozygosity and lacks 3p loss and VHL mutation. It shows thick fibromuscular bands, voluminous clear cytoplasm and acinar areas, and lacks the extensive cup-like CA9 pattern of CCPRCT (Hakimi et al. 2015). CK7 is consistently expressed (CAP 2026a).

Papillary renal cell carcinoma, papillary adenoma and papillary renal neoplasm with reverse polarity

  • Papillary RCC genetics. Papillary RCC is characterized by trisomy of chromosomes 7, 16 and 17 and loss of Y in men. Germline activating mutations of MET (7q31) cause hereditary papillary renal carcinoma with multiple bilateral tumors (Schmidt et al. 1997). Psammoma bodies, foamy macrophages and intracellular hemosiderin occur in papillary RCC (Al-Obaidy et al. 2019).
  • Papillary RCC subtyping (WHO 5th edition). Type 1 and type 2 subcategories are no longer used. Biphasic squamoid alveolar RCC, biphasic hyalinizing psammomatous RCC, papillary renal neoplasm with reverse polarity and Warthin-like papillary RCC are placed in the papillary RCC spectrum (Lobo et al. 2022).
  • Papillary adenoma. Papillary adenoma is a low-grade, unencapsulated papillary or tubulopapillary tumor no larger than 15 mm. The WHO 4th edition (2016) raised the size threshold from 5 mm (WHO 2004) to 15 mm (Moch et al. 2016; Chou et al. 2022). Low WHO/ISUP grade features are essential for its classification (CAP 2026a).
  • Papillary renal neoplasm with reverse polarity (PRNRP). PRNRP shows delicate papillae lined by a single layer of oncocytic cells with apical, luminal nuclei. It is GATA3, L1CAM, high-molecular-weight keratin and CK7 positive and vimentin and AMACR negative, and most tumors carry KRAS exon 2 codon 12 mutations (Trpkov et al. 2026). In 18 tumors, size ranged from 0.6 to 3 cm and all were pT1 (Al-Obaidy et al. 2019). No malignant behavior has been reported (Trpkov et al. 2026).

Chromophobe renal cell carcinoma and oncocytoma

  • Chromophobe RCC morphology and stains. Chromophobe RCC shows perinuclear clearing, binucleate cells and well-defined cell borders (vegetable cells) (Wobker and Williamson 2017). In 45 tumors, binucleation and perinuclear halos were present in all, Hale colloidal iron was positive in all, CK7 was positive in 100% and CD117 in 95.5%. Vimentin was negative except in sarcomatoid areas (Din et al. 2013).
  • Chromophobe RCC genetics. Chromophobe RCC shows losses of chromosomes 1 (70%), 2 (90%), 6 (80%), 10 (60%) and 17 (90%) in the classic form, with a similar pattern in the eosinophilic form. Oncocytoma lacks losses of chromosomes 2, 6, 10 and 17, and loss of chromosome 1 is occasional (Brunelli et al. 2005). Chromophobe RCC originates from the distal nephron and shows recurrent TERT promoter rearrangements (Davis et al. 2014).
  • Chromophobe RCC grading. WHO/ISUP grading is not applicable to chromophobe RCC (Delahunt et al. 2013; CAP 2026a). Alternative schemes, chromophobe tumor grade and grading by necrosis and sarcomatoid change, have been proposed (CAP 2026a). A reproducible universal grading system is still missing (Lobo et al. 2022).
  • Oncocytoma gross and microscopic features. Oncocytoma has a tan or mahogany-brown cut surface, often with a central scar. The scar is characteristic but occurs also in chromophobe RCC and is not always present. Nests of bland oncocytic cells have round, regular nuclei with prominent central nucleoli. Interdigitation with perinephric fat does not alter its benign behavior (Wobker and Williamson 2017).
  • Oncocytoma immunoprofile and outcome. Oncocytoma is CK7 negative in 80% and focally positive in 20%, CD117 positive and HNF1β positive (Kim et al. 2020). No distant metastasis or disease-related death has been reported for oncocytomas on active surveillance, and biopsy and surgical pathology were concordant in 89% (Edwards et al. 2025).

Other oncocytic tumors of the kidney (WHO 5th edition category)

The WHO 5th edition created "other oncocytic tumors of the kidney" for oncocytic tumors with oncocytoma-like or chromophobe-like features (Lobo et al. 2022). The category includes hybrid oncocytic tumors, sporadic or associated with Birt-Hogg-Dubé syndrome, eosinophilic vacuolated tumor (EVT), low-grade oncocytic tumor (LOT) and oncocytic tumors with borderline features (CAP 2026a). GUPS classified EVT as an emerging entity and LOT as a provisional entity in 2021 (Trpkov, Williamson et al. 2021).

Entity Morphology Immunoprofile Molecular Behavior Source
Low-grade oncocytic tumor (LOT) Solid; edematous stroma with loosely arranged cells; low-grade nuclei with focal perinuclear halos; patients 60–70 years CK7 diffuse, CD117 negative, GATA3 and L1CAM positive, FOXI1 negative or weak MTOR (50%), TSC1 (20%), TSC2 (9%), RHEB (8%) Benign Trpkov et al. 2026
Eosinophilic vacuolated tumor (EVT) Solid; large cytoplasmic vacuoles; prominent nucleoli; patients 45–55 years; female predominance CD117 positive, CK7 in scattered cells, cathepsin K at least focal, CD10 positive MTOR (43%), TSC2 (43%), TSC1 (14%) Benign; one case with metastasis Trpkov et al. 2026
FLCN-mutated (hybrid oncocytic) tumor Mosaic of eosinophilic and clear cells CD117 and CK7 focal; cathepsin K positive FLCN mutation, mostly in Birt-Hogg-Dubé syndrome Benign; rare aggressive cases Trpkov et al. 2026
Eosinophilic solid and cystic RCC (separate RCC type) Solid and cystic; voluminous eosinophilic cells with coarse basophilic stippling; marked female predominance CK20 positive (85%), CK7 negative, CD117 negative, vimentin positive Biallelic TSC2 or TSC1 loss; 5% in TSC Metastasis in 5%–10% Trpkov et al. 2026

Collecting duct carcinoma and SMARCB1-deficient renal medullary carcinoma

  • Collecting duct carcinoma. Collecting duct carcinoma constitutes 0.4%–2% of RCCs. It arises in the medulla, is firm, white or gray and poorly circumscribed, and shows a desmoplastic stromal reaction with atypical hyperplasia or carcinoma in situ in adjacent collecting ducts. Distinction from papillary RCC is the main histologic problem (Kuroda et al. 2002). Inherent high-grade nuclei and a uniformly aggressive course make nuclear grading unnecessary (CAP 2026a). The lack of consistent molecular alterations makes collecting duct carcinoma a diagnosis of exclusion, and historical cases have been reclassified as FH-deficient RCC, ALK-rearranged RCC, renal medullary carcinoma or high-grade urothelial carcinoma (Cabanillas et al. 2022).
  • Renal medullary carcinoma: clinical profile. In 40 patients, age ranged from 5 to 32 years, 82% were African American and all tested had sickle cell trait or disease. Survival ranged from 2 weeks to 15 months (Swartz et al. 2002). The diagnosis is considered in patients younger than 50 years with a poorly differentiated carcinoma of the renal medulla, and most patients present with metastatic disease (Beckermann et al. 2017).
  • Renal medullary carcinoma: SMARCB1. Complete loss of SMARCB1 (INI1) expression was found in 6 of 6 renal medullary carcinomas and 1 of 22 collecting duct carcinomas (Calderaro et al. 2012). GUPS requires negative INI1 and sickle cell trait or disease for the diagnosis (Trpkov, Hes et al. 2021). Under the WHO 5th edition, the category is reserved for carcinomas with medullary location or phenotype and SMARCB1 loss, and sickle cell trait or disease is very frequent, although its absence does not exclude the diagnosis (CAP 2026a).
  • Nomenclature (WHO 5th edition). Renal medullary carcinoma is now SMARCB1-deficient renal medullary carcinoma in the molecularly defined group. Clear cell RCC with sarcomatoid change and FH-deficient RCC may show secondary SMARCB1 loss and are classified by their underlying type (CAP 2026a).
  • Protocol choice. Urothelial carcinoma of the renal pelvis is reported with the CAP Ureter, Renal Pelvis protocol, and collecting duct carcinoma and FH-deficient RCC with the Kidney protocol (CAP 2026a).

Mucinous tubular and spindle cell carcinoma, tubulocystic RCC and acquired cystic disease-associated RCC

  • Mucinous tubular and spindle cell carcinoma (MTSCC). MTSCC is an admixture of cuboidal cells in tubules and sheets of spindle cells with variable amounts of mucinous stroma. It was originally considered low grade, but its histologic spectrum ranges from low to high grade and includes sarcomatoid differentiation (Zhao et al. 2015). MTSCC is separated from papillary RCC with overlapping morphology by losses of chromosomes 1, 4, 6, 8, 9, 13, 14, 15 and 22. Tumors with adverse histologic features frequently show CDKN2A/2B (9p) deletions (Trpkov, Hes et al. 2021). WHO/ISUP grading is potentially useful in MTSCC (CAP 2026a).
  • Tubulocystic RCC. In 31 tumors, mean age was 54 years and the male-to-female ratio was 7:1. The cut surface had a spongy "bubble wrap" appearance from closely packed cysts lined by a single layer of cuboidal, flat or hobnail cells with eosinophilic cytoplasm and prominent nucleoli. Disease progressed in 3 patients (Amin et al. 2009). The diagnosis is made only when the tumor is morphologically pure (Trpkov, Hes et al. 2021).
  • Tubulocystic RCC versus FH-deficient RCC. Tubulocystic RCC retains FH (Trpkov et al. 2026). High-grade nuclei are inherent to tubulocystic RCC, and nuclear grading may misrepresent its indolent behavior (CAP 2026a).
  • Acquired cystic disease-associated RCC (ACD-RCC). In 66 tumor-bearing end-stage kidneys, ACD-RCC formed the dominant mass in 36%. It showed microcystic architecture, eosinophilic cytoplasm, Fuhrman grade 3 nuclei and intratumoral oxalate crystals, and it occurred only in kidneys with acquired cystic disease (Tickoo et al. 2006). ACD-RCC is CD10 positive and CA9 negative (Kim et al. 2020). ACD-RCC-like cysts are probable precursors (Trpkov, Hes et al. 2021).

Molecularly defined renal cell carcinomas (WHO 5th edition)

Entity Defining alteration Morphology Confirmatory test Clinical points Source
TFE3-rearranged RCC TFE3 rearrangement (Xp11) Mixed papillary and solid; clear and eosinophilic cells; psammoma bodies TFE3 nuclear IHC; break-apart FISH or sequencing preferred At least one-third of pediatric RCC; adults: female predominance (22 of 28), stage 4 in 14 of 28, nodal metastases in 11 of 13 resected CAP 2026a; Argani et al. 2007
TFEB-altered RCC MALAT1::TFEB fusion from t(6;11), or TFEB (6p21) amplification Rearranged: biphasic, small cells around basement membrane material; amplified: high-grade, papillary or oncocytic Melan-A, HMB45, cathepsin K, TFEB; FISH shows multiple copies when amplified Rearranged median age 31 years; amplified median age 64.5 years with aggressive behavior Argani et al. 2016; CAP 2026a
ELOC-mutated RCC Biallelic ELOC inactivation Clear cells with fibromuscular bands CK7 positive; ELOC sequencing Mostly favorable Hakimi et al. 2015; CAP 2026a
FH-deficient RCC Germline (HLRCC) or rarely somatic FH mutation Papillary, solid, tubulocystic or cribriform; macronucleoli with perinucleolar clearing FH loss with 2SC positivity, or molecular confirmation Aggressive; rare low-grade oncocytic cases CAP 2026a; Trpkov et al. 2026
SDH-deficient RCC Germline SDHB (rarely SDHA, SDHC, SDHD) with somatic second hit Solid, bland eosinophilic flocculent cells with cytoplasmic vacuoles and inclusions SDHB loss; KIT and CK7 negative 0.05%–0.2% of RCC; mean age 37; bilateral 26%; metastasis in 70% with high-grade nuclei Gill et al. 2014; Trpkov et al. 2026
ALK-rearranged RCC ALK fusion with various partners Solid, papillary and cribriform; intracellular and background mucin ALK IHC or break-apart FISH Sickle cell trait in some children; up to 30% metastasize; ALK inhibitors may benefit Trpkov et al. 2026; CAP 2026a
SMARCB1-deficient renal medullary carcinoma SMARCB1 (22q11.23) inactivation Poorly differentiated medullary carcinoma INI1 loss with sickle cell trait or disease Nearly uniformly lethal CAP 2026a; Beckermann et al. 2017
  • FH and 2SC. Dual nuclear and cytoplasmic 2SC staining had a sensitivity of 100% and specificity of 91% for FH-deficient RCC. FH loss is specific and less sensitive, and 2SC is sensitive and less specific (Trpkov et al. 2026).
  • SDHB pitfall. Some SDH-deficient tumors show cytoplasmic blush staining for SDHB that can be misread as retained (Trpkov et al. 2026).
  • Low threshold for testing. GUPS recommends a low threshold for FH, 2SC and SDHB staining in difficult-to-classify RCC, particularly eosinophilic tumors in younger patients (Trpkov, Hes et al. 2021).

Hereditary renal tumor syndromes

Genetic risk assessment is recommended for patients with suggestive family history, bilateral or multifocal tumors or specific histologic types (Bratslavsky et al. 2021).

Syndrome Gene and locus Renal tumors Other features Source
von Hippel-Lindau disease VHL, 3p25–26; autosomal dominant Renal cysts and clear cell RCC Retinal, cerebellar and spinal hemangioblastomas; pheochromocytoma; pancreatic cysts, microcystic serous adenoma and neuroendocrine tumors; epididymal and broad ligament cystadenomas; endolymphatic sac tumors Kim and Zschiedrich 2018; Latif et al. 1993
Hereditary papillary renal carcinoma MET, 7q31 (germline activating) Multiple bilateral papillary RCC Autosomal dominant with reduced penetrance Schmidt et al. 1997
Birt-Hogg-Dubé syndrome FLCN, 17p11.2 Chromophobe RCC (34%), hybrid oncocytic tumors (50%), clear cell RCC (9%); mean 5.3 tumors per patient; microscopic oncocytosis Fibrofolliculomas; spontaneous pneumothorax Pavlovich et al. 2002; Nickerson et al. 2002
Hereditary leiomyomatosis and RCC FH, 1q42.3–q43 FH-deficient RCC Cutaneous and uterine leiomyomas Tomlinson et al. 2002; CAP 2026a
Hereditary SDH-deficient tumor syndrome SDHB, SDHA, SDHC, SDHD SDH-deficient RCC GIST and paraganglioma in the family Gill et al. 2014; Trpkov et al. 2026
Tuberous sclerosis complex TSC1 or TSC2 (mTOR pathway) Angiomyolipoma; ESC RCC (5% of cases arise in TSC); EVT and LOT Brain, skin, heart and lung tumors; lymphangioleiomyomatosis Henske et al. 2016; Trpkov et al. 2026
BAP1 tumor predisposition syndrome BAP1 (germline) RCC Uveal melanoma, malignant pleural mesothelioma, cutaneous melanoma Popova et al. 2013

WHO/ISUP grade applicability by renal tumor type (CAP 2026)

Tumor type Use of WHO/ISUP grade Source
Clear cell RCC; papillary RCC Validated CAP 2026a
Chromophobe RCC Not applicable CAP 2026a; Delahunt et al. 2013
TFE3-rearranged RCC May not be useful CAP 2026a
SDH-deficient RCC; MTSCC; ELOC-mutated RCC; TFEB-altered RCC; RCC NOS; FH-deficient RCC Potentially useful CAP 2026a
Collecting duct carcinoma; SMARCB1-deficient renal medullary carcinoma Not used; inherently aggressive CAP 2026a
Tubulocystic RCC; ACD-RCC; ESC RCC and EVT Potentially misleading CAP 2026a
Papillary adenoma; MCRNLMP; CCPRCT Low-grade features required for the diagnosis CAP 2026a
ALK-rearranged RCC No or limited data CAP 2026a
Other oncocytic tumors of the kidney Low or high grade, but histologic features do not predict behavior CAP 2026a

Differential diagnosis of eosinophilic renal tumors

Tumor Key morphology Key stains Source
Oncocytoma Nests of oncocytic cells CK7 negative or focal; CD117 positive Kim et al. 2020
Chromophobe RCC, eosinophilic Perinuclear halos, binucleation CK7 diffuse; CD117 positive; Hale colloidal iron positive Din et al. 2013; Kim et al. 2020
SDH-deficient RCC Flocculent cytoplasm with vacuoles and inclusions SDHB loss; KIT and CK7 negative Gill et al. 2014; Trpkov et al. 2026
FH-deficient RCC Macronucleoli with perinucleolar halos FH loss; 2SC positive CAP 2026a; Trpkov et al. 2026
ESC RCC Coarse basophilic stippling; cysts with hobnail cells CK20 positive; CK7 negative Trpkov et al. 2026
TFEB-altered RCC Biphasic nests around basement membrane material Melan-A, cathepsin K Argani et al. 2016
Epithelioid angiomyolipoma ≥80% epithelioid cells Cathepsin K and melanocytic markers positive; PAX8 and keratin negative Trpkov et al. 2026

Pediatric, Mesenchymal and Other Renal Tumors, Nephrectomy Grossing, WHO/ISUP Grading and Kidney Cancer Staging

Definition. Pediatric renal tumors include Wilms tumor and its precursor nephrogenic rests, congenital mesoblastic nephroma, clear cell sarcoma of the kidney, rhabdoid tumor and cystic tumors. Other renal tumors include the metanephric family, angiomyolipoma, the mixed epithelial and stromal tumor family, juxtaglomerular cell tumor, sarcomas, lymphoma and metastases. AJCC and UICC TNM staging does not apply to Wilms tumor or other pediatric renal tumors except renal cell carcinoma. These tumors are staged by the Children's Oncology Group (COG) system after upfront surgery in North America, or by the International Society of Paediatric Oncology (SIOP) system after preoperative chemotherapy in Europe and many other countries (CAP 2026c). Renal cell carcinoma is staged by AJCC 8th edition pTNM and graded by the WHO/ISUP system (CAP 2026a; Delahunt et al. 2013). The current CAP protocols are Kidney Resection 4.3.0.0 and Kidney Biopsy 4.3.0.0 (June 2026), Wilms Tumor Resection 4.4.1.0 (September 2026) and Wilms Tumor Biopsy 5.0.0.1 (June 2025) (CAP 2026a; CAP 2026b; CAP 2026c; CAP 2025).

Related page: Urothelial Carcinoma of the Renal Pelvis, Wilms Tumor, Metastases and Lymphoma in Kidney FNA (Wilms tumor on FNA, SIOP and COG biopsy approaches, renal lymphoma and metastases on FNA) Related page: Kidney FNA: Indications, Normal Elements and Benign Lesions (angiomyolipoma on FNA) Related page: Renal Cell Carcinoma Subtypes on FNA (CAP biopsy elements and grade magnifications in cytology and core biopsy) Related page: Renal Cell Carcinoma and Oncocytic Renal Tumors (RCC entities and the use of WHO/ISUP grade in each) Related page: Other Lung Tumors: Hamartoma, Sclerosing Pneumocytoma, Adenomas, Salivary Gland-Type, Mesenchymal and Lymphoid Tumors, and Metastases (PEComa family) Related page: Ovarian Sex Cord-Stromal Tumors, Small Cell Carcinoma of Hypercalcemic Type and Wolffian and STK11 Adnexal Tumors (DICER1 syndrome) Related page: Renal Biopsy Evaluation and Nephrotic Glomerular Diseases: Minimal Change Disease, FSGS, Membranous and Diabetic Nephropathy, Amyloidosis and Monoclonal Immunoglobulin Deposition (WT1-associated glomerulopathy, diffuse mesangial sclerosis, Denys-Drash and Frasier syndromes)

Wilms tumor: histology, immunohistochemistry and genetics

  • Histology. Classic Wilms tumor contains blastemal, stromal and epithelial elements. Overlapping nuclei with finely dispersed chromatin favor Wilms tumor over the round cell tumors most often misdiagnosed as blastemal Wilms tumor: undifferentiated neuroblastoma, Ewing sarcoma and synovial sarcoma (CAP 2026c).
  • Epithelial-predominant tumors. Epithelial-predominant Wilms tumor overlaps with papillary RCC and metanephric adenoma (CAP 2026c).
  • Immunohistochemistry. No marker proves or excludes Wilms tumor. WT1 stains blastemal and epithelial elements and is negative in up to 20%. PAX8 and PAX2 are expressed and help exclude soft tissue round cell tumors (CAP 2026c).
  • Recurrent mutations. Recurrently mutated genes include WT1, CTNNB1, AMER1, DROSHA, DGCR8, XPO5, DICER1, SIX1, SIX2, MLLT1, MYCN and TP53. Copy-number changes include 1q gain, MYCN amplification, LIN28B gain and MIRLET7A loss (Gadd et al. 2017). About 70% of Wilms tumors overexpress IGF2 (CAP 2026c).
  • LOH 1p and 16q. In NWTS-5, combined loss of heterozygosity for 1p and 16q in stage I–II favorable-histology tumors raised the relative risk of relapse to 2.9 and of death to 4.3 (Grundy et al. 2005). Analysis of these loci is routine in North America because augmented therapy is effective for combined LOH (CAP 2026c).
  • 1q gain. 1q gain was present in 28% of 1114 favorable-histology tumors. Eight-year event-free survival was 77% with 1q gain and 90% without it (Gratias et al. 2016). Validation of 1q gain is a main molecular aim of the UMBRELLA protocol (Vujanić et al. 2018).
  • 11p15 and TP53. LOH and loss of imprinting at 11p15 are associated with relapse in young patients with stage I favorable-histology tumors treated by nephrectomy alone. TP53 mutations are found in 50%–75% of anaplastic Wilms tumors (CAP 2026c).
Predisposition syndrome Genetic basis Renal and other features Source
WAGR syndrome Germline contiguous deletion of 11p13 that must include WT1 and the aniridia gene PAX6; isolated PAX6 deletion carries no Wilms tumor risk Wilms tumor risk 45%–60%; aniridia, genitourinary anomalies, developmental delay; intralobar nephrogenic rests. In 43 SIOP-RTSG patients, tumors were bilateral in 37.5% and stromal type in 52.8%, rests were present in 78.9%, anaplasia was not reported, and no patient had metastases Hol et al. 2021; CAP 2026c
Denys-Drash syndrome WT1 exon 8 and 9 mutations Early steroid-resistant nephrotic syndrome with diffuse mesangial sclerosis; Wilms tumor; disorders of sex development; intralobar rests Roca et al. 2019; CAP 2026c
Frasier syndrome WT1 intron 9 splice-site mutation Steroid-resistant nephrotic syndrome; 46,XY female phenotype; gonadal tumor risk Khandelwal et al. 2026
Beckwith-Wiedemann syndrome and hemihyperplasia 11p15 Overgrowth; perilobar nephrogenic rests; nephrolithiasis and medullary dysplasia CAP 2026c; Vujanić et al. 2018
Others listed by CAP REST, TRIM28, Perlman syndrome, trisomy 18, neurofibromatosis, Bloom syndrome Wilms tumor predisposition CAP 2026c

Anaplasia in Wilms tumor: definition and focal versus diffuse distribution

  • Frequency and significance. Anaplasia is present in about 5% of Wilms tumors and is the major prognostic indicator. Anaplastic cells have increased resistance to therapy without increased aggressiveness (Faria et al. 1996).
  • Definition. Anaplasia requires gigantic polyploid nuclei with diameters at least 3 times those of adjacent cells and multipolar or otherwise recognizable polyploid mitotic figures. On a small biopsy, a single multipolar mitosis or an unequivocally gigantic nucleus may suffice (CAP 2026c).
  • Pseudoanaplasia. Cells with rhabdomyoblastic differentiation may show nuclear enlargement and pleomorphism. Pseudoanaplasia has more cytoplasm and lacks atypical mitoses (CAP 2026c).
  • Focal anaplasia. Focal anaplasia requires all of the following: no anaplasia in renal vessels or outside the kidney; anaplasia confined to one or two sharply localized regions, each <15 mm, within the primary intrarenal tumor; nonanaplastic tumor around each focus; and no severe nuclear unrest elsewhere (CAP 2026c).
  • Diffuse anaplasia. Diffuse anaplasia applies when anaplasia is present in any extrarenal site, including renal sinus vessels, extracapsular infiltrates or metastases, in intrarenal vascular involvement, or in a random biopsy, or when the tumor fails any criterion for focal anaplasia (CAP 2026c).
  • Outcome. Among 39 NWTS-3 and NWTS-4 patients with focal anaplasia, only 3 relapsed and 1 died, comparable to nonanaplastic tumors. Of 23 children with stage IV diffuse anaplasia, 22 died of tumor (Faria et al. 1996). Focal and diffuse anaplastic Wilms tumors are separate clinicopathologic entities, and outcomes of stage III and IV diffuse anaplasia remain poor (Vujanić and Mifsud 2024).
  • Mapping. The topographic definition requires documentation of the exact site of every section on a diagram or photograph (CAP 2026c).
  • Anaplasia after therapy. Chemotherapy and radiation do not cause anaplasia, and the same criteria apply after therapy (CAP 2026c).

Nephrogenic rests and nephroblastomatosis

  • Frequency. Nephrogenic rests are foci of embryonal cells persisting after 36 weeks of gestation and are considered Wilms tumor precursors. They are found in 35%–40% of patients with unilateral and more than 90% of patients with bilateral Wilms tumor (Vujanić et al. 2018).
  • Nephroblastomatosis. Nephroblastomatosis denotes multiple, multifocal or diffuse rests. Panlobar nephroblastomatosis, with complete replacement of a renal lobe or the cortex, is a high-risk factor for Wilms tumor (Vujanić et al. 2018). Beckwith classified rests as nascent or dormant, maturing or sclerosing, hyperplastic and neoplastic (Beckwith et al. 1990).
  • Hyperplastic rest versus Wilms tumor. A hyperplastic perilobar rest and Wilms tumor can be cytologically identical. The absence of a peritumoral fibrous capsule is the most helpful feature of the rest (CAP 2026c).
  • Margins and staging. A nephrogenic rest at a resection margin is not a positive margin, and resection of a rest alone is not staged (CAP 2026c).
Feature Perilobar nephrogenic rest Intralobar nephrogenic rest Source
Location Periphery of the lobule, usually subcapsular Deep within the lobule CAP 2026c
Number and borders Often multiple; well demarcated, unencapsulated Usually solitary; indistinct margins CAP 2026c
Composition Blastema and tubules with little stroma Blastema, tubules and prominent stroma interspersed with normal nephrons CAP 2026c
Associated Wilms tumor Blastemal or epithelial predominant; median age 36 months; synchronous bilateral tumors Stromal predominant or teratoid; median age 16 months; metachronous contralateral tumors Beckwith et al. 1990; CAP 2026c
Syndromes Beckwith-Wiedemann syndrome, hemihypertrophy, overgrowth; IGF2 loss of imprinting WAGR and Denys-Drash syndromes Beckwith et al. 1990; CAP 2026c

COG and SIOP staging of Wilms tumor (CAP Wilms Tumor Resection 4.4.1.0)

COG staging assigns the local stage before chemotherapy, and SIOP staging is assigned after neoadjuvant chemotherapy (CAP 2026c). Survival exceeds 90% for all stages together under both approaches (Vujanić et al. 2022).

Stage COG (upfront surgery) SIOP (after preoperative chemotherapy) Source
I Limited to kidney and completely resected; capsule intact; no biopsy before removal; no viable tumor in renal vein or sinus vessels; no nodal tumor Limited to kidney and completely resected; tumor in perirenal fat allowed if surrounded by a fibrous pseudocapsule not reaching the outer surface; encapsulated adrenal infiltration allowed; intrarenal vessel involvement allowed CAP 2026c
II Viable tumor beyond the kidney, completely resected with negative margins: capsular penetration, perirenal fat or adrenal, extrarenal or renal sinus lymphovascular invasion, renal vein tumor not transected, renal pelvis or ureter wall invasion, more than minimal sinus soft tissue invasion Viable tumor in renal sinus or extrarenal vessels, unencapsulated perirenal fat, vena cava or adjacent organs, or renal pelvis or ureter wall, completely excised CAP 2026c
III Viable or nonviable tumor at a margin; rupture or spill; piecemeal excision; abdominopelvic nodal tumor; any biopsy before surgery in pretherapy cases; peritoneal implants Viable tumor at a margin; viable or nonviable tumor in abdominal nodes; microscopically confirmed rupture; thrombus at ureter, renal vein or IVC margins; piecemeal removal of IVC-attached thrombus; open or wedge biopsy; implants; peritoneal penetration CAP 2026c
IV Hematogenous metastases or nodes outside the abdominopelvic region Hematogenous metastases (lung, liver, bone, brain) or nodes outside the abdominopelvic region CAP 2026c
V Bilateral tumors at diagnosis; each side staged separately Bilateral tumors at diagnosis; each side staged separately CAP 2026c
  • Renal sinus. COG accepts minimal renal sinus soft tissue invasion without vascular involvement, a single focus <5 mm located >5 mm from the nearest margin, as stage I. Any sinus involvement is stage II under SIOP. Failure to recognize sinus soft tissue or lymphovascular involvement is the most common cause of upstaging on central review (CAP 2026c).
  • Biopsy. Any pretherapy biopsy is a COG stage III criterion. Under SIOP only an open or wedge biopsy is stage III, and percutaneous needle core biopsy does not upstage (CAP 2026c; Vujanić et al. 2018).
  • Necrotic tumor. Necrotic tumor or chemotherapy-induced change in the renal sinus or perirenal fat does not upstage when completely excised. Necrotic tumor in a lymph node or at a margin is stage III, except at the perinephric margin under SIOP (CAP 2026c).
  • Renal vein margin. A protruding thrombus in a retracted vein is not a positive margin when the thrombus is not transected and the vein wall at the margin is free of tumor (CAP 2026c).

SIOP UMBRELLA 2016 and COG classification of Wilms tumor after preoperative chemotherapy

SIOP UMBRELLA subtype Chemotherapy-induced change Viable blastema Viable epithelium Viable stroma Risk group Source
Completely necrotic 100% 0 0 0 Low Vujanić et al. 2018
Regressive >66% Any Any Any Intermediate Vujanić et al. 2018
Mixed <66% 0%–65% 0%–65% 0%–65% Intermediate Vujanić et al. 2018
Mixed <66% 11%–65% 0%–89% 0%–89% Intermediate Vujanić et al. 2018
Epithelial <66% 0%–10% 66%–100% 0%–33% Intermediate Vujanić et al. 2018
Stromal <66% 0%–10% 0%–33% 66%–100% Intermediate Vujanić et al. 2018
Blastemal <66% 66%–100% 0%–33% 0%–33% High Vujanić et al. 2018
Focal anaplasia Any Any Any Any Intermediate Vujanić et al. 2018
Diffuse anaplasia Any Any Any Any High Vujanić et al. 2018
  • Supersession. Diffuse anaplasia supersedes all subtypes, and focal anaplasia is specifically reported (Vujanić et al. 2018).
  • Blastemal volume and tumor volume. A residual blastemal volume of about 20 mL may improve stratification of localized tumors. Stage II or III mixed, regressive or focal anaplasia tumors with a postchemotherapy volume >500 mL are treated as higher risk (Vujanić et al. 2018).
  • Primarily operated tumors. After immediate nephrectomy, as in children <6 months, SIOP classification depends only on diffuse anaplasia: intermediate risk if absent and high risk if present (Vujanić et al. 2018).
  • COG posttherapy categories. COG uses the SIOP low, intermediate and high-risk categories for treated favorable-histology tumors. High risk is viable tumor >33% of the mass with blastema >66% of viable tumor. A prior biopsy does not upstage a posttherapy specimen to COG stage III (CAP 2026c).
  • SIOP biopsy policy. Pretreatment biopsy is not routine in UMBRELLA. Needle biopsy is considered in young children with stage IV disease and in children older than 10 years because rhabdoid tumor and RCC, respectively, are more frequent in these groups. Biopsy is avoided in children <6 months and in fully cystic tumors (Vujanić et al. 2018).

Handling of pediatric nephrectomy specimens (CAP Wilms protocol)

  • Frozen section. Intraoperative frozen sections are avoided unless the procedure will change, because of the high false-positive rate (CAP 2026c).
  • Tissue banking. Viable tumor (≥1 g) is snap-frozen in 2 or more vials with a separate vial of nonneoplastic kidney (CAP 2026c).
  • Specimen surface. The specimen is received intact, photographed and inked before bivalving. The capsule is never stripped (CAP 2026c).
  • Sampling. At least one section per centimeter of maximal tumor diameter is taken, mostly from the periphery, with sections of the sinus adjacent to tumor, each nodule, suspected rests, normal kidney and the distal ureter margin. Hilar fat is submitted entirely when no lymph nodes are submitted or found. Nephrectomy weight is recorded (CAP 2026c).
  • Wilms tumor biopsy protocol. The CAP Wilms Tumor Biopsy protocol 5.0.0.1 lists favorable histology and diffuse anaplasia and has no focal anaplasia option (CAP 2025). Anaplasia in a random biopsy is classified as diffuse (CAP 2026c).

Congenital mesoblastic nephroma, clear cell sarcoma and rhabdoid tumor of the kidney

Feature Congenital mesoblastic nephroma Clear cell sarcoma of the kidney Rhabdoid tumor of the kidney Source
Age Infancy Mean 36 months (2 months to 14 years); male-to-female ratio 2:1 Most often <1 year; uncommon after 5 years Argani et al. 2000; CAP 2026c
Morphology Classic: bland spindle cells in long sweeping fascicles; cellular: plump cells, higher mitotic rate; mixed Nests or cords 8–12 cells wide separated by arborizing vessels; entrapped tubules; classic, myxoid, sclerosing, cellular, epithelioid, palisading, spindle, storiform and anaplastic patterns Large vesicular nuclei, prominent nucleolus, eosinophilic globular cytoplasmic inclusions; aggressive invasion Argani et al. 2000; CAP 2026c
Immunohistochemistry Cellular type may be PAX8 and desmin positive, CD34 and keratin negative Vimentin; BCOR, cyclin D1 and NGFR; keratin negative Loss of INI1; focal strong EMA; polyphenotypic Argani et al. 2000; Hoot et al. 2004; CAP 2026c
Genetics Cellular (66%): ETV6::NTRK3 with trisomy 11; classic (24%): EGFR internal tandem duplication BCOR internal tandem duplication; YWHAE::NUTM2 fusion in about 12%–15% SMARCB1 (22q11.2) deletion or mutation; germline in some Knezevich et al. 1998; Wegert et al. 2018; Ueno-Yokohata et al. 2015; O'Meara et al. 2012; CAP 2026c
Behavior About 10% recur, virtually all cellular, almost all in the first year Stage I survival 98%; metastasis to bone, brain and soft tissue; recurrence after years to decades 4-year survival 8.8% under 6 months versus 41.1% at ≥2 years; CNS tumor nearly always fatal Argani et al. 2000; Tomlinson et al. 2005; CAP 2026c
  • CMN genetics. ETV6::NTRK3 fusions were detected in 8 of 9 cellular and 2 of 2 mixed CMNs and in none of 4 classic CMNs, linking cellular CMN to congenital fibrosarcoma (Knezevich et al. 1998). EGFR kinase domain internal tandem duplication delineates CMN from other childhood renal tumors (Wegert et al. 2018).
  • CMN margins. Completeness of excision, particularly of the medial margin, is the main determinant of outcome (CAP 2026c).
  • CCSK genetics. BCOR internal tandem duplications were found in 20 of 20 CCSKs and none of 193 other pediatric renal tumors (Ueno-Yokohata et al. 2015). YWHAE fusion-positive tumors were never stage I (O'Meara et al. 2012).
  • CCSK prognosis. Doxorubicin treatment, stage, age and necrosis were independent prognostic factors in 351 cases, and only vimentin stained consistently (Argani et al. 2000).
  • Rhabdoid tumor. INI1 expression was lost in all 44 renal and extrarenal rhabdoid tumors and retained in the nonrhabdoid tumors tested. Synovial and epithelioid sarcomas showed variable or focal staining (Hoot et al. 2004). Renal medullary carcinoma and epithelioid sarcoma also lose INI1 (CAP 2026c). Molecular SMARCB1 testing is not needed for diagnosis and helps identify germline mutations (CAP 2026c).

Pediatric cystic renal tumors

  • Pediatric cystic nephroma. DICER1 mutations are the major genetic event in pediatric cystic nephroma, with loss-of-function and RNase IIIb hotspot mutations at rates similar to pleuropulmonary blastoma. Sarcomas can arise in cystic nephroma and resemble type II or III pleuropulmonary blastoma (Doros et al. 2014).
  • Cystic partially differentiated nephroblastoma (CPDN). CPDN is a Wilms tumor variant of children <3 years composed entirely of cysts and septa without solid nodules. Cystic nephroma and CPDN are molecularly unrelated (Vujanić et al. 2018).
  • Cystic Wilms tumor. Intermediate-risk or high-risk Wilms tumors can be extensively cystic, especially after chemotherapy, but they contain solid nodules. The cysts have no prognostic significance (Vujanić et al. 2018).

Differential diagnosis of pediatric renal tumors by age

Age group Tumors favored Distinguishing features Source
Infants in the first year Congenital mesoblastic nephroma; rhabdoid tumor CMN spindle cells with ETV6::NTRK3 or EGFR duplication; rhabdoid tumor INI1 loss CAP 2026c; Tomlinson et al. 2005
Infants and toddlers Wilms tumor with intralobar rests (median 16 months); CPDN (<3 years) Triphasic histology; cystic septa with blastema Beckwith et al. 1990; Vujanić et al. 2018
About 3 years Wilms tumor with perilobar rests (median 36 months); clear cell sarcoma (mean 36 months) Wilms: pushing border; CCSK: infiltrative border entrapping tubules, BCOR duplication Beckwith et al. 1990; Argani et al. 2000; CAP 2026c
Older than 10 years Renal cell carcinoma Needle biopsy is considered before chemotherapy in this group Vujanić et al. 2018
Any age with sickle cell trait SMARCB1-deficient renal medullary carcinoma INI1 loss with sickle cell trait Trpkov, Hes et al. 2021

Metanephric tumors

  • Metanephric adenoma. BRAF V600E was found in 26 of 29 metanephric adenomas, about 90%, and in only 1 of 129 other renal neoplasms. No recurrence occurred after resection (Choueiri et al. 2012).
  • Metanephric adenoma versus epithelial Wilms tumor. Metanephric adenoma is composed of tightly packed small uniform acini with a low Ki-67 index and expresses WT1 and CD57. Epithelial-predominant Wilms tumors lacked BRAF mutation and had Ki-67 indices up to 60% (Yin et al. 2022).
  • Metanephric stromal tumor. BRAF V600E was present in 11 of 17 metanephric stromal tumors and absent in congenital mesoblastic nephroma (Marsden et al. 2017). Metanephric stromal tumor shows concentric onion-skin cuffing around tubules and is CD34 positive and desmin, S100 and SMA negative (Zhang et al. 2020).
  • Family. BRAF mutations unify the metanephric family of tumors (Trpkov, Hes et al. 2021).

Angiomyolipoma and epithelioid angiomyolipoma

  • Angiomyolipoma (AML). AML is a benign tumor of vessels, smooth muscle and adipose tissue in the perivascular epithelioid cell tumor (PEComa) family, sporadic or associated with tuberous sclerosis complex and lymphangioleiomyomatosis (Lubner et al. 2025). Classic AML expresses melanocytic markers, with melan-A usually stronger than HMB45, together with diffuse SMA. Among 52 AMLs, 31 were classic, 13 leiomyoma-like, 5 lipoma-like, 2 epithelioid and 1 with epithelial cysts (Fejes et al. 2022).
  • Fat-poor AML and complications. Fat-poor AMLs are smooth muscle-predominant. Hemorrhage occurs mostly in large tumors or tumors with aneurysms ≥5 mm, and benign AML may extend into the renal vein and inferior vena cava (Lubner et al. 2025).
  • Epithelioid AML. Epithelioid AML contains ≥80% epithelioid cells. It is positive for cathepsin K, GPNMB, melan-A and HMB45 and negative for keratin and PAX8, and about 5% metastasize (Trpkov et al. 2026). In 76 patients, 70% were female, median age was 48 years, 19 had TSC and 6.7% developed metastases (Pecoraro et al. 2026).

Mixed epithelial and stromal tumor family, juxtaglomerular cell tumor and adult renal sarcoma

  • Mixed epithelial and stromal tumor (MEST) family. The MEST family includes adult cystic nephroma. In 14 tumors, all patients were female (median age 49 years). Tumors contained bland glands, tubules and cysts within an ovarian-type spindle cell stroma, whole chromosome 12 gain occurred in 36%, and no recurrence followed surgery (Coiner et al. 2026). In another series of 8 MESTs, estrogen and progesterone receptors were frequently expressed in the nuclei of the spindle stromal cells (Wang et al. 2013).
  • Renomedullary interstitial cell tumor (medullary fibroma). This tumor of the prostaglandin-producing renomedullary interstitial cells is found incidentally in 16%–42% of adult autopsies (average age 57 years). It lies in the medulla and has abundant fibrous stroma and low cellularity (Yamamoto et al. 2023).
  • Juxtaglomerular cell tumor. In 21 tumors, 16 patients were female and the mean age was 36.9 years. All tumors were positive for renin and CD34, secretory granules were present ultrastructurally, and one tumor metastasized (Zhou et al. 2020).
  • Adult renal sarcoma. Among 489 adults in SEER, median age was 61 years and median size 11 cm. Leiomyosarcoma (175) and liposarcoma (100) were the most frequent types, and 5-year cancer-specific survival was 58% for nonmetastatic and 16% for metastatic disease (Moreira et al. 2015). Sarcomas are reported with the CAP soft tissue protocol (CAP 2026a).
  • Synovial sarcoma and Ewing sarcoma of the kidney. Primary renal synovial sarcoma is monophasic more often than biphasic, and the monophasic form tends to have a better prognosis (Lopes et al. 2013). In 8 renal Ewing sarcoma/PNET cases, the male-to-female ratio was 7:1, mean age was 26.5 years, all tumors were locally advanced, and CD99 supported the diagnosis (Pathak et al. 2024).

Lymphoma and metastases involving the kidney

  • Primary renal lymphoma. Among 14 patients (mean age 60.4 years), all tumors were unilateral. Diffuse large B-cell lymphoma (8), extranodal marginal zone lymphoma (5) and extranodal NK/T-cell lymphoma (1) were found, and median overall survival was 38 months (Wang et al. 2025). Hematopoietic neoplasms are reported with the CAP lymphoid protocols (CAP 2026a).
  • Metastases to the kidney. In 43 surgical cases, common primary sites were lung, breast, female genital tract and head and neck. Metastases were unilateral in 77% and unifocal in 70%, and 19% of resections showed renal vein extension. Urothelial carcinoma and high-grade RCC were the main mimics, and thyroid metastases mimicked low-grade RCC (Wu et al. 2015).

Nephrectomy grossing for renal cell carcinoma

  • Specimen types. A radical nephrectomy contains the kidney, calyces, pelvis, a variable length of ureter and perirenal fat to Gerota fascia. The adrenal gland is removed only when involvement is suspected, and regional lymphadenectomy is not routine. A partial nephrectomy ranges from enucleation to resection with calyceal or pelvic tissue (CAP 2026a).
  • Opening and sampling (ISUP 2012). Radical nephrectomies are opened along the long axis, and radical and partial specimens are inked. Tumors are sampled at one block per centimeter with a minimum of 3 blocks. With multiple tumors, at least the 5 largest are sampled. The length of a renal vein or caval thrombus is not part of the tumor size (Trpkov et al. 2013).
  • Perinephric fat invasion. Perinephric fat invasion is tumor touching the fat or extending as irregular tongues beyond the capsule, with or without desmoplasia, assessed with multiple perpendicular sections (Trpkov et al. 2013). Separate tumor nodules in perinephric fat also qualify. Renal capsule invasion without extension into perinephric tissue does not upstage to pT3 (CAP 2026a).
  • Renal sinus invasion. Sinus invasion is tumor in direct contact with sinus fat or loose connective tissue clearly beyond the parenchyma, or involvement of any endothelium-lined space in the sinus, regardless of size. At least 3 blocks of the tumor-sinus interface are submitted when invasion is uncertain (Trpkov et al. 2013). Sinus invasion is present in more than 90% of tumors ≥7 cm (CAP 2026a).
  • Sinus invasion frequency. In 23 apparently renal-limited pT1 or pT2 carcinomas, 7 (30.4%) had invaded sinus fat, mostly clear cell RCC (Bonsib et al. 2000).
  • Margins. In partial nephrectomy, the parenchymal margin is inked and sectioned perpendicularly, and any benign tissue over the tumor makes the margin negative. Tumor in the renal vein lumen without adherence to or invasion of the wall at the margin is a negative margin (CAP 2026a).
  • Nonneoplastic kidney. Arterionephrosclerosis and diabetic nephropathy are found in about 30% and 20% of nephrectomies. More than 20% global glomerulosclerosis or advanced diabetic glomerulosclerosis predicts significant decline in renal function 6 months after radical nephrectomy. At least 5 mm of nonneoplastic parenchyma is a reasonable minimum for evaluation, with PAS and Jones silver stains as needed (CAP 2026a).

AJCC 8th edition pathologic staging of renal cell carcinoma

Category Definition Source
pT1a ≤4 cm, limited to the kidney CAP 2026a
pT1b >4 cm and ≤7 cm, limited to the kidney CAP 2026a
pT2a >7 cm and ≤10 cm, limited to the kidney CAP 2026a
pT2b >10 cm, limited to the kidney CAP 2026a
pT3a Extension into the renal vein or its segmental branches, invasion of the pelvicalyceal system, or invasion of perirenal or renal sinus fat without extension beyond Gerota fascia CAP 2026a
pT3b Extension into the vena cava below the diaphragm CAP 2026a
pT3c Extension into the vena cava above the diaphragm or invasion of the vena cava wall CAP 2026a
pT4 Invasion beyond Gerota fascia, including contiguous invasion of the ipsilateral adrenal gland CAP 2026a
pN0 or pN1 No regional nodal metastasis, or metastasis in regional nodes (hilar, paracaval, aortic and related nodes) CAP 2026a
pM1 Distant metastasis, including noncontiguous adrenal involvement CAP 2026a
  • Edition. AJCC 8th edition remains the staging standard of the CAP kidney protocol (CAP 2026a). The 8th edition adopted the WHO/ISUP nucleolar grade for kidney cancer (Paner et al. 2018).
  • Adrenal involvement. Contiguous adrenal invasion is pT4, and a separate adrenal nodule is pM1 (CAP 2026a).
  • Patterns of extrarenal extension. Multiple patterns of extrarenal extension carry a higher risk of progression and cancer death than isolated perinephric fat, renal sinus fat or renal vein involvement, which carry similar prognostic weight (CAP 2026a).
Stage group (AJCC 8th) TNM Source
I T1 N0 M0 Shao et al. 2018
II T2 N0 M0 Shao et al. 2018
III T1–T2 N1 M0; T3 N0–N1 M0 Shao et al. 2018
IV T4 any N M0; any T any N M1 Shao et al. 2018
  • Microvascular invasion. Microvascular invasion is not a staging criterion (Delahunt et al. 2013). Lymphatic or small vessel invasion is recorded separately from renal vein involvement (CAP 2026a).

WHO/ISUP grading of renal cell carcinoma and the Fuhrman grade

WHO/ISUP grade Definition Source
G1 Nucleoli absent or inconspicuous at 400× CAP 2026a; Delahunt et al. 2013
G2 Nucleoli conspicuous and visible at 400× and without prominence at 100× CAP 2026a; Delahunt et al. 2013
G3 Nucleoli conspicuous at 100× CAP 2026a; Delahunt et al. 2013
G4 Extreme nuclear pleomorphism, multinucleated giant cells, rhabdoid or sarcomatoid differentiation CAP 2026a; Delahunt et al. 2013
  • Rule of the highest grade. Grade is assigned from the highest grade present in a single high-power field (CAP 2026a).
  • Validation. WHO/ISUP grading is validated for clear cell and papillary RCC and is reported descriptively for other types. It is not applicable to chromophobe RCC (Delahunt et al. 2013; CAP 2026a).
  • Sarcomatoid and rhabdoid differentiation. No minimum proportion is required for diagnosis. The underlying type is reported, and a sarcomatoid tumor without an identifiable type is classified as RCC NOS, grade 4 (Delahunt et al. 2013; CAP 2026a). The percentages of rhabdoid and sarcomatoid components are optional CAP elements (CAP 2026a).
  • Extent of grade 4. In clear cell RCC, tumors with <10% grade 4 component did not differ in outcome from grade 3 tumors, and >50% grade 4 had worse metastasis-free survival than <10% (Dagher et al. 2019).
  • Necrosis. Tumor necrosis is prognostic in clear cell and chromophobe RCC and is recorded as a percentage. Necrosis cannot be assessed after presurgical arterial embolization (CAP 2026a). ISUP recommends quantifying necrosis in clear cell RCC by gross and microscopic assessment (Delahunt et al. 2013).
  • Fuhrman grade (previous rule). Fuhrman grading assigned grades 1–4 by increasing nuclear size, irregularity and nucleolar prominence (Fuhrman et al. 1982). In clear cell RCC, worst nucleolar grade was associated with outcome, and nuclear shape was not (Delahunt et al. 2011). In papillary RCC, only focal nucleolar grade among the Fuhrman components was associated with survival (Sika-Paotonu et al. 2006).
  • CAP 4.3.0.0 grade field. In the June 2026 version, G4 is a separate response and GX (cannot be assessed) is a response (CAP 2026a).

CAP Kidney protocol elements for resection and biopsy

Element Resection 4.3.0.0 Biopsy 4.3.0.0 Source
Procedure and laterality Required Required CAP 2026a; CAP 2026b
Tumor focality and size Required Not included CAP 2026a; CAP 2026b
Histologic type (WHO 5th edition) Required; includes "other oncocytic tumors of the kidney" Required; includes "other oncocytic tumors of the kidney" CAP 2026a; CAP 2026b
WHO/ISUP grade Required Required CAP 2026a; CAP 2026b
Rhabdoid and sarcomatoid features Required, as separate questions Required, as separate questions CAP 2026a; CAP 2026b
Tumor necrosis Required Optional CAP 2026a; CAP 2026b
Tumor extent, margins, nodes, pTNM Required Not included CAP 2026a; CAP 2026b
Lymphatic or vascular invasion Required Required CAP 2026a; CAP 2026b
Additional findings in nonneoplastic kidney Required Optional CAP 2026a; CAP 2026b

References

  1. Al-Obaidy KI, Eble JN, Cheng L, et al. Papillary renal neoplasm with reverse polarity: a morphologic, immunohistochemical, and molecular study. Am J Surg Pathol. 2019;43(8):1099–1111. doi:10.1097/PAS.0000000000001288. PMID 31135486
  2. Al-Rabadi LF, Caza T, Trivin-Avillach C, et al. Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy. J Am Soc Nephrol. 2021;32(7):1666-1681. doi:10.1681/ASN.2020101395. PMID 33952630
  3. Amin MB, MacLennan GT, Gupta R, et al. Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol. 2009;33(3):384–392. doi:10.1097/PAS.0b013e3181872d3f. PMID 19011562
  4. Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007;31(8):1149–1160. doi:10.1097/PAS.0b013e318031ffff. PMID 17667536
  5. Argani P, Perlman EJ, Breslow NE, et al. Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumor Study Group Pathology Center. Am J Surg Pathol. 2000;24(1):4–18. doi:10.1097/00000478-200001000-00002. PMID 10632483
  6. Argani P, Reuter VE, Zhang L, et al. TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am J Surg Pathol. 2016;40(11):1484–1495. doi:10.1097/PAS.0000000000000720. PMID 27565001
  7. Audemard-Verger A, Terrier B, Dechartres A, et al. Characteristics and Management of IgA Vasculitis (Henoch-Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey. Arthritis Rheumatol. 2017;69(9):1862-1870. doi:10.1002/art.40178. PMID 28605168
  8. Babigumira M, Huang B, Werner S, et al. Delayed Manifestation of Shunt Nephritis: A Case Report and Review of the Literature. Case Rep Nephrol. 2017;2017:1867349. doi:10.1155/2017/1867349. PMID 28487790
  9. Baert K, Van Gremberghe I, Koshy P, et al. Idiopathic nodular glomerulosclerosis and diabetic nephropathy: a histological and prognostic comparison highlighting the impact of smoking. BMC Nephrol. 2026;27(1). doi:10.1186/s12882-026-04889-y. PMID 41851871
  10. Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789-796. doi:10.1016/j.kint.2017.11.023. PMID 29459092
  11. Baldwin C, Mohammad AJ, Cousins C, et al. Long-term outcomes of patients with Takayasu arteritis and renal artery involvement: a cohort study. Rheumatol Adv Pract. 2018;2(2):rky026. doi:10.1093/rap/rky026. PMID 31431972
  12. Barbour SJ, Coppo R, Er L, et al. Histologic and Clinical Factors Associated with Kidney Outcomes in IgA Vasculitis Nephritis. Clin J Am Soc Nephrol. 2024;19(4):438-451. doi:10.2215/CJN.0000000000000398. PMID 38261310
  13. Batal I, Domsic RT, Medsger TA, et al. Scleroderma renal crisis: a pathology perspective. Int J Rheumatol. 2010;2010:543704. doi:10.1155/2010/543704. PMID 20981312 (cited as Batal et al. 2010)
  14. Batal I, Domsic RT, Shafer A, et al. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol. 2009;40(3):332–340. doi:10.1016/j.humpath.2008.08.001. PMID 18973923 (cited as Batal et al. 2009)
  15. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21. doi:10.1056/NEJMoa0810457. PMID 19571279
  16. Beckermann KE, Sharma D, Chaturvedi S, et al. Renal medullary carcinoma: establishing standards in practice. J Oncol Pract. 2017;13(7):414–421. doi:10.1200/JOP.2017.020909. PMID 28697319
  17. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatr Pathol. 1990;10(1-2):1–36. doi:10.3109/15513819009067094. PMID 2156243
  18. Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21(10):1628-36. doi:10.1681/ASN.2010050477. PMID 20616173
  19. Berdichevski RH, De Carvalho EM, Edelweiss MI, et al. Collapsing glomerulopathy after hepatitis C pegylated interferon treatment. Recovery of renal function with high-dose steroid treatment. NDT Plus. 2010;3(6):564-6. doi:10.1093/ndtplus/sfq155. PMID 25949468
  20. Bergmann C, Guay-Woodford LM, Harris PC, et al. Polycystic kidney disease. Nat Rev Dis Primers. 2018;4(1):50. doi:10.1038/s41572-018-0047-y. PMID 30523303
  21. Bishara A, Saeed H, Akkielah L, et al. Malakoplakia in Immunocompromised Hosts: A Case Series and Literature Review. Diseases. 2026;14(8). doi:10.3390/diseases14080284. PMID 42645092
  22. Blank ML, Parkin L, Paul C, et al. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86(4):837-44. doi:10.1038/ki.2014.74. PMID 24646856
  23. Böhmig GA, Loupy A, Sablik M, et al. Microvascular inflammation in kidney allografts: New directions for patient management. Am J Transplant. 2025;25(7):1410–1416. doi:10.1016/j.ajt.2025.03.031. PMID 40199388
  24. Bonsib SM, Gibson D, Mhoon M, Greene GF. Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol. 2000;24(3):451–458. doi:10.1097/00000478-200003000-00015. PMID 10716160
  25. Bonsib SM. Renal Hypoplasia, From Grossly Insufficient to Not Quite Enough: Consideration for Expanded Concepts Based Upon the Author's Perspective With Historical Review. Adv Anat Pathol. 2020;27(5):311-330. doi:10.1097/PAP.0000000000000269. PMID 32520748
  26. Boyer O, Schaefer F, Haffner D, et al. Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group. Nat Rev Nephrol. 2021;17(4):277-289. doi:10.1038/s41581-020-00384-1. PMID 33514942
  27. Bratslavsky G, Mendhiratta N, Daneshvar M, et al. Genetic risk assessment for hereditary renal cell carcinoma: clinical consensus statement. Cancer. 2021;127(21):3957–3966. doi:10.1002/cncr.33679. PMID 34343338
  28. Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med. 2002;347(2):103–109. doi:10.1056/NEJMoa013036. PMID 12110738
  29. Brix SR, Noriega M, Tennstedt P, et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018;94(6):1177-1188. doi:10.1016/j.kint.2018.07.020. PMID 30385041
  30. Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol. 2018;13(2):300–317. doi:10.2215/CJN.00620117. PMID 29042465
  31. Brockwell M, Hergenrother S, Satariano M, et al. Pathophysiology of Congenital Anomalies of the Kidney and Urinary Tract: A Comprehensive Review. Cells. 2024;13(22). doi:10.3390/cells13221866. PMID 39594614
  32. Brunelli M, Eble JN, Zhang S, et al. Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod Pathol. 2005;18(2):161–169. doi:10.1038/modpathol.3800286. PMID 15467713
  33. Buxbaum JN, Eisenberg DS, Fändrich M, et al. Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2024;31(4):249-256. doi:10.1080/13506129.2024.2405948. PMID 39350582
  34. Cabanillas G, Montoya-Cerrillo D, Kryvenko ON, et al. Collecting duct carcinoma of the kidney: diagnosis and implications for management. Urol Oncol. 2022;40(12):525–536. doi:10.1016/j.urolonc.2021.04.041. PMID 34116936
  35. Calderaro J, Moroch J, Pierron G, et al. SMARCB1/INI1 inactivation in renal medullary carcinoma. Histopathology. 2012;61(3):428–435. doi:10.1111/j.1365-2559.2012.04228.x. PMID 22686875
  36. Camolese BA, Rainato GS, Garcia ISB, et al. Porous perspectives: a comprehensive review of medullary sponge kidney. Int Urol Nephrol. 2025;57(10):3251-3262. doi:10.1007/s11255-025-04531-0. PMID 40287601
  37. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43–49. doi:10.1038/nature12222. PMID 23792563
  38. Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534-45. doi:10.1038/ki.2009.243. PMID 19571791 (cited as Cattran et al. 2009)
  39. Caza TN, Hassen SI, Dvanajscak Z, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int. 2021;99(4):967-976. doi:10.1016/j.kint.2020.07.039. PMID 32828756
  40. Chan EYH, Warady BA. Acquired cystic kidney disease: an under-recognized condition in children with end-stage renal disease. Pediatr Nephrol. 2018;33(1):41-51. doi:10.1007/s00467-017-3649-9. PMID 28444445
  41. Chau KWT, Thet Z, Gardner LS, et al. Therapeutics controversies in antineutrophilic cytoplasmic antibody-associated vasculitis. Clin Exp Nephrol. 2025;29(11):1515-1523. doi:10.1007/s10157-025-02693-w. PMID 40392453
  42. Choi SE, Fogo AB, Lim BJ. Histologic evaluation of activity and chronicity of lupus nephritis and its clinical significance. Kidney Res Clin Pract. 2023;42(2):166-173. doi:10.23876/j.krcp.22.083. PMID 37037479
  43. Chou YC, Lee WY, Huang SK, et al. Ten-year follow-up of renal adenomatosis with magnetic resonance imaging: a case report. J Med Case Rep. 2022;16(1):168. doi:10.1186/s13256-022-03394-8. PMID 35449090
  44. Choueiri TK, Cheville J, Palescandolo E, et al. BRAF mutations in metanephric adenoma of the kidney. Eur Urol. 2012;62(5):917–922. doi:10.1016/j.eururo.2012.05.051. PMID 22727996
  45. Coiner BL, Bayrak BY, Isikci OT, et al. Adult mixed epithelial and stromal tumor of the kidney harbors recurrent whole chromosome 12 gain. Am J Surg Pathol. 2026;50(12):1508–1514. doi:10.1097/PAS.0000000000002620. PMID 42750419
  46. College of American Pathologists. Protocol for the examination of biopsy specimens from patients with renal cell carcinoma, version 4.3.0.0. Posted June 2026. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17). No DOI or PMID. Cited as CAP 2026b.
  47. College of American Pathologists. Protocol for the examination of resection specimens from patients with renal cell carcinoma, version 4.3.0.0. Posted June 2026. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17). No DOI or PMID. Cited as CAP 2026a.
  48. Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. J Am Soc Nephrol. 2020;31(2):435-446. doi:10.1681/ASN.2019070676. PMID 31896554
  49. Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638-47. doi:10.1016/j.kint.2016.04.008. PMID 27282937
  50. Corwin HL, Schwartz MM, Lewis EJ. The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol. 1988;8(2):85-9. doi:10.1159/000167563. PMID 3394725
  51. D'Agati VD, Alster JM, Jennette JC, et al. Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin J Am Soc Nephrol. 2013;8(3):399-406. doi:10.2215/CJN.06100612. PMID 23220425
  52. D'Agati VD, Fogo AB, Bruijn JA, et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004;43(2):368-82. doi:10.1053/j.ajkd.2003.10.024. PMID 14750104
  53. Dagher J, Delahunt B, Rioux-Leclercq N, et al. Percentage grade 4 tumour predicts outcome for clear cell renal cell carcinoma. Pathology. 2019;51(4):349–352. doi:10.1016/j.pathol.2019.01.004. PMID 30987774
  54. Davis CF, Ricketts CJ, Wang M, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014;26(3):319–330. doi:10.1016/j.ccr.2014.07.014. PMID 25155756
  55. Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37(10):1490–1504. doi:10.1097/PAS.0b013e318299f0fb. PMID 24025520
  56. Delahunt B, Sika-Paotonu D, Bethwaite PB, et al. Grading of clear cell renal cell carcinoma should be based on nucleolar prominence. Am J Surg Pathol. 2011;35(8):1134–1139. doi:10.1097/PAS.0b013e318220697f. PMID 21716085
  57. Dell KM, Hartung EA. Approach to simple kidney cysts in children. Pediatr Nephrol. 2024;39(12):3387-3395. doi:10.1007/s00467-024-06386-6. PMID 38676761
  58. Dharnidharka VR, Webster AC, Martinez OM, et al. Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers. 2016;2:15088. doi:10.1038/nrdp.2015.88. PMID 27189056
  59. Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis. 2008;51(3):491-503. doi:10.1053/j.ajkd.2007.10.044. PMID 18295066
  60. Din NU, Fatima S, Ahmad Z. Chromophobe renal cell carcinoma: a morphologic and immunohistochemical study of 45 cases. Ann Diagn Pathol. 2013;17(6):508–513. doi:10.1016/j.anndiagpath.2013.06.005. PMID 24095630
  61. Doros LA, Rossi CT, Yang J, et al. DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma. Mod Pathol. 2014;27(9):1267–1280. doi:10.1038/modpathol.2013.242. PMID 24481001
  62. Eckardt KU, Alper SL, Antignac C, et al. Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management--A KDIGO consensus report. Kidney Int. 2015;88(4):676-83. doi:10.1038/ki.2015.28. PMID 25738250
  63. Edwards F, Fanshawe JB, Neves J, et al. Natural history of treated and untreated renal oncocytoma: a systematic review and meta-analysis. BJU Int. 2025;136(4):590–601. doi:10.1111/bju.16832. PMID 40623958
  64. El Hennawy HM, Safar O, Aboalsamh G, et al. DSA-negative, C4d-negative microvascular inflammation after kidney transplantation as an endothelial injury syndrome: A narrative review. Transplant Rev (Orlando). 2026;40(4):101056. doi:10.1016/j.trre.2026.101056. PMID 42822228
  65. Faria P, Beckwith JB, Mishra K, et al. Focal versus diffuse anaplasia in Wilms tumor—new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. Am J Surg Pathol. 1996;20(8):909–920. doi:10.1097/00000478-199608000-00001. PMID 8712292
  66. Fejes Z, Sánta F, Jenei A, et al. Angiomyolipoma of the kidney—clinicopathological analysis of 52 cases. Pathol Oncol Res. 2022;28:1610831. doi:10.3389/pore.2022.1610831. PMID 36699622
  67. Floege J, Barratt J, Cook HT, et al. Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4):548-554. doi:10.1016/j.kint.2025.04.003. PMID 40975525
  68. Floyd L, Bate S, Hadi Kafagi A, et al. Risk Stratification to Predict Renal Survival in Anti-Glomerular Basement Membrane Disease. J Am Soc Nephrol. 2023;34(3):505-514. doi:10.1681/ASN.2022050581. PMID 36446430
  69. Fogo AB, Bostad L, Svarstad E, et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant. 2010;25(7):2168-77. doi:10.1093/ndt/gfp528. PMID 19833663
  70. Fotheringham J, Angel CA, McKane W. Transplant glomerulopathy: morphology, associations and mechanism. Nephron Clin Pract. 2009;113(1):c1–c7. doi:10.1159/000228069. PMID 19590229
  71. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655–663. doi:10.1097/00000478-198210000-00007. PMID 7180965
  72. Fujimaru T, Kawanishi K, Mori T, et al. Genetic Background and Clinicopathologic Features of Adult-onset Nephronophthisis. Kidney Int Rep. 2021;6(5):1346-1354. doi:10.1016/j.ekir.2021.02.005. PMID 34013113
  73. Gadd S, Huff V, Walz AL, et al. A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nat Genet. 2017;49(10):1487–1494. doi:10.1038/ng.3940. PMID 28825729
  74. Garrido-Abad P, Rodríguez-Cabello MÁ, Vera-Berón R, et al. Bear Paw Sign: Xanthogranulomatous Pyelonephritis. J Radiol Case Rep. 2018;12(11):18-24. doi:10.3941/jrcr.v12i11.3415. PMID 30647833
  75. Gaut JP, Liapis H. Acute kidney injury pathology and pathophysiology: a retrospective review. Clin Kidney J. 2021;14(2):526-536. doi:10.1093/ckj/sfaa142. PMID 33623675
  76. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329(5993):841-5. doi:10.1126/science.1193032. PMID 20647424
  77. Gill AJ, Hes O, Papathomas T, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol. 2014;38(12):1588–1602. doi:10.1097/PAS.0000000000000292. PMID 25025441
  78. Gonzalez-Roibon N, Albadine R, Sharma R, et al. The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas. Hum Pathol. 2013;44(12):2651–2657. doi:10.1016/j.humpath.2013.07.006. PMID 24071011
  79. Gordon CE, Garimella PS, Perrone RD, et al. Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025. Am J Kidney Dis. 2025;86(4):525-542. doi:10.1053/j.ajkd.2025.05.010. PMID 40844441
  80. Graham PC, Stewart HV, Downie I, Lindop GB. The distribution of renin-containing cells in kidneys with renal artery stenosis: an immunocytochemical study. Histopathology. 1990;16(4):347-355. doi:10.1111/j.1365-2559.1990.tb01138.x. PMID 2193862
  81. Gratias EJ, Dome JS, Jennings LJ, et al. Association of chromosome 1q gain with inferior survival in favorable-histology Wilms tumor: a report from the Children's Oncology Group. J Clin Oncol. 2016;34(26):3189–3194. doi:10.1200/JCO.2015.66.1140. PMID 27400937
  82. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23(29):7312–7321. doi:10.1200/JCO.2005.01.2799. PMID 16129848
  83. Guay-Woodford LM, Bissler JJ, Braun MC, et al. Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international conference. J Pediatr. 2014;165(3):611-7. doi:10.1016/j.jpeds.2014.06.015. PMID 25015577
  84. Gupta K, Mandal S, Mallya V, et al. Multicystic renal dysplasia, a histomorphological spectrum: Seven years experience from a tertiary care hospital. Indian J Pathol Microbiol. 2024;67(2):385-389. doi:10.4103/ijpm.ijpm_202_23. PMID 38427756
  85. Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18(2):293–307. doi:10.1111/ajt.14625. PMID 29243394
  86. Haas M, Racusen LC, Bagnasco SM. IgA-dominant postinfectious glomerulonephritis: a report of 13 cases with common ultrastructural features. Hum Pathol. 2008;39(9):1309-16. doi:10.1016/j.humpath.2008.02.015. PMID 18619648
  87. Haas M, Verhave JC, Liu ZH, et al. A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy. J Am Soc Nephrol. 2017;28(2):691-701. doi:10.1681/ASN.2016040433. PMID 27612994
  88. Haas M. Alport syndrome and thin glomerular basement membrane nephropathy: a practical approach to diagnosis. Arch Pathol Lab Med. 2009;133(2):224-32. doi:10.5858/133.2.224. PMID 19195966
  89. Hakimi AA, Tickoo SK, Jacobsen A, et al. TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. Mod Pathol. 2015;28(6):845–853. doi:10.1038/modpathol.2015.6. PMID 25676555
  90. Hauer HA, Bajema IM, van Houwelingen HC, et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int. 2002;61(1):80-9. doi:10.1046/j.1523-1755.2002.00089.x. PMID 11786087
  91. Helgudottir HR, Runolfsdottir HL, Hardarson S, et al. 2,8-Dihydroxyadenine Crystal Nephropathy and Mediators of Kidney Injury in Adenine Phosphoribosyltransferase Deficiency. Kidney360. 2026;. doi:10.34067/KID.0000001299. PMID 42519978
  92. Henske EP, Jóźwiak S, Kingswood JC, et al. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016;2:16035. doi:10.1038/nrdp.2016.35. PMID 27226234
  93. Herrera GA, Truong LD, Dhingra S, et al. Features that characterize monoclonal light chain ("myeloma") cast nephropathy with immunofluorescence challenges and emphasis on electron microscopy. Ultrastruct Pathol. 2024;48(5):422-437. doi:10.1080/01913123.2024.2390892. PMID 39166773
  94. Hirsch HH, Randhawa PS; AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13528. doi:10.1111/ctr.13528. PMID 30859620
  95. Hol JA, Jongmans MCJ, Sudour-Bonnange H, et al. Clinical characteristics and outcomes of children with WAGR syndrome and Wilms tumor and/or nephroblastomatosis: the 30-year SIOP-RTSG experience. Cancer. 2021;127(4):628–638. doi:10.1002/cncr.33304. PMID 33146894
  96. Hoot AC, Russo P, Judkins AR, et al. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol. 2004;28(11):1485–1491. doi:10.1097/01.pas.0000141390.14548.34. PMID 15489652
  97. Hou J, Markowitz GS, Bomback AS, et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 2014;85(2):450-6. doi:10.1038/ki.2013.340. PMID 24067430
  98. Hu W, Chen Y, Wang S, et al. Clinical-Morphological Features and Outcomes of Lupus Podocytopathy. Clin J Am Soc Nephrol. 2016;11(4):585-92. doi:10.2215/CJN.06720615. PMID 26983707
  99. Ibrahim D, Nadasdy T, Satoskar AA, et al. Kidney Biopsy Techniques to Differentiate Calcium Oxalate and Dihydroxyadenine Tubular Crystals. Kidney Med. 2022;4(9):100525. doi:10.1016/j.xkme.2022.100525. PMID 36147202
  100. Jansi Prema KS, Kurien AA. Atheroembolic renal disease: a case series. Indian J Nephrol. 2019;29(6):427–430. doi:10.4103/ijn.IJN_265_18. PMID 31798227
  101. Jansi Prema KS, Kurien AA. Etiological Spectrum and Histopathological Diagnosis of Rhabdomyolysis Associated Myoglobin Cast Nephropathy in South India. Indian J Nephrol. 2021;31(1):22-26. doi:10.4103/ijn.IJN_383_19. PMID 33994683 (cited as Jansi Prema and Kurien 2021)
  102. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi:10.1002/art.37715. PMID 23045170
  103. Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17(5):603–606. doi:10.1007/s10157-013-0869-6. PMID 24072416
  104. Jung DC, Kim SH, Jung SI, et al. Renal papillary necrosis: review and comparison of findings at multi-detector row CT and intravenous urography. Radiographics. 2006;26(6):1827-36. doi:10.1148/rg.266065039. PMID 17102053
  105. Keddis MT, Garovic VD, Bailey KR, et al. Ischaemic nephropathy secondary to atherosclerotic renal artery stenosis: clinical and histopathological correlates. Nephrol Dial Transplant. 2010;25(11):3615-3622. doi:10.1093/ndt/gfq269. PMID 20501460
  106. Khandelwal MH, Piparva KG, Parchwani D. Familial WT1-associated nephropathy—46,XY Frasier syndrome and 46,XX steroid-resistant nephrotic syndrome in female siblings: a case report and review of literature. World J Nephrol. 2026;15(1):110867. doi:10.5527/wjn.v15.i1.110867. PMID 41884246
  107. Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. Kidney Int. 2024;105(3S):S71-S116. doi:10.1016/j.kint.2023.10.008. PMID 38388102 (cited as KDIGO 2024b)
  108. Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;105(1S):S1-S69. doi:10.1016/j.kint.2023.09.002. PMID 38182286 (cited as KDIGO 2024a)
  109. Kim E, Zschiedrich S. Renal cell carcinoma in von Hippel-Lindau disease—from tumor genetics to novel therapeutic strategies. Front Pediatr. 2018;6:16. doi:10.3389/fped.2018.00016. PMID 29479523
  110. Kim M, Joo JW, Lee SJ, et al. Comprehensive immunoprofiles of renal cell carcinoma subtypes. Cancers (Basel). 2020;12(3):602. doi:10.3390/cancers12030602. PMID 32150988
  111. Knezevich SR, Garnett MJ, Pysher TJ, et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res. 1998;58(22):5046–5048. PMID 9823307
  112. Koirala A, Singh A, Geetha D. Recurrence of glomerular diseases (GN) after kidney transplantation: a narrative review. J Clin Med. 2025;14(18):6686. doi:10.3390/jcm14186686. PMID 41010890
  113. Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22(11):2129-37. doi:10.1681/ASN.2011040388. PMID 21997394
  114. Kopp JB, Winkler CA, Zhao X, et al. Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial. J Am Soc Nephrol. 2015;26(6):1443-8. doi:10.1681/ASN.2013111242. PMID 25573908
  115. Kopp JB. Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder. Curr Opin Nephrol Hypertens. 2013;22(3):266–272. doi:10.1097/MNH.0b013e3283600f8c. PMID 23470819
  116. Kourelis TV, Nasr SH, Dispenzieri A, et al. Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol. 2016;91(11):1123-1128. doi:10.1002/ajh.24528. PMID 27501122
  117. Kudose S, Batal I, Santoriello D, et al. Kidney Biopsy Findings in Patients with COVID-19. J Am Soc Nephrol. 2020;31(9):1959-1968. doi:10.1681/ASN.2020060802. PMID 32680910
  118. Kuroda N, Toi M, Hiroi M, et al. Review of collecting duct carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol. 2002;17(4):1329–1334. doi:10.14670/HH-17.1329. PMID 12371157
  119. Lai KN, Tang SC, Schena FP, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2:16001. doi:10.1038/nrdp.2016.1. PMID 27189177
  120. Larsen CP, Ismail W, Kurtin PJ, et al. Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians. Mod Pathol. 2016;29(4):416-20. doi:10.1038/modpathol.2016.29. PMID 26867784
  121. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317–1320. doi:10.1126/science.8493574. PMID 8493574
  122. Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15(1):45-59. doi:10.1038/s41581-018-0077-4. PMID 30510265
  123. Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292-5. doi:10.1182/blood-2012-07-445304. PMID 23047823
  124. Liapis H, Gaut JP, Klein C, et al. Banff histopathological consensus criteria for preimplantation kidney biopsies. Am J Transplant. 2017;17(1):140–150. doi:10.1111/ajt.13929. PMID 27333454
  125. Lin S, Zhang J, Chen B, et al. Role of crescents for lupus nephritis in clinical, pathological and prognosis: a single-center retrospective cohort study. Eur J Med Res. 2023;28(1):60. doi:10.1186/s40001-023-01022-9. PMID 36732805
  126. Lipska-Ziętkiewicz BS, Ozaltin F, Hölttä T, et al. Genetic aspects of congenital nephrotic syndrome: a consensus statement from the ERKNet-ESPN inherited glomerulopathy working group. Eur J Hum Genet. 2020;28(10):1368-1378. doi:10.1038/s41431-020-0642-8. PMID 32467597
  127. Liptak P, Ivanyi B. Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol. 2006;2(7):398–404. doi:10.1038/ncpneph0225. PMID 16932468
  128. Lobo J, Ohashi R, Amin MB, et al. WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology. 2022;81(4):426–438. doi:10.1111/his.14700. PMID 35596618
  129. Lopes H, Pereira CA, Zucca LE, et al. Primary monophasic synovial sarcoma of the kidney: a case report and review of literature. Clin Med Insights Oncol. 2013;7:257–262. doi:10.4137/CMO.S12243. PMID 24137053
  130. Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. 2020;20(9):2318–2331. doi:10.1111/ajt.15898. PMID 32463180
  131. Lubner MG, Marko J, Taffel MT, et al. Spectrum of renal angiomyolipoma with radiologic-pathologic correlation. Radiographics. 2025;45(7):e240159. doi:10.1148/rg.240159. PMID 40504730
  132. Mahévas M, Lescure FX, Boffa JJ, et al. Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine (Baltimore). 2009;88(2):98-106. doi:10.1097/MD.0b013e31819de50f. PMID 19282700
  133. Maisons V, Demir F, Fillon A, et al. Renal histology findings in malignant hypertension, a systematic review. Hypertension. 2026;83(1):177–188. doi:10.1161/HYPERTENSIONAHA.125.25069. PMID 41185998
  134. Maripuri S, Grande JP, Osborn TG, et al. Renal involvement in primary Sjögren's syndrome: a clinicopathologic study. Clin J Am Soc Nephrol. 2009;4(9):1423-31. doi:10.2215/CJN.00980209. PMID 19679669
  135. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12(6):1164-1172. doi:10.1681/ASN.V1261164. PMID 11373339
  136. Markowitz GS, Perazella MA. Acute phosphate nephropathy. Kidney Int. 2009;76(10):1027-34. doi:10.1038/ki.2009.308. PMID 19675530
  137. Markowitz GS, Stokes MB, Radhakrishnan J, et al. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol. 2005;16(11):3389-96. doi:10.1681/ASN.2005050496. PMID 16192415
  138. Marokakis S, Cui C, Moghimi A, et al. Kidney transplant biopsy adequacy and outcomes in children - is it time for change? BMC Nephrol. 2025;26(1):686. doi:10.1186/s12882-025-04581-7. PMID 41339839
  139. Marsden L, Jennings LJ, Gadd S, et al. BRAF exon 15 mutations in pediatric renal stromal tumors: prevalence in metanephric stromal tumors. Hum Pathol. 2017;60:32–36. doi:10.1016/j.humpath.2016.09.025. PMID 27769870
  140. Martins AC, Gibier JB, Ronsin C, et al. Non-myeloma light chain cast nephropathy: a multicenter retrospective study on clinicopathological characteristics. Haematologica. 2024;109(8):2721-2725. doi:10.3324/haematol.2024.285031. PMID 38546694
  141. McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease-treatment standard. Nephrol Dial Transplant. 2025;41(1):42-54. doi:10.1093/ndt/gfaf190. PMID 40973182
  142. McAdoo SP, Tanna A, Hrušková Z, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017;92(3):693-702. doi:10.1016/j.kint.2017.03.014. PMID 28506760
  143. Mehr JP, Joyce DD, Gordetsky JB, et al. Management of Xanthogranulomatous Pyelonephritis: A Review of Current Evidence and Treatment Strategies and a Proposed Clinical Management Algorithm. Urology. 2026;214:152-158. doi:10.1016/j.urology.2026.06.019. PMID 42309444
  144. Mirioglu S, Daniel-Fischer L, Berke I, et al. Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group. Nephrol Dial Transplant. 2024;39(4):569-580. doi:10.1093/ndt/gfae025. PMID 38341276
  145. Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: renal, penile, and testicular tumours. Eur Urol. 2022;82(5):458–468. doi:10.1016/j.eururo.2022.06.016. PMID 35853783 (summarizes the WHO Classification of Tumours, Urinary and Male Genital Tumours, 5th edition)
  146. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105. doi:10.1016/j.eururo.2016.02.029. PMID 26935559
  147. Moon KC. Interobserver reproducibility in histopathological findings of lupus nephritis: how can we improve it?. Kidney Res Clin Pract. 2026;45(4):444-446. doi:10.23876/j.krcp.25.190. PMID 41035350
  148. Moreira DM, Gershman B, Thompson RH, et al. Clinicopathologic characteristics and survival for adult renal sarcoma: a population-based study. Urol Oncol. 2015;33(12):505.e15–505.e20. doi:10.1016/j.urolonc.2015.07.022. PMID 26321056
  149. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481–508. doi:10.2215/CJN.04800908. PMID 19218475 (cited as Naesens et al. 2009)
  150. Naesens M, Roufosse C, Cornell LD, et al. The Banff 2024 Kidney Meeting Report: Rejection as a spectrum of phenotypes and focus on differential diagnostic reasoning. Am J Transplant. 2026;26(5):922–936. doi:10.1016/j.ajt.2026.01.018. PMID 41888020 (cited as Naesens et al. 2026)
  151. Naesens M, Roufosse C, Haas M, et al. The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics. Am J Transplant. 2024;24(3):338–349. doi:10.1016/j.ajt.2023.10.016. PMID 38032300 (cited as Naesens et al. 2024)
  152. Najafian B, Alpers CE, Fogo AB. Pathology of human diabetic nephropathy. Contrib Nephrol. 2011;170:36-47. doi:10.1159/000324942. PMID 21659756
  153. Nasr SH, Collins AB, Alexander MP, et al. The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney Int. 2016;89(4):897-908. doi:10.1016/j.kint.2016.02.001. PMID 26994577
  154. Nasr SH, Kudose SS, Said SM, et al. Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants. Kidney Int. 2021;99(2):410-420. doi:10.1016/j.kint.2020.07.037. PMID 32818517
  155. Nasr SH, Markowitz GS, Stokes MB, et al. Acute postinfectious glomerulonephritis in the modern era: experience with 86 adults and review of the literature. Medicine (Baltimore). 2008;87(1):21-32. doi:10.1097/md.0b013e318161b0fc. PMID 18204367
  156. Nasr SH, Markowitz GS, Valeri AM, et al. Thin basement membrane nephropathy cannot be diagnosed reliably in deparaffinized, formalin-fixed tissue. Nephrol Dial Transplant. 2007;22(4):1228-32. doi:10.1093/ndt/gfl838. PMID 17277340
  157. Nasr SH, Radhakrishnan J, D'Agati VD. Bacterial infection-related glomerulonephritis in adults. Kidney Int. 2013;83(5):792-803. doi:10.1038/ki.2012.407. PMID 23302723
  158. Nasr SH, Royal V, Best Rocha A, et al. Renal Pathology Society/International Kidney and Monoclonal Gammopathy Research Group consensus on pathologic definitions and terminology of monoclonal gammopathy-associated kidney lesions. Kidney Int. 2025;108(2):184-193. doi:10.1016/j.kint.2025.04.007. PMID 40280412
  159. Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20(9):2055-64. doi:10.1681/ASN.2009010110. PMID 19470674
  160. Nasr SH, Valeri AM, Appel GB, et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol. 2009;4(1):22-32. doi:10.2215/CJN.03480708. PMID 18971369
  161. Nasr SH, Valeri AM, Cornell LD, et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol. 2011;6(4):775-84. doi:10.2215/CJN.08300910. PMID 21441134
  162. Nasr SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7(2):231-9. doi:10.2215/CJN.08640811. PMID 22156754
  163. Nasr SH, Valeri AM, Said SM, et al. Clinicopathologic Characteristics, Etiologies, and Outcome of Secondary Oxalate Nephropathy. Mayo Clin Proc. 2024;99(4):593-606. doi:10.1016/j.mayocp.2023.08.014. PMID 38310502
  164. Nasr SH, Vrana JA, Dasari S, et al. DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney Int Rep. 2018;3(1):56-64. doi:10.1016/j.ekir.2017.07.017. PMID 29340314
  165. Nath KA, Hebbel RP. Sickle cell disease: renal manifestations and mechanisms. Nat Rev Nephrol. 2015;11(3):161-71. doi:10.1038/nrneph.2015.8. PMID 25668001
  166. Nickeleit V, Singh HK, Dadhania D, et al. The 2018 Banff Working Group classification of definitive polyomavirus nephropathy: A multicenter validation study in the modern era. Am J Transplant. 2021;21(2):669–680. doi:10.1111/ajt.16189. PMID 32654412
  167. Nickeleit V, Singh HK, Randhawa P, et al. The Banff Working Group classification of definitive polyomavirus nephropathy: morphologic definitions and clinical correlations. J Am Soc Nephrol. 2018;29(2):680–693. doi:10.1681/ASN.2017050477. PMID 29279304
  168. Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell. 2002;2(2):157–164. doi:10.1016/s1535-6108(02)00104-6. PMID 12204536
  169. Nicolaou N, Renkema KY, Bongers EM, et al. Genetic, environmental, and epigenetic factors involved in CAKUT. Nat Rev Nephrol. 2015;11(12):720-31. doi:10.1038/nrneph.2015.140. PMID 26281895
  170. Nour Eldine M, Kilan H, Hallak P, et al. Systematic review of renal infarction clinical presentation, causes, and outcomes. Kidney Int Rep. 2026;11(11):107049. doi:10.1016/j.ekir.2026.107049. PMID 42824378
  171. O'Meara E, Stack D, Lee CH, et al. Characterization of the chromosomal translocation t(10;17)(q22;p13) in clear cell sarcoma of kidney. J Pathol. 2012;227(1):72–80. doi:10.1002/path.3985. PMID 22294382
  172. Okabayashi Y, Tsuboi N, Marumoto H, et al. Single-Nephron GFR in Different Glomerular Basement Membrane Stages of Membranous Nephropathy. Kidney360. 2023;4(6):e777-e786. doi:10.34067/KID.0000000000000142. PMID 37166967
  173. Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020;11(3):79-87. doi:10.14740/wjon1279. PMID 32494314
  174. Paner GP, Stadler WM, Hansel DE, et al. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol. 2018;73(4):560–569. doi:10.1016/j.eururo.2017.12.018. PMID 29325693
  175. Pathak NJ, Singh AG, Surwase PJ, et al. Primary Ewing sarcoma/primitive neuroectodermal tumors of the kidney: case series of eight cases from a single center with follow-up details. Indian J Urol. 2024;40(3):185–190. doi:10.4103/iju.iju_175_23. PMID 39100602
  176. Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol. 2002;26(12):1542–1552. doi:10.1097/00000478-200212000-00002. PMID 12459621
  177. Pecoraro A, Amparore D, Bertolo R, et al. Renal epithelioid angiomyolipoma: a multi-institutional, international cohort study with emphasis on clinicopathologic prognostic indicators. Urol Oncol. 2026;44(2):122.e11–122.e17. doi:10.1016/j.urolonc.2025.10.018. PMID 41330802
  178. Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM. 2007;100(8):485–494. doi:10.1093/qjmed/hcm052. PMID 17601770
  179. Perazella MA, Herlitz LC. The Crystalline Nephropathies. Kidney Int Rep. 2021;6(12):2942-2957. doi:10.1016/j.ekir.2021.09.003. PMID 34901567
  180. Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6(8):461-70. doi:10.1038/nrneph.2010.71. PMID 20517290
  181. Pettit S, Chalmers D. Neonatal multicystic dysplastic kidney with mass effect: A systematic review. J Pediatr Urol. 2021;17(6):763-768. doi:10.1016/j.jpurol.2021.09.003. PMID 34538561
  182. Pickering MC, D'Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013;84(6):1079-89. doi:10.1038/ki.2013.377. PMID 24172683
  183. Pillebout E, Thervet E, Hill G, et al. Henoch-Schönlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol. 2002;13(5):1271-8. doi:10.1097/01.asn.0000013883.99976.22. PMID 11961015
  184. Pitra T, Pivovarcikova K, Alaghehbandan R, et al. A comprehensive commentary on the multilocular cystic renal neoplasm of low malignant potential: a urologist's perspective. Cancers (Basel). 2022;14(3):831. doi:10.3390/cancers14030831. PMID 35159098
  185. Plouin PF, Perdu J, La Batide-Alanore A, et al. Fibromuscular dysplasia. Orphanet J Rare Dis. 2007;2:28. doi:10.1186/1750-1172-2-28. PMID 17555581
  186. Popova T, Hebert L, Jacquemin V, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet. 2013;92(6):974–980. doi:10.1016/j.ajhg.2013.04.012. PMID 23684012
  187. Prakash J, Singh VP. Changing picture of renal cortical necrosis in acute kidney injury in developing country. World J Nephrol. 2015;4(5):480–486. doi:10.5527/wjn.v4.i5.480. PMID 26558184
  188. Presne C, Fakhouri F, Noël LH, et al. Lithium-induced nephropathy: Rate of progression and prognostic factors. Kidney Int. 2003;64(2):585-92. doi:10.1046/j.1523-1755.2003.00096.x. PMID 12846754
  189. Querin V, Jordan N, D'Cruz DP, et al. Characterizing the NIH Activity and Chronicity Indices in 2 Independent Lupus Nephritis Cohorts. Kidney Int Rep. 2026;11(2):103686. doi:10.1016/j.ekir.2025.11.011. PMID 41542109
  190. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55(2):713–723. doi:10.1046/j.1523-1755.1999.00299.x. PMID 9987096
  191. Raissian Y, Nasr SH, Larsen CP, et al. Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol. 2011;22(7):1343-52. doi:10.1681/ASN.2011010062. PMID 21719792
  192. Ramachandran R, Kumar K, Nada R, et al. Drug-induced acute interstitial nephritis: A clinicopathological study and comparative trial of steroid regimens. Indian J Nephrol. 2015;25(5):281-6. doi:10.4103/0971-4065.147766. PMID 26628793
  193. Remuzzi G, Cravedi P, Perna A, et al. Long-term outcome of renal transplantation from older donors. N Engl J Med. 2006;354(4):343–352. doi:10.1056/NEJMoa052891. PMID 16436766
  194. Rioux-Leclercq NC, Epstein JI. Renal cell carcinoma with intratumoral calcium oxalate crystal deposition in patients with acquired cystic disease of the kidney. Arch Pathol Lab Med. 2003;127(2):E89-92. doi:10.5858/2003-127-e89-RCCWIC. PMID 12562261
  195. Roberts IS, Cook HT, Troyanov S, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76(5):546-56. doi:10.1038/ki.2009.168. PMID 19571790 (cited as Roberts et al. 2009)
  196. Roca N, Muñoz M, Cruz A, et al. Long-term outcome in a case series of Denys-Drash syndrome. Clin Kidney J. 2019;12(6):836–839. doi:10.1093/ckj/sfz022. PMID 31807296
  197. Roccatello D, Fornasieri A, Giachino O, et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis. 2007;49(1):69-82. doi:10.1053/j.ajkd.2006.09.015. PMID 17185147
  198. Rodriguez Mori JE, Dapello Jimenez MDP, Sumire Umeres J, et al. Lecithin-cholesterol acyltransferase deficiency with the finding of "zebra bodies": A diagnostic challenge in the context of suspected Fabry disease. Nefrologia (Engl Ed). 2026;46(3):501444. doi:10.1016/j.nefroe.2026.501444. PMID 41720735
  199. Rossi GM, Vaglio A. New Treatment Regimens, New Drugs, and New Treatment Goals for Lupus Nephritis. J Clin Med. 2025;14(2). doi:10.3390/jcm14020584. PMID 39860589
  200. Roufosse C, Simmonds N, Clahsen-van Groningen M, et al. A 2018 reference guide to the Banff classification of renal allograft pathology. Transplantation. 2018;102(11):1795–1814. doi:10.1097/TP.0000000000002366. PMID 30028786
  201. Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):753-779. doi:10.1016/j.kint.2021.05.015. PMID 34556300
  202. Said SM, Sethi S, Valeri AM, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013;8(9):1515-23. doi:10.2215/CJN.10491012. PMID 23704299
  203. Saraga M, Saraga-Babić M, Arapović A, et al. The Intrarenal Reflux Diagnosed by Contrast-Enhanced Voiding Urosonography (ceVUS): A Reason for the Reclassification of Vesicoureteral Reflux and New Therapeutic Approach? Biomedicines. 2024;12(5):1015. doi:10.3390/biomedicines12051015. PMID 38790977
  204. Savige J, Gregory M, Gross O, et al. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol. 2013;24(3):364-75. doi:10.1681/ASN.2012020148. PMID 23349312
  205. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68–73. doi:10.1038/ng0597-68. PMID 9140397
  206. Scolari F, Ravani P. Atheroembolic renal disease. Lancet. 2010;375(9726):1650–1660. doi:10.1016/S0140-6736(09)62073-0. PMID 20381857
  207. Sethi S, Beck LH Jr, Glassock RJ, et al. Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification. Kidney Int. 2023;104(6):1092-1102. doi:10.1016/j.kint.2023.06.032. PMID 37795587
  208. Sethi S, Debiec H, Madden B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 2020;97(1):163-174. doi:10.1016/j.kint.2019.09.014. PMID 31901340 (cited as Sethi et al. 2020a)
  209. Sethi S, Debiec H, Madden B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int. 2020;98(5):1253-1264. doi:10.1016/j.kint.2020.05.030. PMID 32534052 (cited as Sethi et al. 2020b)
  210. Sethi S, Fervenza FC, Zhang Y, et al. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int. 2013;83(2):293-9. doi:10.1038/ki.2012.384. PMID 23235567 (cited as Sethi et al. 2013a)
  211. Sethi S, Fervenza FC. Antigens in membranous nephropathy: discovery and clinical implications. Nat Rev Nephrol. 2025;21(10):653-670. doi:10.1038/s41581-025-00980-z. PMID 40691733
  212. Sethi S, Haas M, Markowitz GS, et al. Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. J Am Soc Nephrol. 2016;27(5):1278-87. doi:10.1681/ASN.2015060612. PMID 26567243
  213. Sethi S, Madden B, Casal Moura M, et al. Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1. J Am Soc Nephrol. 2022;33(5):1033-1044. doi:10.1681/ASN.2021111488. PMID 35321939
  214. Sethi S, Madden B, Debiec H, et al. Protocadherin 7-Associated Membranous Nephropathy. J Am Soc Nephrol. 2021;32(5):1249-1261. doi:10.1681/ASN.2020081165. PMID 33833079
  215. Sethi S, Madden BJ, Debiec H, et al. Exostosin 1/Exostosin 2-Associated Membranous Nephropathy. J Am Soc Nephrol. 2019;30(6):1123-1136. doi:10.1681/ASN.2018080852. PMID 31061139
  216. Sethi S, Theis JD, Vrana JA, et al. Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy. Clin J Am Soc Nephrol. 2013;8(6):915-21. doi:10.2215/CJN.07030712. PMID 23411427
  217. Sethi S, Vrana JA, Theis JD, et al. Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int. 2012;82(2):226-34. doi:10.1038/ki.2012.108. PMID 22495291
  218. Sethi S. Membranous nephropathy: a single disease or a pattern of injury resulting from different diseases. Clin Kidney J. 2021;14(10):2166-2169. doi:10.1093/ckj/sfab069. PMID 34603694
  219. Shao N, Wang HK, Zhu Y, et al. Modification of American Joint Committee on Cancer prognostic groups for renal cell carcinoma. Cancer Med. 2018;7(11):5431–5438. doi:10.1002/cam4.1790. PMID 30306741
  220. Shimizu T, Hirai T, Unagam K, et al. Mini review Banff 2022 updated classification of renal allograft pathology. Nephron. 2025;149(Suppl 1):40–44. doi:10.1159/000546870. PMID 40484008
  221. Sika-Paotonu D, Bethwaite PB, McCredie MR, et al. Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. Am J Surg Pathol. 2006;30(9):1091–1096. doi:10.1097/01.pas.0000209833.69972.2b. PMID 16931953
  222. Silverman SG, Pedrosa I, Ellis JH, et al. Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment. Radiology. 2019;292(2):475-488. doi:10.1148/radiol.2019182646. PMID 31210616
  223. Smith RJH, Appel GB, Blom AM, et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019;15(3):129-143. doi:10.1038/s41581-018-0107-2. PMID 30692664
  224. Song D, Wu LH, Wang FM, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15(1):R12. doi:10.1186/ar4142. PMID 23320601
  225. Southgate G, Clarke P, Harmer MJ. Renal outcomes in tubulointerstitial nephritis and uveitis (TINU) syndrome: a systematic review and meta-analysis. J Nephrol. 2023;36(2):507-519. doi:10.1007/s40620-022-01478-8. PMID 36396848
  226. Stokes MB, D'Agati VD. Morphologic variants of focal segmental glomerulosclerosis and their significance. Adv Chronic Kidney Dis. 2014;21(5):400-7. doi:10.1053/j.ackd.2014.02.010. PMID 25168828
  227. Stokes MB, Valeri AM, Herlitz L, et al. Light Chain Proximal Tubulopathy: Clinical and Pathologic Characteristics in the Modern Treatment Era. J Am Soc Nephrol. 2016;27(5):1555-65. doi:10.1681/ASN.2015020185. PMID 26374607
  228. Stokes MB, Valeri AM, Markowitz GS, et al. Cellular focal segmental glomerulosclerosis: Clinical and pathologic features. Kidney Int. 2006;70(10):1783-92. doi:10.1038/sj.ki.5001903. PMID 17021605
  229. Suzigan S, López-Beltrán A, Montironi R, et al. Multilocular cystic renal cell carcinoma: a report of 45 cases of a kidney tumor of low malignant potential. Am J Clin Pathol. 2006;125(2):217–222. doi:10.1309/AH6F-C77P-YR2V-6YAY. PMID 16393684
  230. Swartz MA, Karth J, Schneider DT, et al. Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology. 2002;60(6):1083–1089. doi:10.1016/s0090-4295(02)02154-4. PMID 12475675
  231. Szeto CC, Mac-Moune Lai F, Kwan BC, et al. The width of the basement membrane does not influence clinical presentation or outcome of thin glomerular basement membrane disease with persistent hematuria. Kidney Int. 2010;78(10):1041-6. doi:10.1038/ki.2010.285. PMID 20703213
  232. Tannous E, Patel S, Muratoglu B, et al. Localized cystic disease of the kidney: study of 14 cases and review of the literature. Virchows Arch. 2025;487(1):227-236. doi:10.1007/s00428-024-03930-5. PMID 39340667
  233. Tektonidou MG. Antiphospholipid syndrome nephropathy: from pathogenesis to treatment. Front Immunol. 2018;9:1181. doi:10.3389/fimmu.2018.01181. PMID 29904380
  234. Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556-63. doi:10.1681/ASN.2010010010. PMID 20167701
  235. Thomas DB, Franceschini N, Hogan SL, et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int. 2006;69(5):920-6. doi:10.1038/sj.ki.5000160. PMID 16518352
  236. Tickoo SK, dePeralta-Venturina MN, Harik LR, et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol. 2006;30(2):141–153. doi:10.1097/01.pas.0000185382.80844.b1. PMID 16434887
  237. Tomlinson GE, Breslow NE, Dome J, et al. Rhabdoid tumor of the kidney in the National Wilms' Tumor Study: age at diagnosis as a prognostic factor. J Clin Oncol. 2005;23(30):7641–7645. doi:10.1200/JCO.2004.00.8110. PMID 16234525
  238. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30(4):406–410. doi:10.1038/ng849. PMID 11865300
  239. Torra R, Lipska-Zietkiewicz B, Acke F, et al. Diagnosis, management and treatment of the Alport syndrome - 2024 guideline on behalf of ERKNet, ERA and ESPN. Nephrol Dial Transplant. 2025;40(6):1091-1106. doi:10.1093/ndt/gfae265. PMID 39673454
  240. Toyota K, Hashimoto T, Ogino D, et al. A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy. J Hum Genet. 2013;58(5):254-8. doi:10.1038/jhg.2013.8. PMID 23407349
  241. Trimarchi H, Barratt J, Cattran DC, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91(5):1014-1021. doi:10.1016/j.kint.2017.02.003. PMID 28341274
  242. Trpkov K, Grignon DJ, Bonsib SM, et al. Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. Am J Surg Pathol. 2013;37(10):1505–1517. doi:10.1097/PAS.0b013e31829a85d0. PMID 24025521 (cited as Trpkov et al. 2013)
  243. Trpkov K, Hes O, Williamson SR, et al. New developments in existing WHO entities and evolving molecular concepts: the Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021;34(7):1392–1424. doi:10.1038/s41379-021-00779-w. PMID 33664427 (cited as Trpkov, Hes et al. 2021)
  244. Trpkov K, Siadat F, Saleeb R. Recent developments in eosinophilic renal neoplasms: what's new, true and important? Histopathology. 2026;88(1):166–192. doi:10.1111/his.70001. PMID 41384711 (cited as Trpkov et al. 2026)
  245. Trpkov K, Williamson SR, Gill AJ, et al. Novel, emerging and provisional renal entities: the Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021;34(6):1167–1184. doi:10.1038/s41379-021-00737-6. PMID 33526874 (cited as Trpkov, Williamson et al. 2021)
  246. Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 2011;135(1):92–109. doi:10.5858/2010-0478-RAR.1. PMID 21204715
  247. Ubara Y, Kono K, Sawa N. Clinicopathological review of renovascular hypertension and hypertensive emergency-related nephropathy based on case series. Intern Med. 2026 (online ahead of print). doi:10.2169/internalmedicine.8138-26. PMID 42844194
  248. Ueno-Yokohata H, Okita H, Nakasato K, et al. Consistent in-frame internal tandem duplications of BCOR characterize clear cell sarcoma of the kidney. Nat Genet. 2015;47(8):861–863. doi:10.1038/ng.3338. PMID 26098867
  249. Uzzo M, Haas M, Jayne DRW, et al. Role of lupus nephritis classification systems in everyday clinical practice: a questionnaire-based survey of the Renal Pathology Society (RPS). Clin Kidney J. 2026;19(3):sfag028. doi:10.1093/ckj/sfag028. PMID 41877891 (cited as Uzzo et al. 2026a)
  250. Uzzo M, Mescia F, Scott J, et al. Kidney Outcomes in ANCA-Glomerulonephritis According to Induction Immunosuppression and Histopathology. Kidney Int Rep. 2026;11(3):103776. doi:10.1016/j.ekir.2026.103776. PMID 41716736 (cited as Uzzo et al. 2026b)
  251. Vivarelli M, Massella L, Ruggiero B, et al. Minimal Change Disease. Clin J Am Soc Nephrol. 2017;12(2):332-345. doi:10.2215/CJN.05000516. PMID 27940460
  252. Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957-9. doi:10.1182/blood-2009-07-230722. PMID 19797517
  253. Vujanić GM, Gessler M, Ooms AHAG, et al. The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nat Rev Urol. 2018;15(11):693–701. doi:10.1038/s41585-018-0100-3. PMID 30310143
  254. Vujanić GM, Mifsud W. Anaplasia in Wilms tumor: a critical review. Pediatr Blood Cancer. 2024;71(7):e31000. doi:10.1002/pbc.31000. PMID 38605554
  255. Vujanić GM, Parsons LN, D'Hooghe E, et al. Pathology of Wilms' tumour in International Society of Paediatric Oncology (SIOP) and Children's Oncology Group (COG) renal tumour studies: similarities and differences. Histopathology. 2022;80(7):1026–1037. doi:10.1111/his.14632. PMID 35275409
  256. Waldek S, Feriozzi S. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?. BMC Nephrol. 2014;15:72. doi:10.1186/1471-2369-15-72. PMID 24886109
  257. Walker PD, Cavallo T, Bonsib SM. Practice guidelines for the renal biopsy. Mod Pathol. 2004;17(12):1555-63. doi:10.1038/modpathol.3800239. PMID 15272280
  258. Wang CJ, Lin YW, Xiang H, et al. Mixed epithelial and stromal tumor of the kidney: report of eight cases and literature review. World J Surg Oncol. 2013;11(1):207. doi:10.1186/1477-7819-11-207. PMID 23958048
  259. Wang CJ, Wetmore JB, Crary GS, et al. The donor kidney biopsy and its implications in predicting graft outcomes: a systematic review. Am J Transplant. 2015;15(7):1903–1914. doi:10.1111/ajt.13213. PMID 25772854
  260. Wang MY, Yong ZH, Wang S, et al. Light chain Cast Nephropathy: The Relationship between Tamm-Horsfall Protein Immunoreactivity and Clinical Pathological Features and Prognosis. Kidney Dis (Basel). 2026;12(1):237-247. doi:10.1159/000550573. PMID 41783516
  261. Wang T, An Y, Zhai H, et al. Primary renal lymphoma: a single-center study of 14 cases. Clin Genitourin Cancer. 2025;23(2):102299. doi:10.1016/j.clgc.2025.102299. PMID 39880694
  262. Watanabe T. Kidney and urinary tract involvement in Kawasaki disease. Int J Pediatr. 2013;2013:831834. doi:10.1155/2013/831834. PMID 24288547
  263. Watts AJB, Keller KH, Lerner G, et al. Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology. J Am Soc Nephrol. 2022;33(1):238-252. doi:10.1681/ASN.2021060794. PMID 34732507
  264. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241-50. doi:10.1097/01.asn.0000108969.21691.5d. PMID 14747370
  265. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521-30. doi:10.1111/j.1523-1755.2004.00443.x. PMID 14717922
  266. Wegert J, Vokuhl C, Collord G, et al. Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. Nat Commun. 2018;9(1):2378. doi:10.1038/s41467-018-04650-6. PMID 29915264
  267. Wei T, Zhang J, Yang F, et al. Tubuloreticular Inclusions in Kidney Tissues of Patients With Lupus Nephritis: An Ultrastructural Biomarker of Type I Interferon-Driven Disease Activity. Am J Nephrol. 2026;. doi:10.1159/ajn/ablag021. PMID 43007867
  268. Welch TR. An approach to the child with acute glomerulonephritis. Int J Pediatr. 2012;2012:426192. doi:10.1155/2012/426192. PMID 22164186
  269. Williamson SR. Clear cell papillary renal cell carcinoma: an update after 15 years. Pathology. 2021;53(1):109–119. doi:10.1016/j.pathol.2020.10.002. PMID 33223139
  270. Wobker SE, Williamson SR. Modern pathologic diagnosis of renal oncocytoma. J Kidney Cancer VHL. 2017;4(4):1–12. doi:10.15586/jkcvhl.2017.96. PMID 29090117
  271. Wolf MTF, Bonsib SM, Larsen CP, et al. Nephronophthisis: a pathological and genetic perspective. Pediatr Nephrol. 2024;39(7):1977-2000. doi:10.1007/s00467-023-06174-8. PMID 37930417
  272. Wu AJ, Mehra R, Hafez K, et al. Metastases to the kidney: a clinicopathological study of 43 cases with an emphasis on deceptive features. Histopathology. 2015;66(4):587–597. doi:10.1111/his.12524. PMID 25406592
  273. Wu H, Larsen CP, Hernandez-Arroyo CF, et al. AKI and Collapsing Glomerulopathy Associated with COVID-19 and APOL 1 High-Risk Genotype. J Am Soc Nephrol. 2020;31(8):1688-1695. doi:10.1681/ASN.2020050558. PMID 32561682
  274. Xia X, Li S, Jia X, et al. Clinicopathological phenotype and outcomes of NCAM-1+ membranous lupus nephritis. Nephrol Dial Transplant. 2024;40(1):193-205. doi:10.1093/ndt/gfae148. PMID 38991991
  275. Yamamoto K, Kawabata S, Kurisu Y, et al. A case of renomedullary interstitial cell tumor: radiologic-pathologic correlation. Radiol Case Rep. 2023;18(12):4574–4579. doi:10.1016/j.radcr.2023.09.072. PMID 37886730
  276. Yamashita M, Lin MY, Hou J, et al. The Continuing Need for Electron Microscopy in Examination of Medical Renal Biopsies: Examples in Practice. Glomerular Dis. 2021;1(3):145-159. doi:10.1159/000516831. PMID 36751496
  277. Yin X, Zhang X, Pan X, et al. Atypical metanephric adenoma: shares similar histopathological features and molecular changes of metanephric adenoma and epithelial-predominant Wilms' tumor. Front Oncol. 2022;12:1020456. doi:10.3389/fonc.2022.1020456. PMID 36313688
  278. Yu XJ, Zhou XJ, Wang SX, et al. Monoclonal light chain crystalline podocytopathy and tubulopathy associated with monoclonal gammopathy of renal significance: a case report and literature review. BMC Nephrol. 2018;19(1):322. doi:10.1186/s12882-018-1108-x. PMID 30419839
  279. Yuan X, Su Q, Wang H, et al. Genetic Variants of the COL4A3 , COL4A4 , and COL4A5 Genes Contribute to Thinned Glomerular Basement Membrane Lesions in Sporadic IgA Nephropathy Patients. J Am Soc Nephrol. 2023;34(1):132-144. doi:10.1681/ASN.2021111447. PMID 36130833
  280. Zhang W, He J, Yan X, et al. Hyperacute Rejection of a Kidney Allograft Associated with Anti-Histidyl-tRNA Synthetase and Anti-Signal Transducer and Activator of Transcription 6 Antibodies. Kidney Int Rep. 2026;11(8):106656. doi:10.1016/j.ekir.2026.106656. PMID 42436699
  281. Zhang X, Yadav PK, Niu Q, et al. Reevaluation of metanephric stromal tumor two decades after it was named: a narrative review. J Pediatr Urol. 2020;16(6):822–829. doi:10.1016/j.jpurol.2020.08.011. PMID 32893164
  282. Zhao M, He XL, Teng XD. Mucinous tubular and spindle cell renal cell carcinoma: a review of clinicopathologic aspects. Diagn Pathol. 2015;10:168. doi:10.1186/s13000-015-0402-1. PMID 26377921
  283. Zhou J, Zheng S, Zhang Y, et al. Juxtaglomerular cell tumor: clinicopathologic evaluation in a large series emphasizing its broad histologic spectrum. Pathol Int. 2020;70(11):844–856. doi:10.1111/pin.13009. PMID 32870578
  284. Zhou Q, Jiang L, Su T, et al. Overview of aristolochic acid nephropathy: an update. Kidney Res Clin Pract. 2023;42(5):579-590. doi:10.23876/j.krcp.22.211. PMID 37448287